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Abstract
PTEN is a tumour suppressor protein named after its homology with phosphatase 
and tensin and its frequent deletion on chromosome 10.
PTEN was discovered to be mutated in several solid tumours such as breast brain 
and ovarian cancers. This study sought to establish the role of PTEN mutation in 
haematological malignancies. Methods were developed to extract DNA from archival 
material consisting of formalin-fixed, paraffin-embedded tissue sections and 
methanol-fixed, May-Grunwald and Giemsa-stained bone marrow smears. To 
optimise amplification of extracted DNA, PCR primers were developed to produce a 
range of product sizes from human p-globin, prothrombin and PTEN genes. 
Techniques were developed for RTPCR amplification of cDNA from cultured 
haematological cell lines. Electrophoresis methods were developed to demonstrate 
heteroduplex formation using non-denaturing concentrations of denaturing agents 
and different gel media and running temperatures. Primers were designed to flank 
exon sequences and a representative group of myeloid and lymphoid malignancies 
were screened for PTEN mutations. Exons 5, 7 and 8 were initially amplified for 
heteroduplex analysis following reports of frequent mutation. No heteroduplex bands 
were observed in samples assayed. The possible insensitivity of heteroduplex 
analysis to mutations in sub populations of mutant tumour cells led to the 
development of SSCP techniques. These techniques were optimised for analysis of 
DNA that was extracted from frozen archived bone marrow. PCR reactions were 
developed to amplify each PTEN exon. No suitable primers were found for exon 2 
analysis due to extensive non-specific amplification. A total of 912 SSCP assays 
were performed, screening a range of lymphoid and myeloid malignancies for 
mutations in all PTEN exons except exon two. Only two possible aberrant 
conformations were indicated, both in exon 5. The exon 5 PCR product from both 
positive samples were DNA sequenced using forward and reverse primers. Exon 5 of 
seven other leukaemia samples were sequenced as controls to detect possible lack 
of sensitivity of SSCP analysis to PTEN mutations. All samples showed exon 5 DNA 
sequences in agreement with published sequences. These results suggest that small 
deletions and point mutations in the PTEN gene are very rare in haematological 
malignancy. The expression of PTEN mRNA in cultured haematological malignancy 
cells was established by the earlier RTPCR amplification using cultured cells.
Western blotting was performed to establish PTEN protein expression in primary 
malignancies. All samples assayed showed protein expression. Concerns regarding 
the contribution from residual normal cells to the PTEN expression picture in tumour 
cell samples led to the assay of protein by immunofluorescence. PTEN protein was 
demonstrated in all successful reactions with one CGL and one AML M3 showing 
higher levels of expression that control cells. These results suggest that in 
haematological malignancy, the PTEN gene is not mutated and PTEN protein is 
expressed in leukaemic cells.
Research by other workers has demonstrated the importance of PTEN in normal 
haemopoesis. In mouse models, normal PTEN expression is essential for normal 
compartmentalisation and to prevent the acquisition of a leukaemic picture. This 
study suggests that if PTEN dysfunction is involved in the development of 
haematological malignancy, then it is by a subtle mechanism such as a change in 
expressed protein levels. It may be that, with the small number of oncogenic 
mutations necessary to promote a leukaemic phenotype, mutated PTEN does not 
provide a selective advantage to promote further the survival of the malignant cell 
population.
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Chapter 1 Introduction
1.1 Cancer
1.1.1 Cell function in multi- and unicellular organisms.
The millions of cells that comprise a complex multicellular organism are 
characterised by the property of differentiation to a mature state, followed by 
death. This process is associated with maintenance of a germline genotype in 
certain germ cells and stem cells, but for the vast majority of cells, their 
existence is limited to the service of the organism as a whole and with the 
eventual propagation of the genotype in the form of whole organism offspring. 
This cooperative system of multicellular organisms contrasts with that of 
single cell systems which function in a competitive environment purely for the 
benefit of individual cells (Alberts et al. 2002).
1.1.2 Development of cancer
The development of cancer has been described by Alberts et al. (2002) as a 
microevolutionary process. To coordinate their behaviour, the cells are 
subject to an elaborate set of signals that serve as social signals, controlling 
the action of each. In an organism such as Homo sapiens, consisting of 
approximately 1014 cells the maintenance of order is critical. A cell functioning 
outside the constraint of cooperation may acquire a growth advantage and 
begin to act “selfishly” at the expense of the neighbouring cells still 
constrained by the growth control mechanisms. The selective advantage may 
allow it to divide more vigorously than its neighbours and to become a 
founder of a growing mutant clone. The clone may undergo repeated rounds 
of mutation, further removing itself from the bounds of controlled cell growth
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and function. These are the basic ingredients of cancer; it is a state in which 
individual cells begin by prospering at the expense of their neighbours, in an 
uncontrolled manner, possibly to the extent that the continued existence of 
the multicellular organism is untenable (Alberts et al. 2002).
1.1.3 Malignant and benign tumours
Tumour cell clones are classed as either benign or malignant. Benign 
tumours are encapsulated and are usually well differentiated and retain the 
characteristics of the cell of origin and are not usually life threatening. 
Malignant tumours lose the ability to stay localised according to their original 
cell function and invade other tissue, often at a distant physical location within 
the organism, forming metastases that form further tumour masses. Tumour 
cells have several features that distinguish them from normal cells: they 
multiply independently of normal growth signals; they are anchorage 
independent; they may grow over or under each other without inhibition; they 
are less adhesive than normal cells; they continue to proliferate irrespective of 
population density (Blair M E, personal communication, January 2007).
1.1.4 Historical understanding of cancer
By the middle of the 20th century, the precise chemical structure of DNA was 
elucidated and found to be the basis of the genetic code. With the deciphering 
of the genetic code, workers were able to understand how genes worked and 
how they could be damaged by mutation. Chemicals, radiation, and viruses 
could cause cancer, and cancer could be linked to inherited genes. But, as 
understanding of DNA function increased, it became apparent that the
2
damage to DNA by chemicals and radiation or the introduction of new DNA 
sequences by viruses, often led to the development of cancer. It became 
possible to pinpoint the exact site of the damage to a specific gene (Brown 
2002).
It became evident that sometimes, defective genes are inherited as germ-line 
defects and that sometimes these inherited genes are defective at the same 
points that chemicals exerted their effect via somatic mutation. Thus 
carcinogens caused genetic damage, mutations led to abnormal groups of 
cells (clones), mutated cell clones evolved to even more malignant clones 
over time and the cancer progressed by more and more genetic damage and 
mutation. Normal cells with damaged DNA senesce via programmed cell 
death or apoptosis (discussed in section 1.3); cancer cells with damaged 
DNA do not (Strachan and Read 2003 ).
Genes have been discovered that are associated with cancers of the colon, 
rectum, kidney, ovary, oesophagus, lymph nodes, and pancreas and skin 
melanoma. Familial cancer is less common than spontaneous cancer, 
causing less than 15% of all cancers; detection of cancer-associated genes in 
individuals makes possible the identification of persons at very high risk.
In the early twentieth century, cancer-causing elements in viruses that 
infected poultry were shown to be sufficient to cause tumour formation.
Peyton Rous at the Rockefeller Institute in New York reported the cell-free 
transmission of a sarcoma in chickens. The viral agent responsible for 
transmission was named after its discoverer; the Rous sarcoma virus and the 
gene responsible termed src (Coffin 1997). A short cDNA probe specific for 
the src viral oncogene was obtained by Stehelin in 1976 and was found to
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hybridize to sequences in normal cellular DNA. This result showed that src 
was not originally a retroviral gene, but a gene of cellular origin carried in the 
viral genome and transduced by the virus from cell to cell. This finding led to 
an understanding of the molecular basis of cancer via discovery of several 
cellular homologues to cancer-causing elements in viruses. All retroviral 
oncogenes were found to be recent acquisitions from the cell. Many were 
eventually identified as cellular genes with normal functions in mitogenic 
signal transduction: coding for peptide growth factors, growth factor receptors, 
protein kinases, G proteins, and transcription factors (Stehelin et al. 1976, 
Weinberg 1994).
1.2 The Cell Cycle
Division in the eukaryotic cell requires a tightly regulated doubling of the 
genome into exact copies. The phases between cell division are denoted as 
Gi, S, G2 (interphase) and M (metaphase). Gi involves cell growth and 
preparation of genome for replication. S includes synthesis of genome copy 
and centromeres. G2 is a second period of growth prior to M or mitosis 
(Gilbert 2000).
The cell cycle is controlled by a series of proteins termed cyclins (A, B, D and 
E) and their concentrations vary according to stages of the cycle. Cyclins are 
activated by phosphorylation under the influence of cyclin dependant kinases 
(Cdks) (Fig 1.2.1, Fig 1.2.2).
A rising level of G1 -cyclins signal to the cell to prepare the chromosomal DNA 
for replication by binding to their Cdks. A rising level of S-phase promoting 
factor (SPF) - which includes cyclin A bound to Cdk2 - enters the nucleus and
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prepares the cell to duplicate its DNA (and its centrosomes). As DNA 
replication continues, cyclin E is destroyed, and the level of mitotic cyclins 
begins to rise (in G2). M-phase promoting factor (the complex of mitotic 
cyclins with the M-phase CDK) initiates assembly of the mitotic spindle, 
breakdown of the nuclear envelope and condensation of the 
chromosomes within the nucleus. These events take the cell to metaphase of 
mitosis. At this point, the M-phase promoting factor activates the anaphase 
promoting complex (APC) which allows the sister chromatids at the 
metaphase plate to separate and move to the poles (anaphase), completing 
mitosis and destroys the mitotic cyclins. It does this by conjugating the cyclins 
with the protein ubiquitin which targets them for destruction by proteasomes. 
The APC also turns on synthesis of G1 cyclin for the next turn of the cycle 
and degrades geminin, a protein that has kept the DNA freshly synthesized in 
S phase from being re-replicated before mitosis (Kimball 2006).
The cell has several systems for interrupting the cell cycle if errors in 
replication occur. The cell monitors the presence of the short discontinuous 
replicated sequences, termed Okazaki fragments, on the lagging strand 
during DNA replication. The cell is not permitted to proceed in the cell cycle 
until these have been made continuous by DNA ligase enzymes. DNA 
damage checkpoints (such as p53 tumour protein, Ataxia-Telangiectasia 
Mutated Gene (ATM) protein and the Max Dimerization (MAD) protein sense 
DNA damage before the cell enters S phase (a G1 checkpoint), during S 
phase and after DNA replication (a G2 checkpoint). A variety of CDK inhibitor 
proteins exist, such as CDKN1B/p27 which binds to and
5
Fig 1.2.1
The eukaryotic cell cycle
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DNA
replication
Chrom osom e
segregation
START
Cytoki nesis
G rowth
Fig 1.2.1
Figure shows eukaryotic cell cycle and associated events in cell. The Gi growth phase is followed by DNA replication 
in S phase. The G2 phase is associated with spindle pole body duplication and entry into M phase is associated 
with chromosome condensation, spindle formation, chromosome segregation then nuclear division and finally cell 
division. Cells may remain quiescent (GO) or re-enter cell cycle under the influence of cytokines/growth factors (Nigg 
1995)
6
Fig 1.2.2
Cyclins and cyclin dependent kinases expressed within the cell cycle.
Figure 1.2.2 Figure shows cyclins A,B,D and E and their respective protein kinases (cdk2, 4 and 6 and cdc2) at their 
point of action in cell cycle regulation (Gilbert 2000).
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prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and 
thus controls the cell cycle progression at G1. The degradation of this protein, 
which is triggered by its CDK dependent phosphorylation, is required for the 
cellular transition from quiescence to the proliferative state (Hall et al. 2004).
A cell may leave the cell cycle temporarily or permanently. It exits the cycle at 
G1 and enters a stage designated GO. A cell in GO phase is often called 
"quiescent", but GO corresponds with a cell’s functions in the organism, e.g., 
secretion, as in plasma cell immunoglobulin secretion, attacking pathogens. 
Often GO cells are terminally differentiated: they will never re-enter the cell 
cycle but instead will carry out their function in the organism until they die. For 
other cells, GO is followed by re-entry into the cell cycle. Most of the 
lymphocytes in human blood are in GO. However, with proper stimulation, 
such as encountering the appropriate antigen, they can be stimulated to re­
enter the cell cycle (at G1) by cytokines and proceed on to new rounds of 
alternating S phases and mitosis. GO represents not simply the absence of 
signals for mitosis, but an active repression of the genes needed for mitosis. 
Cancer cells cannot enter GO and are destined to repeat the cell cycle 
indefinitely (Kimball 2006).
1.3 Apoptosis
The generation of new cell populations is normally carefully balanced by the 
destruction of an appropriate number of older cells. There are two 
mechanisms that govern cell death: Injury and programmed cell death 
(apoptosis or “suicide”). Injurious physical effects include mechanical, 
chemical, toxic, infection and radiation damage and are characterised by cell
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swelling due to disruption of cell membranes, rupture and leakage of cellular 
contents and subsequently, inflammation (Kimball 2006).
Apoptosis is characterised by cell shrinkage, membrane blebbing, chromatin 
degradation by cleavage of DNA between nucleosomes, mitochondrial 
breakdown and release of cytochrome c and end-stage fragmentation of cell 
into membrane-wrapped fragments. Phosphatidylserine, which is normally 
preferentially expressed on the inner surface of the cytoplasmic membrane, is 
exposed on the exterior surface of these fragments. Phosphatydylserine 
earmarks the fragments for phagocytosis via specific receptors on phagocytic 
cells such as macrophages and dendritic cells, when the fragment is engulfed 
and inhibitors of inflammation are released. Apoptosis is part of a cells normal 
physiology and is important in two cellular processes: firstly, in growth and 
development such as the formation of fingers and toes of the human foetus 
through the removal of tissue between them, the loss of the endometrium at 
the start of menstruation and the formation of synaptic junctions between 
neurons in the brain via the elimination of surplus cells. Secondly, 
programmed cell death is needed to destroy cells that threaten the normal 
function of an organism. Examples include induction of apoptosis in virus- 
infected cells by killer T cells, removal of effector cells once a cell-mediated 
immune response is completed (killer T cells are capable of inducing 
apoptosis in themselves as well as other T cells) and cells with damaged 
DNA (Kimball 2006).
1.3.1 Induction of apoptosis.
Apoptosis is induced in a cell by a change in the positive and negative
9
signalling mechanisms that maintain homeostasis. Negative signals that 
promote apoptosis include: increased intracellular oxidant concentration, UV 
and ionising radiation, cytotoxic drugs, accumulation of proteins with improper 
tertiary structure and binding of specific ligands or “death activators” (tumour 
necrosis factor (TNF)a, TNF(3, CD95). TNF a and (3 bind to TNF receptors 
whilst CD95L binds to a CD95L receptor. Thus, apoptosis may be promoted 
by intracellular or extracellular stimuli. The internal or intrinsic pathway is 
induced by a change in Bcl2 protein expression on the surface of 
mitochondrial outer membranes. Bcl2 is normally bound to Apaf-1 protein (fig 
1.3.1) (Allen et a/., 1998).
Internal cell damage, such as oxidation, causes Bcl2 to release Apafl whilst 
Bax, a Bcl2-related protein, penetrates the mitochondrial membrane causing 
leakage of cytochrome c from the mitochondria. Bcl2 and Bax seem to have 
opposing actions in regulating permeability of the mitochondrial membrane. 
The released cytochrome c and Apa-f1 bind to a further protein, caspase 9. 
This caspase 9-cytochrome c - Apa-f1 complex binds ATP to form an 
“apoptosome” The caspase 9 component of the complex is one of several 
caspase proteases that cleave protein at aspartic acid residues. The complex 
activates other caspases in the cytosol by proteolytic cleavage which, in turn, 
goes on to activate other caspases. This process of signal amplification is 
analogous to that of the blood coagulation cascade. The resulting widespread 
proteolytic activity leads to destruction of structural cytoplasmic proteins, 
degradation of DNA into 200bp fragments and ultimately, phagocytosis of the 
cell by macrophages (Algeciras-Schimnich et al. 2006).
The external/extrinsic/death receptor pathway is initiated by binding of
10
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CD95/CD95 (found predominantly on the surface of activated T cells) and 
TNF to their respective receptors on the cell surface which span the 
cytoplasmic membrane. Binding of the signal molecule leads to activation of 
caspase 8. Caspase 8, like caspase 9, initiates a cascade of caspase 
activation, proteolysis and eventual phagocytosis by macrophages (Fig1.3.1.) 
(Cooper 2000).
1.3.2 Apoptosis and neoplasia.
Several oncogenic viruses exert their tumour-promoting influence by 
preventing apoptosis in transformed cells. The human papilloma virus (HPV) 
produces E6 protein that binds to p53 tumour protein and, as a result, targets 
it for rapid proteasome-mediated degradation. p53 is important in arresting 
the cell cycle and initiating apoptosis in damaged cells by promoting the 
expression of Bax, Apafl and many other genes (Wang 1999).
Some B cell lymphomas have raised levels of Bcl2 protein which block 
apoptosis. This may be achieved by translocation of the Bcl2 gene into a 
highly active immunoglobulin gene enhancer region (t14;18) or amplification 
of the Bcl2 locus by accumulation of repeated copies of the gene.
Melanoma tumour cells block apoptosis by blocking expression of the Apaf-I 
gene. Other cancer cells may express high levels of CD95, essentially 
becoming effective killer cells that lead to the destruction of killer T cells that 
may attempt to bind with the tumour cell and induce apoptosis (Campioni et 
al. 2005).
1.4 Gene regulation and DNA methvlation
The human genome contains approx. 25000 genes. Some are constitutively
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expressed in all cells all the time. These “housekeeping” genes are 
responsible for the metabolic functions (e.g. respiration) common to all cells. 
Other genes such as the cyclin group of proteins are expressed in all cells, 
but only as cells enter a particular pathway of differentiation. Some are 
expressed constitutively only in cells that have differentiated in a specific 
lineage, such as specific immunoglobulin expression in plasma cells. Some 
have transient expression that occurs only in response to external stimuli, 
such as the binding of a growth factor to its specific receptor (Kufe 2006).
The rate of transcription of a gene is the most common form of regulation in 
eukaryotes. Rate of expression pre-transcription is governed by the binding of 
a large group of transcription factor and repressor proteins such as myc and 
p53 to gene promoter, enhancer and silencer regions. Posttranscriptional 
mechanisms for gene regulation include modulation of 5’mRNA capping, exon 
splicing and poly-adenylation. Other control mechanisms include the stability 
of mRNA molecules (and their subsequent degradation) during transfer from 
nucleus to ribosome, and the rate at which the mRNA is decoded into a 
polypeptide during translation (Day and Tuite 1998).
The methylation of carbon 5 in cytidine groups (5-mC) by 
cytosine5methyltransferase in DNA is referred to as DNA methylation. All 
higher eukaryotes have some degree of methylated DNA. Methylation is 
heritable and occurs predominantly in areas of DNA rich in CpG palindromic 
sequences (CpG islands). These islands occur with greatest frequency in 
areas adjacent to highly transcribed genes. Following semi-conservative 
replication, DNA CpG sequences are hemi-methylated with the newly 
synthesised strand un-methylated. Heritability is achieved by the action of a
13
“maintenance methylase” which methylates all cytosine groups in the new 
strand that are diagonally opposite methylated cytosine groups in the 
template strand (Robertson 2005).
The degree of methylation for a given gene is not fixed and can vary in a 
tissue specific manner, or in the case of inactivation of the X chromosome in 
females, between chromosomes. DNA methylation represses transcription 
directly, by inhibiting the binding of specific transcription factors, and 
indirectly, by recruiting methyl-CpG-binding proteins and their associated 
repressive chromatin remodelling activities. Regulated DNA methylation 
patterns are essential for normal mammalian development and for the normal 
functioning of the adult organism. DNA methylation is a potent silencer of 
gene expression and maintains genome stability against a large quantity of 
repetitive DNA, which can otherwise give rise to illegitimate recombination 
events and cause transcriptional deregulation of nearby genes. The 
mechanism that allows changes in the degree of methylation to occur is 
unclear but it is suggested that maintenance of methylation requires constant 
remethylation by a yet unidentified methylase. The relative paucity of CpG 
groups in the human genome can be explained by the tendency of methylated 
C group to deaminate to thymine, leading to an accumulation of A-T pairs 
(Tucker 1996, Kudla 2004).
1.5 Genes involved in cancer
The viral DNA sequences associated with tumour formation that have high 
homology to genes that already exist in animal models are named proto­
oncogenes, and their viral, cancer-causing counterparts are called
14
oncogenes. The distinction between proto-oncogene and oncogene relates to 
the activity of the protein product of the gene. A proto-oncogene is a gene 
whose protein product has the capacity to induce cellular transformation only 
if its normal expressed product is altered. An oncogene is a gene that has 
sustained some genetic damage and therefore, produces a protein capable of 
cellular transformation (Kufe et at. 2003)
1.5.1 Proto-oncogenes
The process of activation of proto-oncogenes to oncogenes can include 
retroviral transduction or retroviral integration, point mutations, insertion 
mutations, gene amplification, chromosomal translocation and/or protein- 
protein interactions (Strachan and Read 2003).
Proto-oncogenes are classified into many different groups based upon their 
normal function within cells or based upon sequence homology to other 
known proteins. Proto-oncogenes have been identified at all levels of the 
various signal transduction cascades that control cell growth, proliferation and 
differentiation. Proto-oncogenes that were originally identified as resident in 
transforming retroviruses are designated as c- indicative of the cellular origin 
as opposed to v- to signify original identification in retroviruses (Lodish 2000). 
The change of an oncogene from normal to oncogenic function can be 
caused by a simple point mutation in the DNA sequence of a gene. A point 
mutation in the ras oncogene, located on human chromosome 11, from 
guanine to cytosine is associated with bladder cancer. This change results in 
a glycine to valine substitution at amino acid 12 of the translated protein. This 
dramatically changes the function of the G-protein encoded by the ras gene.
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Normally, the protein switches from an inactive to active state by a change in 
phosphorylation of bound GDP and GTP. The mutation does not allow the 
release of GTP, and the protein is continuously active (termed a gain-of- 
function, as opposed to loss-of-function mutation). Because the growth signal 
delivered by the ras oncoprotein is permanently switched on, the cell 
continues to grow and divide. This unregulated growth leads to cancer 
(Alberts 2002).
1.5.1.1 Oncogene classification
Hundreds of specific oncogenes have been identified but they have classed 
by King (2003) according to their common function as shown in Table 1.5.1.
1.5.2 Tumour suppressor genes
Tumour suppressor genes encode protein products that inhibit mitosis and 
prevent the uncontrolled cell proliferation. Cell fusion experiments show that 
the transformed phenotype can often be corrected in vitro by fusion of the 
transformed cell with a normal cell. This provides evidence that 
tumourigenesis involves not only dominant activated oncogenes, but also 
recessive, loss-of-function mutations in other genes. When mutated (with rare 
exceptions) the mutant allele is recessive; as long as the cell contains one 
normal allele, tumour suppression continues. Knudson (1971) proposed this 
two-hit model of tumour suppressor gene inactivation, derived from 
mathematical modelling of cancer incidence. This implied that tumour 
suppressors were recessive, requiring mutations in both alleles. Recently it 
has become clear that mutations in tumour suppressor genes are not always
16
Table 1.5.1 Oncogene Class by Function ( King 2003)
Growth Factors:
• The c-Sis gene (the v-sis gene is the oncogene in simian sarcoma 
virus) encodes the PDGF B chain. The v-sis gene was the first 
oncogene to be identified as having homology to a known cellular 
gene.
• The int-2 gene (integration of mouse mammary tumour virus) encodes 
an FGF-related growth factor.
• The KGF/Hst) gene encodes an FGF-related growth factor.___________
Receptor Tyrosine Kinases:
• The c-Fms gene encodes the colony stimulating factor-1 (CSF-1) 
receptor.
•  The Neu gene was identified as an epidemial growth factor (EGF) 
receptor-related gene.
• The Trk genes (A,B and C) encode the NGF receptor-like proteins.
• The Met gene encodes the hepatocyte growth factor (HGF)/scatter 
factor (SF) receptor.
•  The c-Kit gene encodes the mast cell growth factor receptor.cells. 
Membrane Associated Non-Receptor Tyrosine Kinases:
• The v-src gene was the first identified oncogene.
• The Lck gene has been shown to be associated with the CD4 and CD8
 antigens of T cells.________ _______________________________________
G-Protein Coupled Receptors:
• The Mas gene was identified in a mammary carcinoma and has been 
shown to be the angiotensin receptor.
•  Membrane Associated G-Proteins
• Three different homologies of the c-Ras gene, each of which was 
identified in a different type of tumour cell. Analogous to viral protein -
 v-Ras___________________________________________________________
Serine/Threonine Kinases:
• The Raf gene is involved in the signaling pathway of most RTKs. It is 
likely responsible for threonine phosphorylation of MAP kinase
 following receptor activation._______________________________________
Nuclear DNA-Bindinq/Transcription Factors
• Myc gene. A disrupted human c-Myc gene is involved in numerous 
haematopoietic neoplasias. Disruption of c-Myc results from retroviral 
integration and transduction as well as chromosomal rearrangements.
•  Fos gene was identified in the feline osteosarcoma virus. Fos interacts 
with a second proto-oncogenic protein, Jun to form a transcriptional 
regulatory complex.
• p53 The p53 gene is the single most identified mutant protein in human 
tumours. Mutant forms of the p53 protein interfere with cell growth 
suppressor effects of wild-type p53 indicating that the p53 gene
 product is actually a tumour suppressor.____________________________
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completely recessive. Haploinsufficiency occurs when one allele is insufficient 
to confer the full functionality produced from two wild-type TSG alleles. Under 
some circumstances, one hit may be sufficient for inactivation (Payne and 
Kemp 2005).
Tumour suppressor genes have been discovered by three main routes: 
positional cloning of the genes causing rare familial cancers; 
examination of genes at chromosomal locations commonly deleted in tumour 
cells (by loss of heterozygosity analysis or comparative genomic 
hybridization); testing tumours for mutations in genes known to be involved in 
cell cycle regulation (Strachan and Read 2003).
Table 1.5.2 lists the tumour suppressor gene family members (Holland 2003) 
and shows the specific gene, the associated inherited cancer, cancers which 
occur as a result of somatic mutations and the presumed function of the 
protein product.
1.5.2.1 Rb
1.5.2.1.1 Rb Function
Retinoblastoma is a cancerous tumour of the retina. It occurs in two forms. In 
familial retinoblastoma, multiple tumours in the retinas of both eyes occur in 
the first weeks of infancy. In sporadic retinoblastoma, a single tumour 
appears in one eye sometime in early childhood before the retina is fully 
developed and mitosis in it ceases. (Holland 2003) A gene encoding a 
messenger RNA of 4.6 kb, located in the proximity of esterase D, was 
identified by Lee et al. (1987) as the retinoblastoma susceptibility gene on the 
basis of chromosomal location, homozygous deletion, and tumour-specific 
alterations in expression. Biochemical fractionation and immunofluorescence
18
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from DNA-cellulose columns, suggesting a DNA binding activity. Chen et al. 
(1989). demonstrated that the RB1 gene product has the properties of a cell 
cycle regulatory element and that its function is modulated by a 
phosphorylation/dephosphorylation mechanism during cell proliferation and 
differentiation. In G0/G1 cells, virtually all the Rb protein is unphosphorylated, 
whereas during S and G2 phases, it is largely, if not exclusively, 
phosphorylated.
1.5.2.1.1.1 Rb in Apoptosis
Yap et al. (1999) showed that the binding of Rb to MDM2 is essential for Rb 
to overcome both the antiapoptotic function of MDM2 and the MDM2- 
dependent degradation of p53. Since Rb specifically rescues the apoptotic 
function but not the transcriptional activity of p53 from negative regulation by 
MDM2, transactivation by wild type p53 is not required for the apoptotic 
function of p53.
Hill et al (2006) showed that inactivation of the pRb family proteins in 
genetically engineered mice induced epithelial proliferation and was sufficient 
to produce prostatic intraepithelial neoplasia lesions. Apoptosis was 
dependent on PTEN function and not p53, PTEN hemizygosity reduces 
apoptosis by 50%, accelerating progression to adenocarcinomas with 
heterogeneous composition in the Rb deficient model.
1.5.2.1.1.3 Rb and promotion of differentiation
The incidence of osteosarcoma is increased 500-fold in patients who inherit 
mutations in the Rb gene. To understand why the Rb protein is involved in 
osteosarcoma, Thomas etal. (2001) studied its function in osteogenesis.
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Loss of Rb but not p107 or p130 blocked late osteoblast differentiation. Rb 
physically interacted with the osteoblast transcription factor, CBF (core 
binding factor) A1 and is associated with osteoblast-specific promoters in vivo 
in a CBFA1-dependent fashion. Association of Rb with CBFA1 and promoter 
sequences resulted in synergistic transactivation of an osteoblast-specific 
reporter. This transactivation function was lost in tumour-derived Rb mutants, 
underscoring a potential role in tumour suppression. Thus, Rb functions as a 
direct transcriptional coactivator promoting osteoblast differentiation, which 
may contribute to the targeting of Rb in osteosarcoma (Thomas et ai. 2001).
1.5.2.1.1.5 Rb and telomere length
Garcia-Cao et al. (2002) reported a connection between members of the 
retinoblastoma family of proteins, Rb1, RbL1 and RbL2 and the mechanisms 
that regulate telomere length. In particular, mouse embryonic fibroblasts 
doubly deficient in RbL1 and RbL2 or triply deficient in all three genes had 
markedly elongated telomeres compared with those of wildtype or Rb1- 
deficient cells. This deregulation of telomere length was not associated with 
increased telomerase activity. The abnormal elongated telomeres in double or 
triple deficient cells retained their end-capping function, as shown by the 
normal frequency of chromosomal fusions and thus demonstrated a 
connection between the RB1 family and the control of telomere length in 
mammalian cells (Garcia-Cao et al. 2002).
1.5.2.1.1.5 Rb and maintenance of GO phase
Cellular senescence is a stable form of cell cycle arrest that limits proliferation 
of damaged cells and may act as a natural barrier to cancer progression.
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Narita etal. (2003) described a distinct heterochromatic structure that 
accumulates in senescent human fibroblasts, designated senescence- 
associated heterochromatic foci (SAHF). They found that SAHF formation 
coincides with recruitment of heterochromatin proteins and the RB1 protein to 
E2F-responsive promoters and is associated with the stable repression of 
E2F target genes. Both SAHF formation and the silencing of E2F target 
genes depended on the integrity of the Rb pathway and did not occur in 
reversibly arrested cells. This prevents E2F from binding to the promoters of 
proto-oncogenes such as c-myc and c-fos. Transcription of c-myc and c-fos is 
needed for mitosis so blocking the transcription factor needed to turn on these 
genes prevents cell division (fig 1.5.2.1). If cell damage is minor, p53 protein 
halts the cell cycle by stimulating expression of p21 until the damage is 
repaired (Narita et al. 2003).
1.5.2.1.2 Interaction with PTEN
Bai et al (2006), in a study of how the Rb pathway interacts with other 
pathways in tumour suppression, characterized mice with double mutations of 
an INK4 cyclin dependent kinase inhibitor and PTEN (expression of INK4 
retains Rb proteins in their growth-suppressive states). Double mutant mice 
developed a wider spectrum of tumours with nearly complete penetrance in 
anterior and dorsolateral lobe prostate cancer. PTEN protein expression was 
lost in 9 out of 11 prostate tumours from PTEN+/_ mice whilst loss of PTEN 
protein expression was not detected in any tumours from 5 pituitary, 12 
thyroid and 9 adrenal gland tumours. Bai et al (2006) suggested that p18
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and PTEN cooperate in tumour suppression by constraining a positive 
regulatory loop between cell growth and cell cycle control pathways. Their 
results indicated a tissue-specific haploinsufficiency in the tumours studied.
1.5.2.2 P53 Tumour protein
The p53 tumour antigen is found in increased amounts in a wide variety of 
transformed cells. The protein is also demonstrated in many actively 
proliferating normal cells, but it is only present at low levels in resting cells. 
Wild type p53 plays a role in DNA repair and expression of mutant forms of 
p53 may alter cellular resistance to the DNA damage caused by gamma- 
radiation. p53 functions as a cell cycle checkpoint after irradiation, suggesting 
that mutant p53 might change the cellular proliferative response to radiation 
(see section 1.5.2.2.2). p53 is not required for normal development, but under 
conditions such as DNA damage or other cellular stress, p53 expression is 
stimulated. In turn, p53 tetramers bind to p21 regulatory elements and 
transcriptionally activate its expression. The p21 protein subsequently binds 
to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of 
critical cyclin-dependent kinase substrates and blocking cell cycle 
progression. In tumour cells with inactive p53, this pathway is absent, 
permitting unregulated growth. The mechanism by which p53 mediates 
apoptosis is a 3-step process: first, the transcriptional induction of redox- 
related genes; second the formation of reactive oxygen species; and third, the 
oxidative degradation of mitochondrial components, culminating in cell death. 
Thus, p53 has a cytoplasmic and nuclear role in preventing cell proliferation. 
p53 functions in the nucleus to regulate proapoptotic genes, whereas 
cytoplasmic p53 directly activates proapoptotic BCL2 proteins to permeabilize
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Fig 1.5.2.2 Function of p53
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Fig 1.5.2.2 shows action of p53. DNA is damaged; p53 levels rise, protein kinases that phosphorylate p53 are 
activated. MDM2 (or E6 produced by mucosal specific papilloma viruses) bind and target P53 for proteolytic 
degradation. Phosphorylation of p53 blocks its binding to Mdm2: p53 accumulates to high levels and stimulates 
transcription of the gene that encodes the Cdk inhibitor protein p21. The p21 binds and inactivates Gi/S-Cdk and S- 
Cdk complexes, arresting the cell in Gi. (Alberts et al 2003, lliakis 1997))
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mitochondria and initiate apoptosis (fig 1.5.2.2) (Kufe 2003).
1.5.2.2.1 P53 function in oncogenesis
Vogelstein and Kinzler (2004) outlined 5 mechanisms for p53 inactivation:
In the first mechanism, p53 binds as a tetramer to a p53-binding site and 
activates the expression of adjacent genes that inhibit growth. Deletion of one 
or both p53 alleles reduces or abolishes the expression of tetramers, resulting 
in decreased expression of the growth inhibitory genes (such as p21). This 
mechanism is found in tumours of several types.
Secondly, nonsense or splice site mutations that result in truncation of the 
protein do not allow oligomerization, thus resulting in a reduction of p53 
tetramers. Mutations of this gene are common in lung, oesophagus, and other 
cancers.
The third mechanism involves missense mutations resulting in dominant- 
negative effects which mimic and oncogene function due to an even greater 
reduction of functionally active tetramers. Such missense mutations are 
common in colon, brain, lung, breast, skin, bladder, and other cancers. 
Fourthly, a mechanism by which p53 is involved in oncogenesis is common in 
cervical and anal cancers where the expression of the E6 gene of human 
papilloma virus (HPV) results in the functional inactivation of p53 through 
binding and rapid degradation.
Finally, the p53 pathway may also be disrupted by alteration of a cellular 
oncoprotein gene, MDM2 (Kufe 2003).
1.5.2.2.2 p53 and DNA damage.
DNA damage by UV radiation leads to an increase in production of protein
27
kinase directed at p53, which is phosphorylated at ser15 and also lead to a 
transient rise in p53 levels due to posttranslational modifications that increase 
its half-life. The phosphorylation causes a conformational change in p53, 
which leads to reduced interaction of p53 with MDM2, its negative regulator. 
Association of p53 with MDM2 results in ubiquitination and subsequent 
degradation of p53 by cellular proteases (lliakis 1997).
If the cell damage is major and cannot be repaired, degradation does not 
occur, p53 levels increase, and cell senescence is triggered by apoptosis. 
These functions make p53 a key player in protection against cancer. More 
than half of all human cancers harbour p53 mutations and have no 
functioning p53 protein, which, as with Rb, tips the balance of cell growth in 
favour of proliferation (Alberts 2002).
1.5.2.3 p16 and tumour suppression
The involvement of 9p21 in chromosomal inversions, translocations, 
heterozygous deletions, and homozygous deletions in a variety of malignant 
cell lines indicates that this region may contain a gene with tumour 
suppressor function. Lukas et al. (1995) showed that wildtype p16 arrests 
normal diploid cells in late G1 phase of the cell cycle, whereas a tumour- 
associated mutant of p16 does not. Furthermore, the ability of p16 to induce 
cell cycle arrest was lost in cells lacking functional retinoblastoma protein.
This suggests that loss of p16 and loss of retinoblastoma protein have similar 
effects on G1 progression, and may represent a common pathway in the 
promotion of oncogenesis. Stott et al. (1998) stated that p16 was a 
recognised tumour suppressor that induces a G1 cell cycle arrest by inhibiting 
the phosphorylation of the Rb protein by the cyclin-dependent kinases CDK4
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and CDK6 and that the protein was able to generate a p53 response. p16 
protein binds to CDK4 and inhibits the ability of CDK4 to interact with cyclin D 
(see Fig 1.5.2.1) and stimulate passage through the G1 phase of the cell 
cycle. p16 protein exists as 2 distinct transcripts from different promoters. The 
transcripts have been designated p16(INK4A) and p14(ARF). Each has a 5- 
prime exon that is spliced into common exons 2 and 3. Deletions, mutations 
and inactivation by hypermethylation in the p16 gene may affect the relative 
balance of functional p16 and cyclin D, resulting in abnormal cell growth. p16 
dysfunction has been particularly associated with malignant melanoma and 
pancreatic adenocarcinoma. You et al. (2002) found evidence of collaboration 
between PTEN and p16/lnk4a in constraining the growth and oncogenic 
transformation of cultured cells and in suppressing a wide spectrum of 
tumours in vivo such as pheochromocytoma, prostatic intraepithelial 
neoplasia, and endometrial hyperplasia.
1.5.2.4 Adenomatous Polyposis Coli (APC) Gene 
This is a multidomain protein containing 2,843 amino acids and is strongly 
associated with Familial Adenomatous Polyposis coli (APC). It plays a major 
role in tumour suppression by antagonizing the W NT signalling pathway 
(WNT signaling molecules regulate cell-to-cell interactions during 
embryogenesis) where APC is thought to act as a scaffold for a protein 
complex that regulates the phosphorylation and thus degradation of p-catenin 
in the WNT pathway. Inappropriate activation of this pathway through loss of 
APC function contributes to cancer progression (Nathke 2004).
APC also has roles in cell migration, adhesion, chromosome segregation, 
spindle assembly, apoptosis, and neuronal differentiation. Mutations in the
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APC gene are an initiating event for both familial and sporadic colorectal 
tumours. Most of these mutations accumulate in the central region of the APC 
gene, called the mutation cluster region (MCR), and result in expression of 
carboxy-terminally truncated proteins. APC mutations in the first or last third 
of the gene are associated with an attenuated polyposis with a late onset and 
a small number of polyps (Solomon and Burt 2005).
1.5.2.5 BRCA1 and BRCA2
BRCA1 and BRCA2 encode large proteins of 1,863 and 3,350 amino acids, 
respectively. They are both complex genes made up of more than 20 exons. 
Neither gene bears significant homology with other known genes, with the 
exception of the BRCT domain in the C-terminus of BRCA1, a domain found 
in more than 40 other genes associated with response to DNA damage. 
BRCA1 and BRCA2 are important components of the pathway that protects 
cells from the effects of DNA damage. The majority of mutations identified 
thus far lead to protein truncation, and it is believed that cancer then develops 
when the second copy is lost, with BRCA1 and BRCA2 behaving like classic 
tumour-suppressor genes, with the loss of one copy predisposing the carrier 
to the development of the characteristic cancers of this classic cancer 
syndrome (Petrucelli 2005).
Several lines of investigation have implicated BRCA1 and BRCA2 in DNA 
damage-response pathways. An association between BRCA1 and p53 and 
the subsequent enhancement of p53 activity incriminates BRCA1 in p21- 
mediated cell-cycle arrest following DNA damage In addition, BRCA1 forms 
complexes with both BRCA2 and Rad51 the human homolog of the 
Escherichia coli gene RecA, which is essential to normal recombination and
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genome stability. Co-localization of BRCA1, BRCA2, and Rad51 in “nuclear 
dot” structures is seen to disappear following treatment of cells with DNA- 
damaging agents that cause double-stranded chromosome breaks. In 
addition, mouse embryonic stem cells that are homozygous for BRCA1 null 
and BRCA2 truncations are hypersensitive to ionizing radiation and other 
forms of oxidative damage (Jin 1997, Kufe 2003).
BRCA1 may also play a role in transcription regulation, cell-cycle control, and 
development. Both BRCA1 and BRCA2 are nuclear proteins. BRCA1 
associates with a RNA polymerase holoenzyme and binds CREB implicating 
it in transcriptional regulation. BRCA1 protein levels are also altered by 
variations in hormone levels. During the cell cycle, BRCA1 and BRCA2 
mRNA levels increase from low levels at the start of G1 to maximum levels at 
the G1/S transition in parallel to cyclin A levels. Phosphorylation of BRCA1 
also occurs in a cell-cycle-dependent manner in sporadic breast cancer. 
Thompson etal. (1995) found that BRCA1 mRNA levels are markedly 
decreased during the transition from benign tumour to invasive cancer. 
Experimental inhibition of BRCA1 expression with antisense oligonucleotides 
produced accelerated growth of normal and malignant mammary cells but 
had no effect on non-mammary epithelial cells. They interpreted these results 
as indicating that BRCA1 may normally serve as a negative regulator of 
mammary epithelial cell growth and that this function is compromised in 
breast cancer, either by direct mutation or by alterations in gene expression.
1.5.2.6 WT1 and WT2
The principal gene for Wilms Tumour (WT1) is located on chromosome 
11 p13. There is a second predisposition locus (WT2) at 11 p15.5. The
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W H gene encodes a protein that suppresses transcription downstream from 
epidermal growth factor receptor 1 and insulin-like growth factor II. It is a zinc 
finger DNA-binding protein and acts as a transcriptional activator or repressor 
depending on the cellular or chromosomal context. It has 4 major isoforms, 
due to the insertion of 3 amino acids between zinc fingers 3 and 4, and the 
insertion of an alternatively spliced 17-amino acid segment encoded by exon 
5 in the middle of the protein (Hossain and Saunders, 2001). The 
conservation in structure and relative levels of the 4 WT1 mRNA species 
suggests that each encoded polypeptide makes a significant contribution to 
normal gene function. Haber et al., (1991) suggested that the control of 
cellular proliferation and differentiation exerted by the WT1 gene products 
may involve interactions between the 4 polypeptides with distinct targets and 
functions.
The candidate Wilms tumour gene was expressed specifically in the 
condensed mesenchyme, renal vesicle, and glomerular epithelium of the 
developing kidney, in the related mesonephric glomeruli, and in cells 
approximating these structures in tumours. Niksic et al. (2004) found that 
WT1 protein is not restricted to the nucleus and shuttles continuously 
between the nucleus and cytoplasm. The other main sites of expression were 
the genital ridge, fetal gonad, and mesothelium. This was interpreted as 
indicating that the anomalies of the urinary tract and genitalia, which are 
frequent in both sporadic and syndrome-associated Wilms tumours, are a 
pleiotropic effect of the W T1 gene.
1.5.2.7 NF1
NF1 is a large gene (59 exons) located on chromosome 17q11.2. The NF1
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gene encodes a GTP-activating protein known as neurofibromin. The gene 
product negatively regulates signals transduced by ras proteins. NF1 
functions as a tumour-suppressor gene in immature myeloid cells but 
inactivation of both NF1 alleles has not been demonstrated in leukaemic cells 
from patients with neurofibromatosis type 1 (Friedman 2002).
1.5.2.8 VHL
The von Hippel-Lindau tumour suppressor protein (pVHL) has been 
implicated in a variety of functions including transcriptional regulation, post- 
transcriptional gene expression, protein folding, extracellular matrix formation, 
and ubiquitinylation Normal pVHL binds to elongin C, which forms a complex 
with elongin B and cullin-2 (CUL-2). This complex resembles the SCF 
ubiquitin ligase or E3 complex in yeast that catalyzes the polyubiquitinylation 
of specific proteins and targets them for degradation by proteosomes. Under 
normoxic conditions, HIF1a is hydroxylated at two specific proline residues by 
a member of the EGLN family of prolyl hydroxylase enzymes. The VHL 
protein then binds to hydroxylated HIF1a and targets it for degradation.
Under hypoxic conditions, HIF1a is not hydroxylated, pVHL does not bind, 
and HIFIasubunits accumulate. H IFIaform s heterodimers with HIF1H and 
activates transcription of a variety of hypoxia-inducible genes (i.e., VEGF, 
EPO, TGF a, PDGF&). Likewise, when pVHL is absent or mutated, HIF1a 
subunits accumulate, resulting in cell proliferation and the neovascularization 
of tumours characteristic of VHL disease (Kaelin 2002).
1.5.2.9 Men1
Menin is a protein of 610 amino acids and is localised in the nucleus and has
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two nuclear localization signals near the carboxyl terminus. Menin does not 
show similarity with any other known protein. The MEN1 transcript has been 
detected in all human tissues.
Menin is widely expressed and may play different roles in different tissues. It 
is involved in the regulation of several cell functions, including DNA replication 
and repair, and in transcriptional machinery. Menin inhibits JunD-mediated 
transcriptional activation, as studies of deletion mutants have shown the 
existence of interacting regions of both the proteins. Menin inhibits JunD- 
mediated transcription by modification of chromatin structure recruiting a 
specific histone deacetylase targeted to a promoter by binding JunD. 
Moreover, when compared to controls, lymphocytes from individuals with a 
heterozygous MEN1 mutation show both premature division of the 
centromere and hypersensitivity to alkylating agents. Thus, menin is a 
negative regulator of cell proliferation after DNA damage 
Most germline or somatic mutations in the MEN1 gene predict truncation or 
absence of encoded menin. Similarly, 11 q13 loss of heterozygosity in 
tumours predicts inactivation of the other MEN1 copy. Neither the finding of a 
tumour suppressor mechanism nor the identification of binding partners has 
established the ultimate pathways of menin action in normal tissues or in 
tumours (Agarwal et al 2004).
1.5.2.10 PTCH
Johnson etal. (1996) cloned the human Drosophila patched (PTC) 
homologue gene by screening a human lung cDNA library with mouse PTC 
cDNA clones. They assembled 5.1 kb of contiguous sequence containing a 
4.5-kb open reading frame that encodes a 1,447-amino acid protein. The
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predicted amino acid sequence has 96% identity to mouse and a 40% identity 
to Drosophila PTC proteins. The hydrophobic PTC protein is predicted to 
contain 12 membrane-spanning domains and 2 large hydrophilic extracellular 
loops. PTC acts as a receptor for Sonic hedgehog (Shh) proteins, which are a 
family of secreted signal molecules that act as local mediators in many 
developmental processes in both invertebrates and vertebrates.
Abnormalities in the hedgehog pathway during development can be lethal and 
in adult cells can also lead to cancer. High levels of PTC induced by Shh 
serve to sequester free Hh and therefore create a barrier to its further 
movement. (Chen and Struhl 1996).
1.5.2.11 SMAD4
The protein product of this gene is a tumour suppressor that is critical for 
transmitting signals from TGFp by mediating transcriptional activation of 
target genes by interaction with Smad4-interacting transcriptional co-activator 
(SMIF) protein. The proteins form a mRNA de-capping complex, a key factor 
in the regulation of mRNA decay (Haidle & Howe 2006).
1.5.2.12 E-Cadherin
Cadherins are transmembrane glycoproteins that mediate extracellular 
calcium-dependent cell-cell interactions (Jou et al 1995). E-Cad is involved in 
epithelial cell-cell communication and is localised to the cell membrane in 
adherent junctions. E-Cad functions as a metastasis suppressor molecule in 
several cell lines. Semb and Christofori (1998) showed that loss of gene 
expression was correlated with increased invasiveness and metastatic 
potential, and replacement or augmentation of gene expression resulted in
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suppression of the invasive phenotype.
1.5.2.13 LKB1/STK11
Loss of STK11 is associated with gastrointestinal polyposis. This 
serine/threonine-protein kinase has a prenylation motif suggesting that it is 
involved in protein-protein interactions and membrane binding. The predicted 
protein structure also shows an autophosphorylation domain along with a 
cylic AMP-dependent protein kinase phosphorylation site. STK11 expression 
was shown to cause apoptosis in epithelial cells. The transport of STK11 to 
the mitochondria appears to be an early step in apoptosis. STK11 co- 
localises with p53 during apoptosis. The ability of STK11 to induce apoptosis 
also depends upon p53. These results suggest that signalling through STK11 
may be an early event leading to apoptosis through p53 pathways.
Truncating mutations prior to amino acid 311 abrogate the kinase activity of 
STK11 (Jenne etal. 1998).
1.5.2.14 SNF5/INI1
The INI1 gene encodes a member of the SWI/SNF ATP-dependent 
chromatin-remodelling complex and is the target of recurrent loss-of-function 
alterations in renal and extra renal malignant rhabdoid tumour (MRT), a highly 
aggressive Wilms-like tumour. The observation of biallelic, truncating 
mutations on chromosome 22 in tumours strongly supports the hypothesis 
that hSNF5/INI1 is a new tumour-suppressor gene consistently inactivated in 
MRT. In addition to somatically acquired alterations, constitutional mutations 
of this gene also have been observed very recently in patients with MRT 
(Versteege 1998).
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1.5.2.15 EXT1 and EXT2
These two genes are associated with d-glucuronyltransferase and N-acetyl-d- 
glucosaminyltransferase reactions in heparan sulfate biosynthesis, Heparan 
sulphate (HS) proteoglycans occur at cell surfaces and in the extracellular 
matrix of most tissues. A two-hit mutational model was proposed for EXT 1 
and EXT2 in the formation of exostoses, based on the observation of loss of 
heterozygosity in chondrosarcomas. The protein product also participates in 
cell signalling and chondrocyte proliferation and differentiation, roles which 
are thought to give rise to their tumour suppressor function (Schmale 2005).
1.5.2.16 Tuberous sclerosis complex
The TSC1 gene at 9q34 encodes the protein hamartin and TSC2 at 16p13.3 
encodes the protein tuberin. Tuberin has GTPase-activating protein functions 
for the small G-proteins (R apla and Rab5) and functions as a major regulator 
of small G-protein Rheb and downstream pathway on protein translation, 
growth and cell proliferation. Hamartin interacts with the ezrin-radxin-moesin 
(ERM) family of actin-binding proteins Hamartin also regulates the cell cycle 
through interacting with CDKs. The two proteins form heterodimers, 
suggesting that they may act in concert to regulate cell proliferation. Most 
recently, tuberin and hamartin were shown to be key regulators of the AKT 
pathway and to participate in several other signaling pathways including the 
MAPK, AMPK, b-catenin, calmodulin, MTOR/S6Kinase, CDK, and cell cycle 
pathways. (Crino et al. 2006)
1.6 Blood cell Production
All cells in the blood cell compartment are produced from a quiescent
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undifferentiated “stem” cell. Subsequent stimulation leads these cells to self- 
renew or differentiate into cells of the appropriate lineage. This differentiation 
is associated with a loss of self renewal capacity and increased proliferation 
rates (Hoffbrand et al. 2006). The progenitor cells are named according to 
their ability to form colonies of haemopoetic cells in a semi-solid growth 
medium. The earliest colony forming unit (CFU) BLAST contains cells that 
give rise to a progenitor termed the CFU-GEMM (granulocyte, erythroid, 
macrophage and megakaryocytic). These cells are capable of differentiating 
into other lineages (but no longer have the capacity of self renewal) via more 
terminally differentiated CFUs such as CFU-GM. The entire differentiation 
process in normal haematopoiesis is modulated by a series of growth factors 
or colony stimulating factors, some with broad spectrum modes of action, 
some specific for a particular lineage (Hoffbrand et al. 2006)
1.7 Haematoloaical malignancy
All of the cellular components of the haemopoetic system, composed of 
erythroid, myeloid, lymphoid and megakaryocytic lineages, are affected by 
malignancy. The various disorders have historically been classified, grouped 
and sub-grouped according to the cell type from which the malignant clone 
arose and the degree of maturation/differentiation of the malignant cells. More 
recent classification systems have veered towards classes delineated in 
terms of common genetic lesions in the first instance and then levels of 
differentiation as a secondary class (Appendix I and II).
Whatever the cell of origin, the malignant phenotype results in mitotic division 
in successive generations until, when sufficiently large, the clonal population 
causes clinically apparent disease. Diffuse tumours such as leukaemias
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display a smaller number of mutations that solid tumours and this is borne out 
by the more rapid appearance of leukaemia after the initial mutagenic episode 
that solid tumours (Volgestein and Kinzler 1998). Because a normal 
haemopoietic stem cell (HSC) and leukaemic stem cell (LSC) share various 
developmental pathways and the ability to self-renew, it is possible that 
LSCs are HSCs that have become leukaemic as the result of accumulated 
mutations. In contrast to other more differentiated cells, HSCs have the 
machinery for self-renewal already activated and therefore may require fewer 
mutations to maintain a leukaemic phenotype. HSCs also persist throughout 
life and therefore have greater opportunities to accumulate mutations than 
more mature cells, which persist only for a short period (Passegue et al.
2003).
1.7.1 Chronic myeloid (or myelogenous) leukaemia (CML)
CML occurs with greatest frequency at age > 50 years. It has an incidence of 
1-2 per 100000 per person per annum. Although the condition is rare it 
constitutes 20% of all types of adult leukaemia (Faderl 1999). Patients with 
CML are often asymptomatic at diagnosis, and present incidentally with an 
elevated white blood cell count on a routine laboratory test. CML must be 
differentiated from reactive neutrophilia due to infection, which can have a 
similar appearance on a blood smear (Faderl 1999).
Symptoms of CML may include: tiredness, low-grade fever, susceptibility to 
infections, anaemia, and thrombocytopenia with easy bruising and, 
paradoxically, thrombocytosis in some CML cases. Splenomegaly may also 
be present (Savage et al. 1997).
CML is amongst the most studied of leukaemias, if not all cancers, in terms of
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its cellular and molecular biology. It serves here as a useful model to describe 
the events surrounding the generation of neoplastic disease. The intensity of 
study was prompted by the fact that CML was the first neoplastic disease to 
be associated with a consistent chromosomal abnormality and the first to be 
characterised as a clonal disorder. The chromosomal abnormality was 
described by Nowell and Hungerford (1960) as a loss of the long arm of what 
was thought to be chromosome 21. Improved Giemsa banding techniques 
allowed Rowley (1973) to identify accurately the “Philadelphia chromosome” 
(Ph) as involving a reciprocal translocation between the long arms of 
chromosomes 9 and 22 (fig. 1.7.1). The presence of the translocated 
chromosome in myeloid erythroid and megakaryocytic cell lineages 
suggested that the disease resulted from a defect in a “pluripotent” or non- 
terminally differentiated progenitor cell. Fialkow et al (1977) demonstrated the 
clonal nature of CML by observing a single glucose 6 phosphate 
dehydrogenase isoform in CML affected cells of a patient that were otherwise 
heterozygous for this disease.
The typical course of the disease is presentation with the “chronic” phase 
consisting of an indolent leukocytosis consisting predominantly of mature 
polymorphonuclear neutrophils in bone marrow, peripheral blood, and 
extramedullary sites. These cells have essentially normal morphology and 
function but are present in blood at 10-100 times their normal numbers. The 
myeloid progenitor cell constituting the majority of the tumour load has, like its 
normal counterpart, a normal response to positive and negative growth and 
differentiation stimulants. The median duration of the chronic phase has 
historically been about 3 years after which the biology of the disease
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Figure 1.7.1
Schematic view of the formation of the Philadelphia chromosome with the 
reciprocal translocation of chromosomes 9 and 22
Fig 1.7.1 Schematic view of formation of Philadelphia chromosome.
Reciprocal translocation occurs between chromosomes 9 and 22 resulting in a longer chromosome 9 and shorter 
(Philadelphia) chromosome 22. Chimeric fusion genes Bcr/Abl and Abl/Bcr result from translocation (Kimball 2003)
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becomes more aggressive. The “accelerated phase” phase lasts 4 to 6 
months and is characterized by an increase in disease burden and in the 
frequency of progenitor/precursor cells rather than terminally differentiated 
cells. Bone marrow progenitors progressively lose their ability to differentiate 
leading to a proliferation of undifferentiated blast cells that fill the bone 
marrow cavity and lead to the final phase and bone marrow failure. This 
phase is referred to as “blast crisis" and is morphologically similar to acute 
leukaemia. The variable lineage of the blast cells at this stage confirms the 
primary disorder as a stem cell defect with cells appearing from myeloid, 
lymphoid, erythroid, megakaryocytic o rT  cell lineages (Geary 2000).
The Ph chromosome is present in 95% of CML cases and a smaller 
proportion of other acute leukaemias and, at the molecular level, leads to the 
translocation of a proto-oncogene, c-abl from chromosome 9 to 22. c-abl is 
the human equivalent of the transforming element of the Ableson murine 
leukaemia virus, known as v-abl, which causes pre B-cell leukaemia in mice. 
The translocation leads to the formation of a chimeric gene with the 3’ section 
of the Abl sequence and the 5’ section of a gene termed Bcr (breakpoint 
cluster region) (Sawyers1999).
1.7.1.1 Abl.
The human Abl gene encodes a tyrosine kinase that is a ubiquitously- 
expressed 145-kd protein with 2 isoforms arising from alternative splicing of 
the first exon (Deininger et al 2000). Several structural domains can be 
defined within the protein. Three homology domains (SH1-SH3) are located 
toward the N terminus. The SH1 domain carries the tyrosine kinase function, 
whereas the SH2 and SH3 domains allow for interaction with other proteins.
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Proline-rich sequences in the centre of the molecule can, in turn, interact with 
SH3 domains of other proteins. Nuclear localization signals and DNA-binding 
and actin-binding motifs are encoded toward the 3' end of the Abl gene. 
Studies in fibroblasts have revealed that Abl serves a complex and ill-defined 
role as a cellular element that modulates signals from various extra-cellular 
and intra-cellular sources that influence the cell cycle and apoptosis (Barila 
and Superti-Furga 1998).
1.7.1.2 Bcr
The 160-kd Bcr protein, like Abl, is ubiquitously expressed and encodes a 
serine-threonine kinase in the first N-terminal exon. The substrate of this 
kinase may be Bcr itself as a coiled-coil domain at the N-terminus of Bcr 
allows dimer formation in vivo. Bcr contains a binding site for growth factor 
receptor binding protein (GRB-2) (Calabretta and Perrotti 2004) and in 
addition, Bcr can be phosphorylated on several tyrosine residues, especially 
tyrosine 177. The exact physiological role of Bcr is unclear and confounded 
by the fact that Bcr knockout mice are viable. Maru and Witte (1991) reported 
that the first exon of Bcr encodes a novel serine/threonine kinase domain. 
Regardless of the exact location of the translocation breakpoint, splicing of the 
primary hybrid transcript yields an mRNA molecule in which Bcr sequences 
are fused to Abl exon a2 giving rise to a chimeric protein of between 190 and 
230 Daltons, (commonly 210). The variable character of the Bcr component 
and constant nature of Abl suggests Abl is responsible for the transforming 
principle.
The transforming ability of Abl mutants is activated by loss of the SH3 domain 
which appears to regulate the activity of the protein. In v-abl, the domain is
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replaced by viral gag sequences; in CML, by Bcr sequences. Mechanisms 
implicated in the pathogenesis of CML include decreased adhesion to bone 
marrow stroma cells and extracellular matrix, deregulated mitogenic signaling 
and reduced apoptosis (Pane et al. 2002).
Adhesion to stroma negatively regulates cell proliferation, and CML cells 
escape this regulation by virtue of their perturbed adhesion properties. 
Interferon-ot (IFN-oc), an active therapeutic agent in CML, appears to reverse 
the adhesion defect (Karti et al. 2002)
1.7.1.3 Bcr/Abl and the PI3 kinase pathway.
PI3 kinase activity is required for the proliferation of Bcr/Abl-positive cells. 
Bcr/Abl forms multimeric complexes with PI3 kinase, Cbl, and the adapter 
molecules Crk and Crkl, in which first, PI3 kinase and then Akt is activated. 
Akt is implicated in anti-apoptotic signalling (see fig 1.8.2) (Garcia 2006). Akt 
is in the downstream cascade of the IL-3 receptor and the pro-apoptotic 
protein Bad is a key substrate of Akt. Phosphorylated Bad is inactive because 
it is no longer able to bind anti-apoptotic proteins such as Bclxi_and it is 
trapped by cytoplasmic 14-3-3 proteins. Together this indicates that Bcr/Abl 
might be able to mimic the physiologic IL-3 survival signal in a PI3 kinase- 
dependent manner. Ectopic expression of a mutant form of BAD, which 
cannot be phosphorylated by Akt, induces massive apoptosis, suggesting that 
inactivation of BAD proapoptotic effects is important for survival of Bcr/Abl - 
expressing cells. Ship and Ship-2 inositol phosphatases modulate PI3-kinase 
signalling and are activated in response to growth factor signals and by 
Bcr/Abl. Bcr/Abl interacts indirectly with the p85 regulatory subunit of PI-3K 
via GRB-2/Gab2 and this appears pathologically relevant because Gab2-
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deficient marrow cells are resistant to Bcr/Abl transformation (Sattler et al. 
2002). Thus, Bcr/Abl has a profound effect on phosphoinositol metabolism, 
which might mimic growth factor stimulation.
1.7.1.4 Bcr/Abl and Ras activation
Bcr/Abl activates several substrate proteins that are in turn responsible for 
holding Ras in its phosphorylated conformation. Unlike most other solid 
tumours affected by Ras, CML cells show low rates of Ras mutation. Ras is 
expressed constitutively in CML without direct activation by mutation and 
down-regulation of this pathway in vitro suppresses proliferation and 
sensitizes cells to apoptotic stimuli (Sawyers et al 1995). Negative signalling 
through the SHIP phosphatases discussed above appears to inhibit the ras 
pathway by competition with grb2 and she for SH2 domain binding (Kashige 
2000)
1.7.1.5 STAT5 pathway
STAT5 is activated by Bcr/Abl via the Src family haematopoietic cell kinase 
(HcK). On interaction with the SH3 and SH2 domains of Bcr/Abl, HcK is 
activated and phosphorylates tyrosine 699 of STAT5B, leading to its 
translocation to the nucleus where it functions as a transcription factor. 
Nieborowska-Skorska et al. (1999) showed that mutants defective in STAT5 
activation were less efficient than the wild-type form in transformation of 
32Dcl3 myeloid precursor cells. Furthermore, a constitutively active STAT5 
mutant rescued the leukemogenic potential of STAT5 activation-deficient 
Bcr/Abl mutants and ectopic expression of a dominant-negative STAT5 
mutant suppressed Bcr/Abl -dependent transformation of primary mouse
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marrow cells. The role of STAT5 is likely to depend on transcriptional 
activation of the target genes potentially involved in Bcr/Abl 
leukaemogenesis, such as the antiapoptotic Bcl-XL gene (Horita etal. 1999).
1.7.1.6 Apoptosis in CML
The effect of Bcr/Abl expression on apoptosis is demonstrated by the failure 
of apoptosis in response to removal of growth factors in factor dependent cell 
lines expressing the Bcr/Abl protein and this resistance to apoptosis has 
been shown to correlate with activation of Ras. Bcr/Abl positive cells also 
show resistance to apoptosis induced by DNA damage. It is suggested that 
Bcr/Abl may inhibit apoptosis by blocking the release of cytochrome c from 
mitochondria, thus blocking caspase activation (Wang 2000). Bcr/Abl has 
been shown to up-regulate Bcl-2 in a Ras or a PI3 kinase-dependent manner 
in Baf/3 and 32D cells, respectively. Another link between Bcr/Abl and the 
inhibition of apoptosis might be the phosphorylation of the pro-apoptotic 
protein Bad. In addition to Akt, Raf-1, immediately downstream of Ras, 
phosphorylates Bad on 2 serine residues. Two studies (Neshat et al. 2000, 
Keeshan et al. 2002) provide evidence that the survival signal provided by 
Bcr/Abl is at least partially mediated by Bad and requires targeting of Raf-1 to 
the mitochondria. It is also possible that Bcr/Abl inhibits apoptosis by down- 
regulating the interferon consensus sequence binding protein (ICSBP). 
Furthermore, ICSBP knockout mice develop a myeloproliferative syndrome, 
and haemopoietic progenitor cells from ICSBP2/2 mice show altered 
responses to cytokines (Hao and Ren 2000).
Thus, Bcr/Abl may shift the balance towards the inhibition of apoptosis while 
simultaneously providing a proliferative stimulus. This is in line with the
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concept that a proliferative signal leads to apoptosis unless it is 
counterbalanced by an anti-apoptotic signal, and Bcr/Abl fulfils both 
requirements at the same time.
1.7.1.7 The cell cycle in CML
Early reports of higher than normal frequency of actively cycling progenitors in 
CML (Eaves et al. 1986) coexist with studies that failed to find increased cell 
proliferation rates in CML (Kramer etal. 2001). Subsets of very immature 
CML progenitors survive and proliferate in vitro in the absence of exogenous 
growth factors, whereas their normal counterparts die rapidly underthe same 
conditions. By contrast, more differentiated subsets appear to lack the 
capacity for autonomous growth in vitro. Expansion of myeloid progenitors is 
caused by p210Bcr/Abl expression in primitive progenitors; that is these cells 
would normally remain quiescent, but Bcr/Abl may promote cell division to 
maintain the pool of stem cells and to generate committed late progenitors. 
Primitive CML progenitor cells appear to have a greater proportion of cycling 
cells than normal progenitors,whereas Clarkson etal. (1998)found the more 
abundant, committed CML progenitors might have a lower proliferative 
potential of their normal counterpart.
Exit from quiescence induced by Bcr/Abl in primitive progenitor cells may 
depend on its effect on cyclins and Cdk inhibitors (Deininger et al. 2002). 
Cyclin D2 levels are increased in Bcr/Abl -expressing lymphoblasts and are 
required for stimulation of proliferation induced by Bcr/Abl in these cells, and 
down-regulation or cytoplasmic relocation of CdkN1 B/p27 has been 
demonstrated in mouse and human lymphoid and myeloid Bcr/Abl - 
expressing cells (Jena et al. 2002). As mentioned above, p27 Cdk inhibitor
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maintains quiescence and thus regulates the expansion of haematopoietic 
stem cells and early progenitors. The ability of Bcr/Abl to modulate levels of 
cyclin and Cdk inhibitors may promote the entry of primitive haematopoietic 
cells into the cell cycle. Autocrine production of interleukin 3 (IL-3) by primitive 
CML progenitors is proposed as a mechanism causing the initial expansion of 
these cells and would, in turn, increase cyclin D2 and down-regulate p27 
levels, possibly allowing CML primitive progenitors to leave quiescence and 
start cycling (Eaves et al. 2003).
A possible explanation for the different effects induced by endogenous 
Bcr/Abl in the CD34+ and CD34' subset may rest in its levels of expression; 
low levels of Bcr/Abl expression typically found in most CML cells may be 
sufficient for anti-apoptotic, but not for proliferative signals, whereas higher 
levels of Bcr/Abl expression in the more primitive subsets of CD34+ cells may 
be sufficient for both anti-apoptotic and proliferative signals (Calabretta and 
Perrotti 2004).
1.7.1.8 Progression to Blast Crisis
The mechanisms underlying the blast phase/crisis (BC) process are poorly 
understood. There is no specific genetic change associated with disease 
transformation, though p16 p53 and Rb have been implicated. It is suggested 
that a variety of cooperating genetic lesions are responsible (Melo 1996). p53 
is mutated in approximately 30% of blast cell crisis cases Bcr/Abl expression 
leads to enhanced expression of the low fidelity DNA polymerase p, and it is 
suggested that this in turn leads to the accumulation of genetic lesions 
amongst the rapidly proliferating cells of the chronic phase (Calabretta and 
Perrotti 2004). This is compounded by the possibility that Bcr/Abl inactivates
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(by phosphorylation) the error prone DNA repair mechanism associated with 
xeroderma pigmentosum group B protein (Takeda etal. 1999). Bcr/Abl may 
also deregulate expression of critical genes involved in monitoring and repair 
of DNA damage such as RAD51, DNA-PKcs, and BRCA-1. Thus, Bcr/Abl 
expression is consistent with the phenotype of these cells and implicates 
reduced apoptosis susceptibility and enhanced proliferative potential of 
specific cell subsets in progression to blast phase. The vast majority of 
secondary changes leading to blast crisis involve genes encoding nucleus- 
localized proteins that directly or indirectly regulate gene transcription; 
mutations/loss of function of tumour suppressor genes is predominant over 
mutation/activation of oncogenes; and p53 is genetically or functionally 
inactivated in a large fraction of CML BC cases (Melo and Deininger 2004) 
Several other haematological malignancies are associated with varying 
degrees to specific genetic lesions, though with the exception of the recently- 
discovered V617F mutation in the Jak2 Janus kinase gene and 
polycythaemia vera, few show the same specificity for a given phenotype as 
that seen in CML (Kralovics et al. 2005)
1.8 PTEN tumour suppressor protein
The common involvement of phosphorylation in the activation of oncogenes 
led to the hypothesis that a tumour suppressor protein with phosphatase 
function may exist. This was confirmed with the discovery of PTEN. Li et al. 
(1997) noticed loss of heterozygosity (LOH) at 10q23 as an alteration that 
occurred at high frequency in a variety of human tumours. Although rarely 
seen in low-grade glial tumours and early-stage prostate cancers, LOH at 
10q23 occurs in approximately 70% of glioblastomas (the most advanced
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form of glial tumour) and approximately 60% of advanced prostate cancers. 
(Li et al. 1997) The finding that wild-type chromosome 10 suppresses the 
tumourigenicity of glioblastoma cells in mice suggested that 10q23 may 
encode a tumour suppressor gene. Li et al. (1997) mapped homozygous 
deletions on 10q23 and isolated a candidate tumour suppressor gene that 
they called PTEN for “phosphatase and tensin homolog” deleted on 
chromosome ten. Steck etal. (1997) independently isolated the same gene 
(termed MMAC1) by exon trapping.
1.8.1 Structure of PTEN
Sequence analysis of the predicted 403-amino ORF revealed a protein 
tyrosine phosphatase domain with a large homologous region to chicken 
tensin, a protein that interacts with actin filaments at focal adhesions and 
bovine auxilin. The preliminary homologies discovered in PTEN structure 
suggested a tumour suppressor function exerted by opposing tyrosine 
kinases action and by modulating tumour cell metastases by interaction at 
focal adhesions.
Lee etal. (1999) determined PTEN’s crystalline structure and revealed an N- 
terminal phosphatase domain and a tightly associated C-terminal C2 domain. 
These two domains together form a minimal catalytic unit, and comprise 
almost the entire protein, excluding only a very short N-terminal tail and a 
longer 50-amino-acid C-terminal tail. The phosphatase and C2 units form the 
catalytic domain, whilst the terminal sections appear to regulate function and 
localisation. The N-terminal sequence contains a polybasic motif, extending 
into the start of the phosphatase domain, with sequence similarity to that 
found in proteins that have been proposed to bind PI2 (Walker et al. 2004).
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PTEN is a member of the PTP enzyme family, all of which have a reactive 
active-site cysteine residue for catalysis, which are sensitive to oxidation 
involving the formation of a disulphide bond between the active site and an 
adjacent cysteine residue (fig 1.8.1) (Lee etal. 2002).
The longer C-terminal tail in PTEN contains a cluster of serine and threonine 
residues that become phosphorylated in many cells. Raftopoulou et al. (2004) 
have shown that expression of the C2 domain of PTEN alone, in the absence 
of the phosphatase domain, is able to suppress cellular motility. These 
findings suggest a function for PTEN in addition to its ability to remove 
phosphate groups from its substrate molecule. Their study also provided 
evidence that a weak protein phosphatase activity in PTEN acts to 
dephosphorylate its own C-terminal phosphorylation sites.
1.8.2 Function of PTEN
PTEN has been shown to be primarily a lipid phosphatase and a ubiquitous 
regulator of the cellular PI (phosphoinositide) 3-kinase signalling pathway 
This signalling pathway is characterized by the regulated activation of class I 
PI3-kinase enzymes, producing the second messenger PI3 from its relatively 
abundant precursor PI2 which is profuse in the interior of the phospholipid cell 
membrane. Inositol is a sugar-like molecular having a circular six-carbon ring 
structure that can be reversibly
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Fig 1.8.1
Proposed structure of PTEN
PTEN
Ptdlns(4,5)P2 binding site
PDZ binding site
Phosphorylation sites
Cys-71 Cys-124
15 Phosphatase 186 C2 3 5 2  4 0 3
Fig 1.8.1
Proposed PTEN structure showing N terminal PI binding site, catalytic phosphatase site and phosphorylation sites 
on tail at carboxy terminus end (Leslie and Downes 2004)
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phosphorylated at free carbon groups. PI3 mediates downstream signalling 
through a range of effector proteins, including the proto-oncogene product 
Akt/protein kinase B that are able to recognize this lipid and bind it selectively. 
PTEN antagonizes PI3-kinase signalling by dephosphorylating the 3-position 
of the inositol ring of PI3 and thus inactivating downstream signalling (Fig 
1.8.2). Although other 3-phosphorylated inositol lipids and phosphates have 
been proposed as substrates for PTEN, current evidence indicates that PI3 
may well be its only important physiological substrate of this type (Leslie and 
Downes 2004).
Over expression of PTEN in MCF-7 breast cancer cells causes G1 arrest 
followed by cell death. Weng et al. (2001a) demonstrated increased PTEN- 
mediated cell death of MCF-7 breast cancer cells cultured in low levels of 
growth factors. The caspase-9-specific inhibitor ZVAD blocked PTEN-induced 
cell death without altering the effect of PTEN on cell cycle distribution. Over 
expression of dominant-negative Akt, a downstream protein kinase, induced 
more cell death but had less effect on the cell cycle than over expression of 
PTEN. The authors suggested that the apoptotic cells induced by the over 
expression of PTEN are not derived from the G1-arrested cells. Further, they 
hypothesized that the effect of PTEN on cell death is mediated through the 
PI3K/Akt pathway, whereas PTEN-mediated cell cycle arrests depend on 
both PI3K/Akt-dependent and -independent pathways (Weng etal. 2001b).
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Fig 1.8.2
Proposed function of PTEN
Receptor
Ptdlns(3,4,5)P3 Ptdlns(3,4)P2
SHIP
PI3K
PKB/Akt and other targets
?
Growth
Proliferation
Survival
Motility
Polarity
Fig 1.8.2
Proposed function of PTEN (Leslie and Downes 2004). Binding of extracellular ligand stimulates phosphorylation (by 
PI3 kinase PI3K) and activation of membrane phospholipid -  phosphatidyl inositol. Phosphorylation results in 
downstream activation of Akt and subsequent growth/proliferation signal.
PTEN phosphatase returns membrane phospholipids to inactive form by removing the 3’ inositol ring phosphate and 
abrogating proliferation/growth signal. Src-homology 2-containing inositol 5' phosphatase (SHIP) also 
dephosphorylates PI3 at the V site but may not abrogate activation of Akt (Choi etal. 2002)
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1.8.2.1 PTEN Protein Phosphatase function
PTEN also has a weak protein phosphatase activity, and several target 
proteins have been proposed, including PTEN itself (see below) and the 
platelet-derived growth factor receptor, which may form a complex with 
PTEN. Resolving whether these proteins are physiological substrates for the 
phosphatase is an important area for future work. Leslie et al. (2007) reported 
that a PTEN mutant (G129E) with only protein phosphatase activity is capable 
of inhibiting the epithelial-to-mesenchymal transition of chick embroyo 
mesoderm cells ingressing through the anterior and middle primitive streak 
during embryo development. Directional motility of mesoderm cells during 
embryo development was dependent on PTEN’s lipid phosphatase activity.
The PI3K/Akt pathway is also involved in down-modulating the expression or 
the function of the CDK inhibitor p27. Akt directly phosphorylates p27 and 
prevents its nuclear translocation. Activated mutants of Akt induce down- 
regulation of p27, which is prevented by proteasome inhibitors, 
suggesting that Akt modulates p27 stability. It is unclear whether 
phosphorylation by Akt leads to p27 degradation or whether other Akt- 
dependent mechanisms are involved in this process. Regardless of the 
mechanisms, Bcr/Abl-activated Akt may enhance the proliferative potential of 
Bcr/Abl-expressing cells by disruption of p27 activity (Wu et al. 2003).
Weng et al. (2001 b) further demonstrated that over expression of wildtype 
PTEN leads to the suppression of cell growth through the blockade of cell 
cycle progression, an increase in the abundance of p27, a decrease in the 
protein levels of cyclin D1, and the inhibition of Akt phosphorylation.
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1.8.2.3 Role of PTEN in the Nucleus
Shen etal. (2007) reported a function for PTEN in the nucleus in controlling 
chromosomal integrity. Mutation of PTEN leads to centromere breakage and 
increased chromosomal translocations. PTEN was physically associated with 
CENP-C (an integral component of the kinetochore) at the centromeres. Shen 
et al. (2007) reported that PTEN with C-terminal mutations disrupted the 
association of PTEN with centromeres and caused centromeric instability. 
PTEN null cells also exhibit spontaneous DNA double-strand breaks. The 
group suggested that PTEN maintains chromosomal stability by physical 
interaction with centromeres and control of DNA repair, possibly by 
stimulation of Rad51 expression.
Denning et al. (2007) identified a short sequence in the N-terminal region of 
PTEN required for cytoplasmic localization which they denoted as a 
cytoplasmic localization signal. Mutations within this region induced nuclear 
localization and impaired growth suppression activities of PTEN while 
maintaining lipid phosphatase activity. Denning et al. (2007) ascribed to this 
signal a function as a nuclear export or as a cytoplasmic retention signal of 
PTEN.
Trotman etal. (2007) suggested that nuclear PTEN is essential for tumour 
suppression and that PTEN nuclear import is mediated by its 
monoubiquitination. A lysine mutant of PTEN, associated with Cowden 
syndrome, retains catalytic activity but fails to accumulate in nuclei of patient 
tissue due to an import defect. The group identified several lysine residue as 
major monoubiquitination sites essential for PTEN import. While nuclear 
PTEN was stable, polyubiquitination lead to its degradation in the cytoplasm. 
Thus, mutations of PTEN target its posttranslational modification and controls
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tumour progression by differentiating between degradation and protection of 
PTEN. The group suggested that failure of tumour suppression could occur in 
PTEN with normal enzyme activity but incorrect post translational modification 
and subsequent ubiquitination leading to aberrant localisation in the nucleus.
1.8.2.4 PTEN and Chemotaxis
Cell migration is inhibited by overexpression of PTEN but is enhanced when 
low levels of PTEN are induced by an antisense silencing method. Integrin- 
mediated cell spreading and the formation of focal adhesions are down 
regulated by wildtype PTEN but not by PTEN with an inactive phosphatase 
domain. PTEN interacts with the focal adhesion kinase FAK , reducing its 
tyrosine phosphorylation. Overexpression of FAK partially antagonizes the 
effects of PTEN. Thus, PTEN phosphatase may function as a tumour 
suppressor by negatively regulating cell interactions with the extracellular 
matrix Tamura et al. (1998)
Raftopoulou et al. (2004) demonstrated that PTEN inhibits cell migration 
through its C2 domain, independent of its lipid phosphatase activity. This 
activity depends on the protein phosphatase activity of PTEN and on the 
dephosphorylation at a single residue, threonine-383. Raftopoulou et al.
(2004) suggested that the ability of PTEN to control cell migration through its 
C2 domain is likely to be an important feature of its tumour suppressor 
activity. Nishio et al. (2007) showed that, in contrast to their study of the 
phosphatase SHIP1, bi-allelic loss of PTEN had no impact on neutrophil 
chemotaxis. Subramanian etal. (2007) studied PTEN function in cells in 
which PTEN was disrupted only in myeloid-derived cells. Neutrophils studied 
in chemotaxis assays displayed small but significant errors in directionality.
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Chemoattractant-stimulated myeloid cells lacking PTEN showed significantly 
higher Akt phosphorylation and actin polymerization. Overall, chemotaxis was 
not affected. Because of the increased responsiveness of PTEN deficient 
neutrophils, the in vivo recruitment to the inflamed peritoneal cavity was 
significantly enhanced (Subramanian et al. 2007).
1.8.3 Regulation of PTEN
1.8.3.1 C terminus and PTEN regulation
PTEN lacks obvious regulatory domains, and appears to have relatively high 
constitutive phosphatase activity, both in vitro and in vivo (Leslie and Downes 
2004). This contrasts with other PI3 phosphatases such as the SHIP 
phosphatases, that are tightly regulated, with low basal cellular activity. Cells 
lacking PTEN expression have been found to have greatly elevated basal PI3 
levels, whereas cells lacking SHIP demonstrate a greater magnitude and 
duration of stimulated rises in the levels of this lipid (Stambolic etal. 1998). 
Stambolic et al. (2001) identified a p53-binding element directly upstream of 
the PTEN gene. Deletion and mutation analyses showed that this element is 
necessary for inducible transactivation of PTEN by p53. A p53-independent 
element controlling constitutive expression of PTEN was also identified. In 
contrast to p53 mutant cell lines, induction of p53 in primary and tumour cell 
lines with wildtype p53 increased PTEN mRNA levels. Thus, the primary 
control of PTEN levels may be exercised by modulation of protein production 
levels.
Other studies suggest a model for PTEN regulation in which phosphorylation 
plays a major role through induction of a conformational switch. Most cellular 
PTEN appears to be phosphorylated at a cluster of serine and threonine
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residues in the acidic stretch of the C-terminal tail. In this form, PTEN appears 
monomeric and cytosolic (Vazquez et al. 2000)
Using PTEN mutants in which the putative phosphorylation sites were 
changed to alanine residues, it has been inferred that dephosphorylation 
makes PTEN highly susceptible to proteolysis, increases its affinity for anionic 
lipids and enhances its localization to the plasma membrane. Also, non- 
phosphorylatable PTEN mutants have greatly enhanced biological activity in 
cells, presumably due to co-localization with their membrane-incorporated 
substrate. It has been proposed that the dephosphorylation of these C - 
terminal residues causes a conformational opening up of the protein that 
mediates many of these effects of phosphorylation (Leslie and Downes 2004). 
Dephosphorylated PTEN is more sensitive to protease digestion in vitro, it 
interacts much more efficiently with some protein binding partners and also 
associates more effectively with cellular membranes. It is likely that the 
opening up of the dephosphorylated PTEN structure reveals the basic regions 
in PTEN that can mediate its binding to acidic membranes, and that in the 
phosphorylated protein, these basic regions are hidden, perhaps through 
direct interaction with the highly acidic phosphorylated C-terminus tail region 
(Leslie and Downes 2004).
It has been proposed that the PTEN C-terminus is phosphorylated by the 
protein kinase CK2 (Torres and Pulido 2001), which is constitutively active. 
This kinase phosphorylates PTEN at several C-terminal residues in vitro, and 
inhibitors of CK2 greatly decrease PTEN phosphorylation in cells, though the 
inhibitors are weak and non-specific, so this mechanism is putative. 
Nevertheless, most cellular PTEN appears to be maintained in a 
phosphorylated, inactive state, and its transient activation can be mediated
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through dephosphorylation (Sarno et al. 2003).
The above mechanism suggests a potential feedback control mechanism and 
it is possible that PTEN may initiate this regulatory switch itself (Fig 1.8.3), 
through dephosphorylation of Thr-383, by its own weak protein phosphatase 
activity. This idea is supported by the finding that phosphatase-inactive PTEN 
mutants are found to be more highly phosphorylated upon C-terminal 
residues than the wild-type enzyme (Birle et al. 2002).
Odriozola et al. (2007) investigated the role of PTEN C-terminal tail domain in 
regulating its membrane-targeting and catalytic functions. Characterization of 
a panel of PTEN phosphorylation site mutants revealed that mutating Ser385 
to alanine (S385A) promoted membrane localization in vivo, and phosphatase 
activity in vitro. S385A mutation was associated with a substantial reduction in 
the phosphorylation of the Ser380/Thr382/Thr383 cluster.
1.8.3.2 N terminus and PTEN regulation
PTEN has greater activity towards substrates incorporated into lipid surfaces 
that have an acidic character, such as the inner surface of the cell plasma 
membrane. PTEN shows increased activity in vitro against substrates 
presented in vesicles that include non-substrate acidic lipids.
The polybasic motif at the PTEN N-terminus plays an important role in both 
the binding to anionic vesicles and the enhancement of activity, such that a 
mutation in this motif identified in a human glioblastoma specifically impairs 
this binding and activation, and removes the ability of the enzyme to regulate 
cellular proliferation in culture.
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recruited to, and active against, lipids within membranes that contain relatively 
high levels of anionic lipids, such as PI2 and phosphatidylserine and that PTEN is 
active only against substrates located within the acidic plasma membrane, but 
not within internal membranes such as the less charged endoplasmic reticulum.
1.8.3.3 Regulation of PTEN Expression and Ubiauitination 
The importance of correct regulation of the expression of PTEN is demonstrated 
by the developmental abnormalities and numerous benign polyps that appear to 
result from reduced expression of the PTEN protein in experimental animals and 
human subjects with inherited PTEN defects such as Cowden syndrome (Marsh 
etal. 1997). Several transcription factors have been demonstrated to regulate 
PTEN. The PPARg (peroxisome proliferator-activated receptor g) agonist 
rosiglitazone, and egr-1 have been shown to bind the PTEN promoter and 
regulate its expression, and it appears that p53 and egr-1 may play a role in the 
up-regulation of PTEN expression caused by irradiation. (Stambolic etal. 2001, 
Virol I e etal. 2001).
The constitutive expression of PTEN may be regulated by factors that affect the
stability of the protein. Vazquez et al. (2002) showed that the protein
phosphorylated at the C terminus is relatively stable. Dephosphorylation of these
residues leads to a functional activation of the protein as described above but
also to dramatic destabilization. Several studies have implicated proteosomal
degradation as a control mechanism, since in some circumstances PTEN stability
appears to be increased by proteasome inhibitors (Vazquez et al. 2001) and the
detection of ubiquitinated forms of PTEN has been reported (Tolkacheva 2001).
Nedd4 (Neural precursor cell Expressed Developmentally Down regulated)
modifies substrate proteins by the addition of ubiquitin groups in a process known
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as ubiquitination. Wang et al. (zuu / )  reported tnat Nedd4 regulates r  l tN  levels 
by ubiquitin-mediated proteosomal degradation. Wang et al. (2007) suggested 
that aberrant upregulation of NEDD4-1 can post translationally suppress PTEN in 
tumour cells. They also suggested that the role Nedd4 played in PTEN regulation 
was analogous to that of MDM2 in P53 regulation.
During apoptosis, it appears that PTEN protein becomes cleaved at several C- 
terminal sites, probably by caspase 3, sensitising the protein to further 
degradation, and blocking interaction with PDZ domain-containing scaffold 
proteins (Torres et al. 2003).
Salmena and Pandolfi (2007) suggested that the monoubiquitinylation of PTEN 
described by Denning et al. (2007) and Trotman et al. (2007) coupled to nuclear- 
cytoplasmic shuttling might be a novel regulatory mechanism that directly 
influences the function of PTEN
1.8.4 PTEN function in Leukaemia
Yilmaz et al. (2006) noted the functional similarities between normal and cancer 
stem cells and the associated difficulty of eliminating tumour stem cells without 
affecting normal stem cells. The group also reported that deletion of PTEN in a 
murine model causes the generation of transplantable leukaemia-initiating cells 
and causes the depletion of normal haemopoetic stem cells (HSCs). Their data 
suggested that PTEN promotes quiescence in HSCs and that in the absence of 
PTEN , HSCs are driven into cell cycling but the increase is transient as the cells 
are unable to sustain themselves after depletion of PTEN. Irradiated mice were 
rescued with transplantation of PTEN -deficient cells but failed over eight weeks 
to develop full lineage reconstitution, although they did not develop leukaemia. 
Yimaz et al (2006). suggested that HSC depletion resulted from inhibition of self­
renewal rather than promotion of apoptosis. The mammalian target of rapamycin
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(m lO R ) is a protein kinase that controls cell growth by modulation ot upstream
growth factor signals and is also a sensor of cellular nutrient and energy levels
and redox status (Hay & Sonenberg 2004). The observations that the PI3 kinase
pathway initiated mTOR kinase pathway, led the group to administer the mTOR
inhibitor, rapamycin to PTEN deficient leukaemic mice to assess whether
rapamycin depleted the leukaemic cell population. When administered
concurrently with leukaemic cells, rapamycin-treated mice showed no evidence of
leukaemia. Rapamycin also restored the multilineage reconstitution in irradiated
mice treated with PTEN deficient HSCs. This group suggest that persistent
activation of the PI3 kinase pathway leads to the depletion of PTEN-deficient
HSCs via a gradual increase in the rate at which HSCs exit the stem cell pool or
alternatively, the depletion of PTEN may lead to the acquisition of secondary
mutations that inactivate the senescence response (Yilmaz et al. 2006).
In a study of HSC numbers in PTEN deficient mice, Zhang et al. (2006)
demonstrated a two to three-fold decrease in the proportion of HSCs in GO phase
and a parallel increase in the proportion in S, G2 and M phase and that the
proportion of cycling HSCs was aberrantly high. The group suggested that PTEN
helps control the transitions that stem cells make between the quiescent and
active states and whether to progress further though the cell cycle or return to a
quiescent (GO) state. Disrupting PTEN in stem cells results in more active cycling
and a loss of the quiescent pool of stem cells that is necessary for long-term stem
cell maintenance. PTEN’s role in cell adhesion and migration might lead to a
mobilisation of HSCs into the peripheral circulatory system, though in vitro assays
of PTEN deficient cells’ ability to bind to fibronection collagen and laminin were
normal. In vivo homing assays showed that PTEN mutants were less efficient at
populating bone marrow niches when in competition with fully competent cells.
Zhang et al. went on to suggest that the ability to lodge within bone marrow was
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linked to quiescent stages ot cell cycling irrespective ot P i bN status but the 
reduced ability of PTEN deficient cells to lodge in bone marrow may be a 
reflection of their activated state.
Cheong et al. 2003 observed that phosphorylation of PTEN affects the protein’s 
stability and function. In this study, phosphorylated PTEN (pPTEN) was observed 
in 45 (73.8%) of 61 cases with acute myeloid leukaemia (AML). Phosphorylation 
of Akt and its downstream molecules (Forkhead (Drosophila) homologue 1; and 
glycogen synthase kinase 3 beta) was significantly associated with pPTEN. The 
complete remission rates were not different with respect to pPTEN, but overall 
survival was significantly shorter in patients with pPTEN. The group suggested 
that PTEN phosphorylation may add insight into the molecular pathogenesis of 
AML, and may be a parameter for an unfavourable outcome.
1.9 The aims of this thesis
Frequent mutations in PTEN have been detected in several types of human 
cancer, including glioblastoma, prostate cancer and endometrial cancer 
(reviewed in Introduction). The main aim of this thesis was to investigate the 
occurrence of PTEN mutations in leukaemia. For this purpose a range of 
unpaired normal and primary haematological malignancy samples from the 
stored archives of the Department of Haematology, Wirral Hospitals NHS Trust 
was studied. Ethical approval for this study was obtained from the Wirral 
Hospitals Research and Development Committee. Immortalised cell lines were 
obtained from the Department of Haematology, Royal Liverpool Hospital.
The project involved several objectives:
1. Developing DNA extraction methods for formalin-fixed and paraffin wax 
embedded cells and for cells micro-dissected from Romanowsky-stained 
bone marrow smears.
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Z. Optimisation ot PCK conditions tor amplification ot the nine exons ot the 
PTEN gene.
3 Conformation-based screening of PCR products by SSCP and DGGE to 
detect point mutations, small deletions and insertions in primary 
haematological malignancies.
4. DNA sequencing of samples identified as possessing mutation(s) to 
precisely determine their nature and location and evaluate their effect on 
PTEN protein.
5. Studies of PTEN gene expression at the mRNA level in cell lines by RT- 
PCR.
6. Investigation of PTEN protein expression in primary haematological 
malignancies by immunohistochemistry and Western blotting-based 
techniques.
7. Analysis of results to correlate DNA mutation and protein expression with 
disease classification.
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Materials and Methods
2.1 DNA extraction
DNA was extracted from a variety of fresh, fixed, stained cells and tissue. 
Heterogeneity between and within source material and degree of fixation 
prompted the development of several differing methods for DNA extraction of the 
cells.
2.1.1 Extraction from fresh and frozen cells, blood and bone marrow
These cells were unfixed and unstained but had been collected in Starsted tri­
potassium EDTA blood collection tubes to prevent coagulation. DNA was 
extracted from blood or bone marrow samples and cultured cell suspensions 
according to the following protocol modified from that originally suggested by 
Wilcockson (1973).
Total nucleated cell numbers in samples were not calculated as PCR has the
ability to generate large quantities of amplified DNA, potentially from single copy
sequences. Cultured cells which had been grown to confluence were pelleted by
centrifugation in a 50ml centrifuge tube at a relative centrifugal force (RCF) of
1000g in a MSE Micro Centaur centrifuge for 5 mins, and started at the point of
sodium perchlorate addition step in the extraction procedure below.
Blood and bone marrow samples were collected in EDTA- or Citrate-
anticoagulant and centrifuged at 2000g RCF for 5min at room temperature. The
Buffy coat was removed with a sterile disposable pipette and transferred to a 2ml
microcentrifuge tube. 1.5ml of RBC lysis buffer (8.3g NaCI; 1.0g KHCO3; 0.3g Na2
EDTA in 11 sterile water) was added to lyse RBCs. The tube was vortex-mixed
and incubated at room temp for 5 min. The tube was centrifuged for 5 min at 12
OOOg RCF in a MSE Micro Centaur centrifuge to pellet the nucleated cell fraction
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and the supernatant discarded into Z 7o  virKon solution (Anacnem Ltd UK). I he 
RBC lysis wash process was repeated. 500pl of 5M sodium perchlorate was 
added to the cell pellet which was homogenized by repeated pipetting with a 
100pl Anachem M100 direct displacement pipette and incubated at RT for 5min. 
The extracted samples were transferred to an air extraction fume cupboard and 
700pl of chloroform (-20°C) was added and thoroughly vortex-mixed at maximum 
speed for 15 min. The tube was centrifuged at 12 OOOg for 5 min and the 
supernatant transferred to a clean micro-tube. 1ml of isopropanol (-20°C) was 
added and mixed thoroughly prior to centrifugation at 12 OOOg for 15 min. The 
supernatant was removed and 1.5ml of 70% ethanol (-20°C) was added and 
mixed by gentle inversion. The tube was centrifuged at 12000g for 1 min and the 
supernatant ethanol decanted. The nucleic acid pellet was re-suspended in 500pl 
of TE buffer pH 8.0 (10 mM Tris HCL, 1mM EDTA). DNA concentration of extract 
was estimated by measuring the ratio of 260/280nm absorption on a GeneQuant 
UV spectrophotometer (Biochrom UK).
2.1.2 Extraction of DNA from fixed, stained bone marrow smears
This object of this procedure was to develop a method to extract PCR-amplifiable
DNA from archived bone marrow smears.
Archived bone marrow smears had been fixed in methanol and ethanol then
stained in May-Grunwald and Geimsa stain (Raymond A Lamb Ltd UK) following
routine lab procedures SOP (Appendix 1). Several procedures were utilized
including proteinase K digestion, phenol/chloroform extraction, chloroform
extraction, extraction without removal of stain and extraction of dry scrapings.
Slides were de-stained in methanol for 5 min then washed in deionised water.
100pl of PCR buffer (Bioline ltd, UK) was spread out over the surface of the slide
with a second glass slide and soaked for 5 min. The entire slide surface was
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scraped off with a scalpel and collected into a 2ml microtube, zuupl ot PUK 
buffer (Bioline ltd, UK) plus 5pl of proteinase K solution 10mg ml'1 (Amresco Inc, 
USA) was added and incubated for 60 min. at 55°C then 5 min at 100°C. The 
sample was centrifuged for 5 min. at 12 OOOg and the supernatant collected in a 
conical 1.5ml micro-tube. 5pl of extract was used per 100 pi of PCR mix.
The following optimised protocol with an added ethanol precipitation step was 
adopted:
Slides were de-stained in methanol for 5 min then washed in water.
100pl of PCR buffer was spread out over the surface of the slide with a second 
glass slide and soaked for 5 min. The entire slide surface was scraped off with a 
scalpel and collected into a 2ml microtube. 200pl of PCR buffer (Bioline Ltd UK) 
plus 5pl of proteinase K solution 10mg ml'1 (Amresco Inc USA) in PCR buffer was 
added and incubated for 60 min. at 55°C then 5 min at 100°C. The sample was 
centrifuged for 5 min at 12 OOOg and the supernatant collected in a conical 1.5ml 
micro-tube. 0.1 volume of 3M sodium acetate solution and 2 volumes of -20°C  
ethanol was added. The tube was placed at -20°C for 15 min then centrifuged at 
12 OOOg for 15 min.
The pellet was then washed in 70% ethanol and resuspended in 50pl of TE  
buffer (10mM Tris HCI, 1mM EDTA pH 8.0).
DNA concentration was measured by spectrophotometric absorption at 260 nm 
using a GeneQuant spectrophotometer.
2.1.3 Microdissection of tumour cell DNA from stained bone marrow smears
This technique made use of the fact that nucleated cells in stained blood and
bone marrow smears appear as discrete cells surrounded by non-nucleated red
blood cells and platelets. Mature red cells could be collected with the nucleated
tumour cells without contributing to the nucleic acid component of the sample
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whilst avoiding the collection ot normal ceils.
The smear was dipped in PCR buffer and blotted lightly on filter paper then 
placed on a inverted stage (subject illuminated from above, viewed from below).
A narrow gauge insulin syringe needle was tapped on a glass slide to produce a 
slight “hook” at the sharp end. Using the 20 times magnification objective, an area 
of smear was found with well spaced-out, nucleated cells. Using the microscope 
stage as a hand rest, the tip of the needle was brought into the field of view. With 
a mixture of slight hand movements and the fine adjustment wheel of the 
microscope stage, the slide was “trawled” for tumour cells whilst avoiding normal 
nucleated cells.
Approximately 100 cells were collected and placed in 50pl of proteinase K buffer 
(5pl 10mg ml-1 proteinase K plus 45pl PCR buffer) in a 0.5 ml PCR tube.
The tube was incubated at 55°C for 1 hour and 100°C for 5min then centrifuged at 
12000g for 1min. The supernatant was transferred to a fresh tube and 10pl 3M 
sodium acetate, and 200pl of -20°C ethanol was added. Tube was incubated at - 
20°C for 15 min then centrifuged at 12 OOOg for 15 min.
PCR components were added directly to this tube.
2.1.4 Extraction of DNA from fixed paraffin-embedded tissue sections
2.1.4.1 Extraction of DNA from formalin-fixed paraffin-embedded tissue sections
using phenol/chloroform
10 x10pm sections were cut from the tissue block using a microtome.
Microtome blade was washed with extreme care between block samples using a
tissue soaked in xylene. Sections were placed in a 2ml microtube and xylene
added (to approx 1.5ml) to de-paraffinise the sections.
After 30 mins at room temp, tube was centrifuged at 12000g for 1 min and the
xylene was discarded. The tissue was washed with three consecutive changes of
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etnanoi.
DNA was extracted by the phenol/chloroform method (Sambrooke et al 1998).
2.1.4.2 DNA extraction from wax embedded tissue sections by de-waxinq and 
proteinase K digestion
Trial PCR reactions using beta globin primers yielded poor levels of 438 bp 
specific product with a high level of non-specific amplification. The method was 
modified by using proteinase K digestion in place of phenol/chloroform after de- 
paraffinisation:
Sections were cut and de-waxed as in 2.1.4.1. 0.5ml Proteinase K buffer (5pl 
10mg ml-1 proteinase K plus 45pl PCR buffer) was added and incubated at 55°C  
for 30min. Tube was incubated at 95 °C  for 5min to destroy proteinase activity. 
5pl of extract was added to a 50pl PCR reaction.
This extraction technique gave an increased yield compared to the phenol 
chloroform method.
2.1.4.3 DNA extraction from wax embedded tissue sections by heat-based de- 
waxinq and proteinase K digestion
To further increase the yield of specific product, the following protocol was 
applied:
Sections were cut as in 2.1.4.1. Samples were placed in a 2ml microcentrifuge 
tube 1.5ml of TE buffer pH 8.0 and incubated for 5 mins at 95°C. The tube was 
centrifuged at 12 OOOg then the solidified wax and TE buffer was discarded. 
0.5ml Proteinase K buffer (5pl 10mg ml'1 proteinase K plus 45pl PCR buffer) 
was added and incubated at 55°C for 30min. The tube was incubated at 95°C  
for 5 mins to destroy proteinase activity. 5pl of extract was added to a 50pl PCR 
reaction.
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This extraction method gave optimum POK product levels with minimum non­
specific amplification and was used for subsequent PCR.
2.1.5 RNA extraction from cultured cells
This technique was modified from Sambrooke et al. (2000) and was designed to 
isolate total cellular RNA.
Total RNA was extracted from the following cell lines: CV605, K260, THP1, 
JURKAT, HL60, K562. Cells had been grown to confluence. Cell numbers were 
not estimated as the subsequent RTPCR amplification was not a quantitative 
procedure and RTPCR has the theoretical ability to generate billions of target 
sequences from a single copy template .
The cell suspension was centrifuged at 2000g for 5min and supernatant 
discarded into 2% Virkon. 500pl of 5M guanidine HCL was added per 100pl of 
cell pellet.
The cell pellet was homogenised by repeated pipetting with a fine-tip100pl direct- 
displacement pipette (Gilson M100, Anachem Ltd UK) and incubated at RT for 
5min. The sample was transferred to an air extraction cabinet and 500pl of 
phenol/chloroform/iso-amyl alcohol 45:45:10 pH 6.0 was added and mixed by 
inversion then incubated for 5min at RT. The sample was centrifuged at 12 OOOg 
for 5 min. The supernatant was transferred to a new micro-tube and the 
procedure repeated from the “500pl of phenol/chloroform/iso-amyl alcohol” step 
until the organic/aqueous interface was clear. The supernatant was transferred to 
a new micro-tube and 500pl of chloroform added. The sample was mixed by 
vigorous shaking and centrifuged at 12 OOOg for 5 min. The supernatant was 
removed and 1 volume of ice-cold isopropanol and 0.1 vol. of 3M sodium acetate 
added. The tube was incubated at -20°C for 15 min and centrifuged at 12 OOOg
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tor 15 min. I he KNA pellet was washed in / U7o ethanol.
Ethanol was decanted and the pellet was re-suspended in 50pl of RNase-free 
water (Amresco Inc. USA). RNA concentration was established by measuring 
spectrophotometric absorption at 260nm.
2.2 PCR Primer design
PTEN DNA sequences for spanning exons 1-9 including the intron exon boundary 
region (Nucleotide, http://www.ncbi.nlm.nih.gov) were used to design intronic 
PCR primers for amplification of each exon. Primers were designed to produce 
PCR products of a size greater than 300bp to achieve maximum CSGE sensitivity 
(Ganguly et al. 1995). Primers were designed manually with a target melting 
temperature of 60°C using the formula Tm = 4(G + C) + 2(A + T)°C (Thein and 
Wallace 1986). Primer regions were selected that had <60% GC base content 
and primer length was dictated by the target annealing temperature. Primer 
sequences were then checked with a computer program (Primer - Whitehead 
Institute for Biomedical Research, USA) to detect self complementarity and 3’ 
overlaps that might generate primer dimers. The use of primers situated within 
the intron sequences 50 bp from the intron/exon boundary on each side of the 
exon, was necessary to prevent amplification of PTEN homologous sequences 
(which lack intron sequences) and also to counter reduced sensitivity of the 
proposed Conformation Sensitive Gel Electrophoresis (CSGE) to heteroduplex 
(HD) mismatches occurring within 50 bp of the 5’ and 3’ ends of the target exon 
sequence.
To confirm the expression of PTEN mRNA in cultured cells, the PTEN mRNA
sequence (Entrez, NCBI http://www.ncbi.nlm.nih.gov) was used to design cDNA
primers including as much of the transcribed sequence as possible using the
methods as per exon 1-9 primers. The DNA sequence for the PTEN homologous
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sequence r m z  was ootainea (tntrez, NObi nttp://www.ncoi.nim.nin.gov; ana 
compared to the cDNA sequence for PTEN using a computer program (DNASIS, 
Hitachi Software Engineering Company, Ltd). Subsequent sequence differences 
were used to identify restriction endonuclease (RE) recognition sites that would 
be useful in differentiating PTEN cDNA amplification products from PTH2 
amplification products. An Mse1 RE site was identified 235bp from the 5’ end of 
the mRNA coding sequence that was present in PTEN gene cDNA but not in the 
PTH2 homologue.
The cDNA primers were designed to give a 397bp amplicon that would give 
MSE1 digest fragments of 143, 194 and 60bp for PTEN cDNA plus 337 and 60bp 
fragments for PTH2 DNA. Human Beta globin primers were supplied by JK 
Douglas Research Laboratories, Clatterbridge Cancer Research Trust UK,
Control primer set. PCR Primers for the SSCP reactions are shown in Table 2.2. 
All sequences are 5’-» 3 \
2.3 PCR optimisation
A “standard” reaction was used to establish the initial conditions of reaction. If a 
specific product of the expected molecular weight was evident, optimisation was 
limited to magnesium chloride concentration. Magnesium concentration was titred 
in 0.5mM steps initially. If the titre results showed a narrow range of optimum 
magnesium concentration, a fine titre was performed using 0.2 mM increments. 
Other more problematical reactions such as the PCR of exons 1 and 3 were 
optimized as indicated with betaine and DMSO additives. Initial PCR reactions 
were carried out in a Biometra Uno thermocycler using the following parameters: 
Initial denaturation 3min - 95°C, then 35 cycles of: denaturation 30 sec - 95°C, 
annealing 60 sec - 55°C, extension, 60 sec - 70°C, Using the following 50pl PCR
74
I able 2.2 primers used in tne neteroaupiex analysis reactions
Primers for B-qlobin DNA (J K Douglas research labs.)
Forward: AGT CAG GGC AGA GCC ATC TA 
Reverse: GCC CAG TTT CTA TTG GTC TTC  
Primers for Prothrombin gene (Bioline UK Ltd.)
Forward: ATA GCA CTG GGA GCA TTG AAG 
Reverse: AGA AGG TCA TTG ATA AGC TTG GAG AG 
Primers for PTEN cDNA/PTH2 DNA (Bioline UK Ltd.)
Forward: GCT ATG GGA TTT CCT GCA GA 
Reverse: CTC CCT TTT TGT CTC TGG TCC 
Primers for Heteroduplex analysis PTGS 1-9 (Bioiine UK Ltd.)
Exon 1 forward: ATC AGC TAC CGC CAA GTC CA 
Exonl reverse: TGA CCT AGC AAC CTG ACC AG 
Exon 2 forward: CCC CTG TGC AGT TGA AAA TT 
Exon 2 reverse: AAC TGT ATC CCC CTG AAG TC  
Exon 3 forward: AAA ATC TGT CTT TTG GTT TTT CTT G 
Exon 3 reverse: TCT GTG CCA ACA ATG TTT TAC C 
Exon 4 forward: GTG TCA CAT TAT AAA GAT TCA GGC 
Exon 4 reverse: CCT GAC AAT ATT AAT AGC TTT ATG CA 
Exon 5 forward: GCA ACA TTT CTA AAG TTA CCT ACT TG 
Exon 5 reverse: AAG AAA CCC AAA ATC TGT TTT CC 
Exon 6 forward: GTT GTG ACC TTT GAA TAA ATG GG 
Exon 6 reverse: ACA GTG CCA CTG GTC TAT AAT C 
Exon 7 forward: GTT TTT GAC AGT TTG ACA GTT AAA GG 
Exon7 reverse: ACA CCT GCA GAT CTA ATA GAA AAC A 
Exon 8 forward: TGT TTA ACA TAG GTG ACA GAT TTT C 
Exon 8 reverse: TTC ATC AGC TGT ACT CCT AGA ATT 
Exon 9 forward: AAT TAA TAT GTT CAT CTG CAA AAT GG 
Exon 9 reverse: AAA AAG GTC CAT TTT CAG TTT ATT C
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mixture: lb  pMoie torwara primer; no pivioie reverse primer; ix  k u k  Duner (witn 
1.5mM Fermentas MgCbJjIx Fermentas dNTP mix; 2U 
Fermentas Taq supreme; 1pl DNA extract (Approx 100ng pi’1).
Samples for heteroduplex analysis were amplified using the following optimised 
50pl reactions 5 pMole forward primer; 15 pMole reverse primer; 1x Bioline PCR 
buffer; 1x Bioline dNTP mix; 2U Bioline Taq polymerase; 2.0 mM Bioline MgCh 
;1pl DNA template solution (Approx 100ng).
2.3.1 RTPCR
cDNA synthesis was carried out using a Gibco/BRL superscript kit using a 
random hexamer primer in a 20pl reaction:-100 pMoles random hexamer primer 
(Pharmacia); 10pg total RNA; 4pl 5x First Strand Buffer; 2pl 0.1 M DTT; 1.0pl 
dNTP mix (Bioline); 20U RNase inhibitor (Amresco); 200U Superscript RT (Life 
Technologies UK). The cDNA PCR step was titred for optimum Mg++ 
concentration as for PCR and performed in a 50pl reaction as follows: 15 pMole 
forward primer, 15 pMole reverse primer, 1x PCR buffer (Bioline), 1x dNTP mix 
(Bioline), 1.5 mM Mg++ (Bioline),1U Taq polymerase Fermentas, 5pl cDNA mix 
-using the following programme: Initial denaturation 3min at 95°C to allow 
complete dissociation of target sequences. Then 35 cycles of: denaturation 30 
sec - 95°C annealing - 60 sec at 55°C extension - 60 sec at 70°C, followed by 
Final extension 180 sec 70°C
2.3.2 Analysis of PCR products
PCR products were analysed by electrophoresis through a 2% agarose minigel
prepared and run in 1 x TBE buffer (0.045M Tris-borate, 0.001 M EDTA) at 100V
for 60 mins. PCR fragments were visualised by 312nm UV trans-illumination of
gels stained initially with 10pg ml'1 ethidium bromide in TBE buffer and
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subsequently by tne less mutagenic ana more sensitive ije ib ta r (hMU Lta UbA) 
stain 1:10000
2.4 Heteroduplex (HD) analysis
2.4.1 Sample disease types in the heteroduplex study of PTEN exons 5, 7 and 8 
All lymph node samples were non-Hodgkin’s lymphoma. Initial bone marrow 
smear samples for heteroduplex analysis consisted of 3 chronic myelogenous 
leukaemia,10 chronic lymphocytic leukaemia, 12 acute myelogenous leukaemia,
2 hairy cell leukaemia, 10 non-Hodgkins lymphoma, 13 myelodysplasia, 13 
myeloma and 2 Waldenstrome’s macroglobulinaemia. Smears with a tumour load 
of less than 10% of nucleated cells were excluded. PTEN exons 5,7 and 8 were 
examined initially.
2.4.2 PTEN exon 5 7 and 8 Heteroduplex Analysis Electrophoresis 
Heteroduplex analysis or conformation sensitive gel electrophoresis (Korkkd et al. 
1998) is designed to detect differences in electrophoretic migration between 
homo- and heteroduplex sequences. Heteroduplexes are formed when amplicons 
with one or more point mutations are mixed with wild type sequences. They were 
first described by Nagamine etal. (1989) as PCR artefacts. Heat denaturation, 
followed by slow annealing allows the formation of heteroduplex DNA. 
Heteroduplex control DNA consisted of a heterozygous HbS commercial control 
sample (Helena Biosciences). This preparation was heterozygous for the point 
mutation associated with sickle haemoglobin which yielded a heteroduplex 
sequence when subjected to PCR amplification of the area of the p-globin gene 
containing the mutated allele. This yielded a 438bp sequence with an ATT allelic 
site 92 bp from the 5’ end.
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z.4.2.1 Heteroaupiex sample generation
Residual polymerase activity was inhibited in the PCR product with 1 mM EDTA 
(final concentration). 10pl of sample and normal control PCR product were mixed 
in a 0.5 ml PCR tube. Samples and controls were heated to in a Biometra 
thermocycler to 95°C and cooled in steps of 2.5°C at 15 sec intervals to RT.
2.4.2.2 Heteroduplex gel preparation
Gel mix (for six 0.1 x 15 x 20cm or two 0.1 x 50 x 20cm gels) was prepared in a 
250ml plastic Universal bottle: 130ml Pure water, 20ml ethylene glycol (Amresco), 
30ml formamide (Amresco), Acrylamide/bis acrylamide 19:1 40% 60ml.
Gel solution was filtered through a 0.45 urn filter just before use then degassed 
under vacuum. One plate was treated with silane substitute to ease disassembly. 
500pl 10% ammonium persulphate, (Amresco) and 50pl TEMED (Amresco) was 
added.
The gel was poured and allowed to polymerize for 1 hr at RT.
HD analysis was initially run on a standard 50cm 6% acrylamide gel at 500v for 6 
hours in 1x TBE buffer with fan-driven air cooling. Migrant bands were visualized 
prior to excision for silver staining with 1 mg ml’1 ethidium bromide solution.
2.4.2.3 Silver Staining
The area of gel containing the heteroduplex fragments was excised and stained 
with silver staining adapted from protocol of Silver Stain Kit, Pharmacia Ltd., 
according to the following protocol:
Gel was fixed in fixative/stop reagent (10% acetic acid) for 10min with constant 
mixing. Gel was rinsed three times for 2min in pure water then stained in staining 
solution (1 gl'1 AgN03  in pure water with 1.5ml 40% formaldehyde per litre) for
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3Umin with constant mixing. I ne gel was tnen rinsea orieny in pure water sec 
max) and developed in developing solution (30g Na2CC>3 (Prepared fresh for each 
staining);1.5ml 40% Formaldehyde; 200pl of 10mg ml'1 Sodium Thiosulphate in 11 
of pure water) until the first bands were visible. Gel was then transferred to fresh 
developer for 2 min and placed in reagent fixative/stop reagent to stop the 
staining reaction. Gels were rinsed 2 x 2  mins in water and photographed using a 
cold white light viewer. The digital image was transferred to a personal computer 
and using Adobe Photoshop software, the cyan and magenta channels were 
deleted to enhance the contrast of the yellow/brown silver stain.
2.4.2.4 Preparation of BAP/Glvcerol/TTE Heteroduplex gels 
Bis-acrylamide was replaced with Bis acryl piperazine (BAP) in 0.5x Tris-Taurine 
EDTA (TTE) buffer at 19:1 ratio of acrylamide and bis-acrylamide using a 10% gel 
as specified by Ganguly and Prockop (1995). TTE Glycerol Tolerant Buffer (20X) 
is a concentrated Tris-Taurine-EDTA buffer solution prepared in 
distilled/deionised water.
TTE (20X) eliminates the band distortion associated with DNA samples in glycerol 
run with borate containing buffers. With TTE Buffer (20X), DNA/glycerol samples 
can be used without diluting the samples (Product instruction sheet, Geneflow 
Ltd, UK).
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ZA.z.b  use ot MaqeMius Heteroaupiex qeis
A commercial poly-acrylamide preparation with a modified cross-linking agent of 
unknown formulation (10% PagePlus, Amresco Inc, USA) was used in place of 
acrylamide/BAP in an attempt to improve resolution and prevent diffusion. 
Running conditions of 600V for 20 hours with fan-assisted cooling at room temp 
provided optimum separation and resolution of HD bands.
2.4.2.5.1 PagePlus Gel preparation
Gel mix (for six 0.1 x 15 x 20cm or two 0.1 x 50 x 20cm gels) was prepared by 
combining: 180ml Pure water, 60 ml 40% Page-plus stock solution,
Gel solution was filtered and degassed as previously. 500pl 10% ammonium 
persulphate and 50pl TEMED was added. The gel was poured and allowed to 
polymerize for 1 hr at RT.
2.5 Single Strand Conformation Polymorphism analysis of PTEN exons 1-9
SSCP is designed to detect conformational differences in single stranded species 
that have been generated by heat denaturation of PCR product followed by rapid 
cooling. (Ganguly etal. 1993). Folding of single stands into a particular 
conformation is defined by order of bases and is sensitive to single base 
changes. PCR primers (Table 2.5.1) were redesigned manually as for 
heteroduplex analysis and checked for self-complementary regions and hairpin 
loops using a computer programme (PCR Primer, Rozen and Skaletsky,
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I aoie z.b. 1 rUK primers tor bbUK analysis
PCR Primers for SSCP analysis (Life technologies, UK) 5’>3’
Exon 1 forward: AGT CCA GAG CCA TTT CCA TC 
Exonl reverse: GAC CTA GCA ACC TGA CCA GG
Exon 2 forward: TTG AAC AAC ACA GAG GGT AGG
Exon 2 reverse: CAT CAC AAA GTA TCT TTT TCT GTG G
Exon 2.1 forward alternatel: CCT GTG CAG TTG AAA ATT CAC
Exon 2.2 forward alternate: 2 TAT CCA TGA CAG TTG ACC CTT G
Exon 2.1 reverse alternatel: ATC ACA AAG TAT CTT TTT CTG TGG C
Exon 3 forward: GGA AAA AGA AAA TCT GTC TTT TGG
Exon 3 reverse: CTT GGC CTT CTT GAC TTA ATC GG
Exon 4 forward: TGG GGG TGA TAA CAG TAT CTA CTT
Exon 4 reverse: CTG GAT GAC TCA TTA TTG TTA TGA CA
Exon 5 forward: TGC AAC ATT TCT AAA GTT ACC TAC TT
Exon 5 reverse: GGA AGA GGA AAG GAA AAA CAT C
Exon 6 forward: AGG GAG GAG AGT TAT TCT GAT ATC C
Exon 6 reverse: CAT CTT GTG AAA CAA CAG TGC C
Exon 7 forward: CAT TAA AAT CGT TTT TGA CAG TTT G
Exon 7 reverse: TAG CTT TTA ATC TGT CCT TAT TTT GG
Exon 8 forward: ATG TCA TTT CAT TTC TTT TTC TTT TC
Exon 8 reverse: TCA CAT ACA TAC AAG TCA CCA ACC
Exon 9 forward: ATG TCC ATC TGC AAA ATG GA
Exon 9 reverse: TGG TAA TCT GAC ACA ATG TCC TA
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Whiteneaa institute, zuuuj to acmeve tragment sizes ot approx zuu-juu case 
pairs for each of PTEN exons 1-9.
This technique was employed as a result of the very low number of samples with 
results indicating the presence of sequence mutations obtained with heteroduplex 
analysis. All DNA samples screened were from fresh frozen bone marrow 
samples. 114 samples of various disease classifications (Table 3.1.1, Results 
chapter) were PCR amplified using the SSCP primers for PTEN exons 1-9. Each 
exon was amplified as a run of 2 x 55 samples using a microtitre format in a 
Eppendorf Gradient Multicycler thermocycler using a 50pl reaction under 
optimised reaction conditions of: 15pmole forward and reverse primer; 1x 
Immolase buffer (Bioline); 1x dNTP mix; 1U Immolase (Bioline); 2.0mM Mg++; 
approximately 100ng DNA template.
Vertical gel electrophoresis was performed using a Biorad Protean multi cell unit 
and power supply with an LKB cooling unit and 6 x 20 sample combs. The 
sample loading buffer consisted of: 800pl formamide; 100pl of 1% Bromophenol 
blue; 100pl of 1% Xylene cyanol; 2pl 0.5 M EDTA; 1pl 10 M NaOH;
2.5.1 Generation of single stranded complexes
50pl of sample loading buffer was added to the PCR reaction tube and placed in 
a thermocycler to denature the samples at 95 °C  for 5 min. The reaction was 
snap cooled in a methanol ice bath at -20°C, and then transferred to an ice block 
until electrophoresis.
5pl of each sample was loaded onto the SSCP gel. Running conditions were: I x
TBE buffer at 13°C at 12 W constant power for 16hours using a Protean (Biorad
UK) vertical electrophoresis system cooled by a refrigerated circulation unit (LKB
UK). A lane of double-stranded DNA ladder (PCR ladder Amresco Inc USA) was
included to indicate the likely position of the faint staining single strand
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complexes.
Different concentrations of Gene-page (1x and 2x manufacturer’s recommended 
concentration) and standard 19:1 bis/acrylamide mixes were tried with and 
without added glycerol and ethylene glycol at 10% concentration, using exon 7 
primers and an NIH 33 (which contained a mutated PTEN allele cell line DNA as 
positive control). Optimum resolution of single strand complexes was obtained 
with: 10% Gene-page; 10% ethylene glycol; 1 x Tris-Borate-EDTA buffer pH 8.3.
A range of running temperatures were tried using a refrigerated coolant 
recirculation unit (LKB UK) varying from 5 °C  to 25 °C  as recommended by 
Ganguly et al. (1993). The optimized conditions adopted were 12 W constant 
power for 16h at a plate temperature (measured in the centre of the plate) of 
13°C, which corresponded to a coolant temperature of 10 °C. The cooling unit 
was switched on for 30 mins prior to electrophoresis to prevent overheating at the 
start of the run. Gels were removed and provisionally stained with 2x GelStar 
(FMC bio-products USA) and examined under UV at 312nm light to reveal the 
position of the single strand complexes. The width of gel containing the 
complexes was excised as a strip of approx 10cm length to ease the silver 
staining process as though the PagePlus gels were more resilient than standard 
acrylamide-based gels they were still prone to tearing during the agitation steps of 
the silver staining process. Gels were silver stained as in section 2.4.2.3 for the 
heteroduplex gels and dried under vacuum in a gel drier at 50°C overnight to 
enhance visualization of staining. Dried gels were scanned into a PC running 
Adobe Photoshop and the cyan and magenta colour channels deleted to enhance 
the yellow silver stain. Gel images were converted to greyscale, magnified and 
contrast increased as necessary then images were visually inspected for aberrant 
band migration.
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2.6.1 PCR product sequencing using the Meqabace sequence analyzer 
The exon five PCR products that displayed aberrant migration bands were 
sequenced along with four adjacent samples with normal conformers on either 
side of the gel.
A Biometra thermocycler was pre-programmed as per cycling times below.
All kit reagents (DYEnamic ET Amersham Pharmacia) were thawed and placed 
on ice prior to use.
2.6.1.1 Preparation of sequencing reaction.
DNA sequencing was performed using a DYEnamic DNA sequencing kit 
(Amersham UK). Template DNA (PCR product) was diluted 1:10 in pure water to 
a volume of 12 pi.
For each template to be sequenced, the following were combined in a 0.5 ml 
microcentrifuge tube: DYEnamic ET terminator reagent premix 8 pi forward 
Primer (5 pM) 1 pi; DNA template 11 pi; Total volume 20 pi.
Reagents were mixed thoroughly by gentle pipetting and centrifuged briefly to 
bring contents to the bottom of the tube. Capped tubes were placed into the pre­
programmed thermocycler. Cycling program was started using the following 
cycling parameters: 95°C for 20s; 50°C for 15s; 60°C.1 min for a total of 30 cycles
After cycling, reactions were centrifuged to collect the reaction mixtures at the 
bottoms of the tubes .
2.6.1.2 Post-reaction clean-up
2 pi of 7.5 M Ammonium acetate was added to each reaction tube.
2.5 volumes (55 pi) of 95% ethanol were added to each reaction and mixed well.
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supernatant removed by aspiration then samples were washed in 70% ethanol 
and left to air dry at RT.
The pellet was re-suspended in 10 pi of loading solution and vortexed vigorously 
for 10-20 sec to ensure complete re-suspension then briefly centrifuged to collect 
the sample at the bottom of the tube.
2.6.1.3 Injection and run parameters for the Meqabace sequencing system 
Samples were loaded into the Megabace capillary system using run parameters 
of 3 kV for 40 s with run conditions of 100 min at 9 kV. After completion of the 
sequencing run the electropherrogram was downloaded into a Macintosh 
computer and the automated base calling checked for accuracy. The published 
DNA sequence for each exon was checked against the sample sequence: 
(http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi7vaN51467897&from=8371711 &to 
=8474918&view=gbwithparts) to identify possible point mutations, small deletions 
or additions.
2.7 Western blotting of proteins by enhanced chemiluminesence.
The lack of evident sequence mutation in the samples screened by both HD and 
SSCP ruled out small-scale deletions and point mutations in the PTEN gene, but 
protein expression could be reduced or abolished by other mechanisms such as 
large scale deletions and mutations, or by epigenetic mechanisms such as 
methylation of promoter regions. These mechanisms would not be detected by 
the PCR-based methods used for the PTEN exons studied. Therefore, western 
blotting performed to establish whether PTEN protein was being expressed in the 
leukaemic cell samples studied.
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2.7.1 Protein purification for western blotting from bone marrow samples
Protein purification/white blood cell lysis buffer: 5ml glycerol (Sigma UK), 0.5g 
sodium dodecyl sulphate (SDS) (Sigma UK), 0.5g dithiothreitol(Sigma UK), 5ml 
1MnaF (Sigma UK), 0.5ml 2m Na4P207(Sigma UK), 0.05ml 1 MNa3V04  (Sigma 
UK), 0.5ml PMSF(Sigma UK), 300UI Sigma protease inhibitor cocktail(Sigma 
UK), 3.125ml 1M TRIS HCI buffer pH6.8 (Sigma UK), sterile water to 50ml.
The red cell lysis buffer consisted of: 9g ammonium chloride, 100 ml 10x tris 
EDTA pH 7.2, sterile water to 11.
The samples consisted of approximately 1ml of fresh and frozen bone marrow 
samples anticoagulated with Tri-potassium EDTA in Starstedt blood collection 
tubes.
The sample was centrifuged at 3000g for 10 mins. The Buffy layer (approx.
0.5ml) was added to a 2ml microcentrifuge tube with 1.5ml red cell lysis buffer 
and mixed gently, incubated at RT for 5 mins then centrifuged at 12000g for 1 min 
in a Sanyo microcentaur centrifuge. The supernatant was removed into 2%
Virkon solution. A further 1.5ml of RBC lysis solution was added and the process 
repeated. 150pl of protein purification lysis buffer was added on ice.
The cell lysates were transferred to sterile 1.5 ml Eppendorf tubes and 
incubated on ice for 30 minutes to allow complete lysis of the cells. The lysates 
were cleared of insoluble material by centrifugation for 10 mins at 12,000g at 4°C  
and the supernatant transferred to clean tubes on ice.
2.7.2 Bradford assay for determination of protein concentration.
Protein concentration was determined to ensure uniform application of sample to
eletrophoresis gels. Protein concentration in each sample was determined using
the Bradford Assay (Friedenauer & Berlet, 1989). This method quantitates the
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amount of protein in a sample by the proportional binding of Coomassie blue dye 
to the protein, which can be measured at an absorbance of 595nm.
Each protein sample was diluted 1:200 in sterile water. 500pl protein dilution was 
added to 500pl Bradford reagent (Sigma) and incubated at room temp for 5 min. 
Absorbance was read at 595nm. Protein concentration was interpolated from an 
albumin standard curve from 0-10 pg ml'1
2.7.3 SDS Protein gel electrophoresis
SDS-polyacrylamide gels were prepared based on the Laemmli system of protein 
separation (Laemmli, 1970) using an 8cm BioRad miniprotean II vertical 
electrophoresis system. Proteins separated by SDS electrophoresis are 
denatured and differences in native charge are abolished by the presence of 
SDS. Electrophoresis of proteins is then based on molecular weight only. The 
separated proteins are then transferred by electro-blotting to a PVDF membrane 
for detection by specific antibodies.
Buffers used were: R Buffer - 1.5M Tris/HCI pH 8.8; S Buffer - 0.5M Tris/HCI pH 
6.8; 10x Running Buffer- 0.25M Tris/HCI, 2M glycine, 1% SDS(w/v) pH 8.3.
8% Resolving Gel mix (2x minigels of 0.75mm thickness) consisted of: 3.0ml R- 
Buffer; 1.6ml 19:1 acrylamide/bis-acrylamide (Amresco); 3.2ml deionised water;
80 pi 10% SDS.
The gel solution was de-gassed under vacuum for 2 mins before polymerization 
was initiated by adding 100 pi 10% Ammonium persulphate solution and 40pl 
TEMED
Stacking gel consisted of: 1.25 ml S-Buffer; 0.5 ml 40% bis/Acrylamide 19:1;
3.1ml H2O; 20 pi 10% SDS. The gel solution was de-gassed under vacuum for 2
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Biorad Protean glass plates were cleaned with 1M HCI then ethanol and 
assembled according to the manufacturer’s instruction. The resolving gel was 
prepared in the proportions shown (8% for PTEN), and overlaid with ethanol.
After 1 hour, the ethanol was poured off and the gel surface washed three times 
with water. The stacking gel was prepared and poured over the resolving gel. 
Ten-well combs were inserted and left for 30 mins. The combs were removed and 
the wells washed thoroughly with 1x running buffer. The gels were inserted into 
the tank and filled with buffer.
The protein samples were prepared by mixing 10pg of each sample with 1pl of 
loading buffer and boiling at 100°C for 1 minute on a thermocycler. A coloured 
molecular weight (C1992 Sigma UK) marker was also boiled at 100°C for 1 
minute, according to the manufacturer's instructions.
The entire 11 pi volume of each sample was loaded into the wells of the SDS- 
PAGE gel using gel loading pipette tips, ensuring that the samples sank to the 
bottom of each well. To one well of each gel was added 4ul of boiled colour 
marker and 0.5ul of a biotinylated molecular weight marker (b2787 Sigma). Gels 
were connected to a power supply and electrophoresed at 120 V for 90 minutes.
2.7.4 Blotting to PVDF membrane
Transfer buffer (pH8.3) consisted of: 25mM Towbin Buffer- 3.0 g Tris base; 14.4g
glycine; 200 ml methanol -20°C. PVDF membrane (immunoblot Biorad UK) was
wetted in methanol, then covered with Towbin Buffer. The polyacrylamide gels
were separated from plates and covered with Towbin buffer. PVDF, gels, fibre
pads and blotting paper were soaked in buffer for 10 min.
The gel sandwich was assembled with blotting paper and pads in cassette and
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conditions were 150v for 1 hour with constant stirring. After the run sandwiches 
were removed and PVDF placed on a towel to air dry. The gel was stained with 
Coomassie blue to detect residual protein and thus assess the efficiency of 
protein transfer process
2.7.5 Western blot for PTEN/B-Actin
Buffers used in the Western Blot were: 1x Phosphate buffered saline (PBS); 
PBST- PBS with 0.1% Tween 20 (Amresco USA); Blocking buffer- 3% marvel 
dried milk powder in PBST.
Developing solutions used were: Anti PTEN mouse monoclonal clone 
a2b1(Becton Dickinson Bio-sciences UK); Vector elite anti mouse IgG detection 
kit; Anti mouse kit (Vector labs UK); Lumiglo ECL kit (Amersham UK); anti p-actin 
mouse monoclonal clone ac5 (Sigma UK).
PVDF membrane from electrophoresis step was pre-wetted with methanol and 
washed three times with PBST for 5mins each. The colour marker was used to 
orientate the membrane so that the proteins faced upwards and to indicate the 
portion of the membrane to be cropped prior to processing. The membrane was 
placed in blocking solution for 1 hour then washed 3 times in PBST, then 
incubated with anti-PTEN (1:300) or anti-actin (1:20,000) in PBST, for 90 mins. 
Membrane was washed 3 times then Incubate with anti-mouse antibody, 1:800 
for 40mins then Vector ABC complex for 30 mins (prepared 30 mins before use). 
After a further 3 washes, ECL reagent was added and agitated for 1 min. Excess 
was drained and PVDF wrapped in Saran wrap.
The membrane was exposed to photographic x-ray film for 1 min and the film 
developed.
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2.8.1 Immunocvtochemistrv
Bone marrow smears were subjected to immunostaining using a Shannon 
Sequence staining system and a double dilution titre of primary antibody in TBS. 
Positive control without primary antibody was included as a reagent control. The 
titre was started at the maximum concentration recommended by the 
manufacturer. The degree of immunostaining staining, characterised by a brown 
DAB precipitate, was assessed microscopically. The diamino-benzidine 
hydrochloride technique was chosen because DAB produces a precipitate that is 
very stable, not subject to diffusion away from the site of enzyme activity, and is 
insoluble in organic solvents which permits the use of non-aqueous mounting 
media. This media allows clearer resolution of the magnified image in 
microscopy.
The streptavidin/biotin complex (StrepABC) immunostaining was carried out 
using the following protocol:
Slides were fixed in ice-cold methanol/acetone for 5 min and then immersed in 
0.5% hydrogen peroxide in methanol for ten minutes to inhibit endogenous 
peroxidase activity, then washed in running tap water. Slides were loaded onto a 
Shandon Sequenza staining rack and wash with Tris Buffered Saline (TBS100 
mM Tris-CI, pH 7.5;
0.9% NaCI) for five min. All slides were incubated with normal goat serum (1:5
with TBS) for 20 min to block non specific binding of primary antibodies then
treated with 1:300 dilution of PTEN primary antibody (Becton Dickinson UK) for
60 min at room temp. Slides were washed in TBS for five min then incubated in
Biogenex Streptavigen Multilink (Biomen Ltd., UK) diluted 1:60 in TBS for 30 min.
Slides were washed in TBS for 5 min then incubated in "Biogenex"
StrepABC/horse radish peroxidase label diluted 1:60 in TBS for 30 min. Slides
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(Sigma UK) for 5 min then washed in running tap water before counterstaining 
with Harris's Haematoxylin (Merck UK) for 10 seconds. The blue counterstain was 
enhanced by immersion for 1 min in tap water. Slides were then dehydrated 
through consecutive changes of ethanol (BDH, UK) (70—>100%), cleared in 
xylene (BDH, UK) and mounted in non aqueous mounting media (Sigma UK). 
(Internal Standard Operating Procedure, Dept of Histopathology, Arrowe Park 
Hospital. 1998 (Appendix))
2.8.2 Immunofluorescence
Bone marrow smear slides (Haematology Department, Arrowe Park Hospital) 
used for immunofluorescence were methanol-fixed slides selected at less than 
one month old. Slides were rinsed in PBS for 2x2 min then incubated in normal 
goat serum for 30min. Slides were incubated in anti PTEN (1:100) Primary 
Antibody: for 1 hour at room temperature then rinsed in PBS for Rinse 3x2 min. 
Slides were incubated sections in biotinylated secondary antibody (1:500, Vector 
Labs UK) for 30 minutes at room temperature. Slides were rinsed in PBS for 3x2 
min Slides were incubated in FITC-Avidin D (1:500, Vector Labs UK) in PBS for 
30 minutes at room temperature in a black box. Slides were rinsed in PBS for 3x2 
min and counterstained with DAPI (Sigma) for 20-30 minutes at room 
temperature. Slides were rinsed in PBS for 3x2 min then mounted with Vector 
aqueous anti-fade fluorescent mounting medium and examined under UV using 
an Olympus epi-fluorescence microscope.
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Results
3.1 Extraction of nucleic acids from fresh and archived tissue
3.1.1 Extraction of Nucleic acid from fresh cells
The DNA sodium perchlorate/chloroform extraction method provided high yields
of high purity DNA from all 114 SSCP samples tested with no failed extractions
(Table 3.1.1). >50 pg ml'1 concentrations of extracted DNA could be achieved
from lower yields by adding smaller quantities (approx 50ul) of TE buffer to the
precipitated DNA pellet during reconstitution. Occasional samples of very cellular
nature such as CML and CLL produced very viscous sodium perchlorate
homogenates, and this is reflected by the skewed correlation of DNA extract
concentration and DNA purity (corr. coef.= -0.36) (Chart 3.1.1).
This method replaces phenol with 5M sodium perchlorate solution and avoids the
use of the toxic and corrosive chemical used in conventional nucleic acid
extraction methods. The concentrated salt solution acts as a chaotropic agent
and causes rupture of the cell and nuclear membranes and the dissociation of
nucleic acid/protein complexes. The resulting cellular homogenate was mixed
with chloroform, which disrupts protein tertiary structure and exposes hydrophobic
groups that reduce the protein solubility and cause protein precipitation. Lipid-
based cell components dissolve in the organic phase and precipitated protein can
be removed by centrifugation. DNA was precipitated from the resulting aqueous
phase by the addition of isopropanol. The alcohol dehydrates the DNA molecule.
The solubility of DNA depends on the highly soluble, polar deoxy-ribose group
and the highly soluble, negatively charged phosphate group. DNA is insoluble in
alcohol and partial exclusion of water by alcohol results in DNA precipitation. The
purine and pyrimidine base groups in DNA are hydrophobic and the presence of
30% water in the ethanol wash prevents relaxation of torsion pressure in the DNA
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Table 3.1.1 Sample disease types, % tumour cells. DNA concentration and DNA 
purity of samples analysed in the SSCP reactions
Samp.
No.
Leukaemia/
lymphoma
type
%
tum­
our
cells
DNA 
concentr 
ation. pg 
ml'1
Purity
of
DNA
%
1 CML 70 104 80
2 CML >80 336 71
3 CML >80 127 95
4 CML 80 101 86
5 CML 90 71 89
6 CML >80 92 88
7 CML >80 72 93
8 CML 80 107 82
9 CMLT 100 194 76
10 CML 75 140 75
11 CML 75 107 91
12 CLL 100 91 87
13 CLL 100 73 92
14 CLL 100 107 90
15 CLL 82 115 86
16 CLL 75 139 76
17 CLL 100 61 95
18 CLL 57 377 68
19 CLL 73 102 83
20 CLL 64 74 89
21 CLL 83 67 92
22 CLL 95 46 96
23 CLL 84 40 90
24 CLL 87 293 84
25 CLL 71 83 90
26 CLL 77 222 73
27 CLL 81 125 74
28 CLL 71 88 87
29 AMLM1 100 61 82
30 AML M1 30 28 94
31 AMLM1 100 137 82
32 AML M0 90 190 85
33 AMLM0 100 25 90
34 AMLM0 90 39 91
35 AMLM2 70 295 77
36 AMLM2 70 32 93
37 AMLM3a 100 118 75
38 AML4 30 238 82
39 AML4 45 210 78
40 AMLM1 75 109 85
41 AMLM1 87 474 78
42 AMLM1 81 506 70
43 AMLM1 88 36 86
45 AMLM1 96 67 76
46 AMLM1 69 43 86
47 AMLM1 82 69 79
48 HCL 20 43 87
49 HCL 60 27 35
50 NHL 22 35 76
51 NHL LG 51 43 99
52 NHL LG 30 43 78
53 NHL LG 52 25 88
54 NHL LG 11 13 93
55 NHL LG 60 60 91
56 NHL LG 18 53 89
57 NHL LG 45 13 95
58 NHL LG 22 16 72
59 NHL LG 18 96 86
60 NHL LG 31 45 89
61 NHL LG 29 102 79
62 NHL LG 11 45 81
63 NHL LG 22 42 84
64 NHL LG 14 21 81
65 NHL LG 28 70 76
66 NHL LG 24 137 83
67 NHL LG 17 68 92
68 NHL LG 15 33 90
69 NHL LG 25 38 97
70 NHL HG 63 50 82
71 NHL HG 58 68 95
72 NHL HG 43 67 87
73 NHL HG 53 71 91
74 NHL HG 47 87 89
75 NHL HG 50 78 81
76 NHL HG 45 58 79
77 NHL HG 68 11 95
78 RARS 20 36 89
79 RARS 10 61 85
80 RARS 10 85 77
81 RARS 10 65 85
82 RARS 15 52 85
83 RARS 10 52 79
84 RARS 13 73 75
85 RARS 15 17 94
86 RAEB 20 95 98
87 RAEB 29 86 86
88 RAEB 22 65 90
89 RAEB 23 41 87
90 RAEB 18 50 81
91 RAEBT 58 90 97
92 RAEBT 16 55 93
94 RAEBT 23 69 83
94 RAEBT 20 61 88
95 RAEBT 20 77 96
96 RAEBT 33 75 86
97 MYELOMA 31 93 91
98 MYELOMA 39 71 77
99 MYELOMA 28 33 86
100 MYELOMA 23 163 79
101 MYELOMA >30 48 73
102 MYELOMA 10 13 88
103 MYELOMA 23 27 89
104 MYELOMA 26 85 91
105 MYELOMA 18 54 97
106 MYELOMA unk 71 84
107 MYELOMA 10 42 89
108 MYELOMA 20 33 84
109 MYELOMA 20 96 83
110 MYELOMA 19 58 91
111 MYELOMA 31 171 87
112 MYELOMA 26 32 86
113 WM 45 50 93
114 WM 64 47 85
Table 3.1.1 shows the disease type of leukaemia/lymphoma; tumour cells as a percentage of the total sample nucleated 
cells, the concentration of DNA extract established by spectrophotometry at 260nm; the purity of DNA extract using the 
ratio of absorbance at 260nm and 280nm
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molecule and prohibits the formation of alternative helical conformations which is 
essential for binding of DNA binding proteins. The method was used for all fresh 
bone marrow DNA extractions and examples of amplified product are shown in 
the PTEN heteroduplex analysis and SSCP analysis sections. (Calladine et al 
2004).
3.1.2 Extraction of DNA from fixed unstained bone marrow tissue 
Amplification of DNA by PCR reaction using DNA extracted from archived, 
methanol-fixed, unstained DNA smears used a Proteinase K based method. In 
this method , DNA was extracted by the action of Proteinase on membrane 
proteins and nuclear DNA binding proteins. The use of organic solvents was 
avoided though digested protein was not removed prior to precipitation with 
alcohol and the purity of the DNA extract was reduced in comparison to the 
method used for fresh cells. Varying levels of amplification products were 
obtained from samples (Fig 3.1.2) but with lower levels of staining in the smaller 
prothrombin gene product. The prothrombin gene sequence amplified was 
relatively gc rich compared to the p-globin sequence and may be amplified less 
efficiently. The prothrombin primers also have miss-matches two bases from the 
3’ end of the forward primer which may reduce the efficiency of primer binding. 
Also, ethidium bromide staining occurs in proportion to the size of the DNA 
product (Sambrooke et al 1988). The lower levels of staining seen in the 
prothrombin gene product may be a reflection of its smaller size (149bp) 
compared to the p-globin product.
3.1.3 Extraction of DNA from fixed, stained bone marrow smears and comparison 
with unstained smears.
95
Fig 3.1.2 Amplified DNA from fixed stained and unstained smears
A
1 2 3 4 5 6 7 9Origin I ' i a w . * 5® 'insHill1 ill i i i J a
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A Amplified DNA from random normal, fixed, unstained bone marrow smears.
Acceptable levels of amplification are present in all samples.
Top lanes (a) 147 bp human Prothrombin PCR product. Bottom lanes (b) 438bp human Pglobin gene PCR product. Lanes 
1-6: (a and b) random normal bone marrow smears. Lane 7: Blank. Lane 8: 100bp Ladder (8cm Agarose minigel, ethidium 
bromide stain, negative image)
B Amplified DNA from PTEN gene exon 5 and 8 using heteroduplex primers and DNA extracted from random normal fixed, 
stained bone marrow smears
Amplification was less successful compared to unstained smears using the PTEN primers. In this reaction, exon 8 primers 
show higher levels of amplification than exon 5 primers.
Top lanes (a) - PTEN exon 5, bottom lanes (b) - PTEN exon 8. Lanes 1-6: (a and b) random normal bone marrow smears. 
Lane 7: Blank. Lane 8: 100bp Ladder (8cm Agarose minigel, ethidium bromide stain, negative image)
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Amplification of DNA by PCR reaction using DNA extracted from archived, 
methanol-fixed, Romanowsky-stained bone marrow smears by proteinase K 
based extraction from total cell content of the slide (Fig 3.1.2) shows varying 
levels of specific product amplification with no product evident in lane 1. The gel 
shows lower levels of product compared to unstained smear DNA extraction.
Exon 8 products appear brighter than exon 5 despite similar fragment sizes. 
Levels of amplification are reduced compared to unstained smear extracts.
3.1.4 Extraction of DNA from fixed. Romanowskv stained bone marrow smears by 
micro dissection
DNA was extracted and amplified by PCR using DNA extracted from archived, 
methanol-fixed, Romanowsky-stained bone marrow smears by an improvised 
micro-dissection procedure using an ultra fine, hooked needle and inversion 
microscope.
The gel (Fig 3.1.3 A) shows the (3-globin product with varying levels of 
amplification and no amplification at all in lane 1 and 5. Products are specific but 
amplification levels were poor and not considered sufficient for heteroduplex 
analysis which required high levels of amplified product to offset band diffusion 
during the extended electrophoresis run.
3.1.5 Extraction of DNA from formalin-fixed wax-embedded tissue sections. 
Amplification of p-globin DNA by PCR reaction using DNA extracted from 
archived formalin-fixed wax-embedded tissue sections (FFPE) was performed 
using three methods of DNA extraction: deparaffinisation with xylene and DNA 
extraction using organic solvents; deparaffinisation using xylene followed by 
proteinase K treatment; heat-based deparaffinisation followed by proteinase K
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treatm ent. The gel in fig 3.1.3 B shows varying levels of specific amplification 
with very little product in lane 2 and non in lane 5 but acceptable levels of specific 
amplification in lanes 1, 3, 4 and 6. A characteristic smear of higher molecular 
weight DNA was evident in all PCR reactions using FFPE and amplification levels 
were lower than fresh cells. Lehmann et al (2001) have reported that tissue 
storage in formaldehyde solution for more than one week might damage nucleic 
acids, because fixation in formaldehyde induces extensive cross-linking of tissue 
proteins, and nucleic acid fragmentation. The smear of background DNA may 
represent DNA subject to the high rate of fragmentation 
Other extractions showed similar levels of amplified product (not shown) with 
similar rates of successful amplification. The PCR products obtained with the 
heat-based de-waxing technique were amplified as successfully as xylene-treated 
sections. The use of proteinase k gave similar levels of amplification to extraction 
with phenol and chloroform. De-waxing by boiling for 15 min followed by 
proteinase K digestion overnight was the method used for subsequent DNA 
extractions from FFPE. The FFPE subjected to boiling only has a characteristic 
odour of formaldehyde after processing which was not present in the other 
methods. This could explain the lack of amplification if the thermostable 
polymerase protein was denatured by formaldehyde as indicated by Lehmann et 
al. (2001). Fig 3.1.4 shows a titre of DNA template levels from boiling extraction 
and demonstrates the inhibition.
The level of amplification was poor throughout the titre but decreases with 
increasing template, which suggests an inhibition of the reaction. Interestingly, 
primer dimer formation present in the reaction decreases in proportion to the 
added template and at the same rate as the specific product which further 
suggests the presence of an inhibitory factor such as formaldehyde.
Fig 3.1.3 PCR amplification of DNA extracted from fixed, stained bone marrow
smears and FFPE tissue
A -
1 2 3 4 5.  . 6 7
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B - 1 2  3 4 5 6 7 8
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300bp
150bp
A
PCR amplification of 438bp beta globin gene DNA extracted from fixed, stained bone marrow smears by micro dissection. 
Amplification was variable and only reaches acceptable level in lane 2. Two of six reactions have failed (lanes 1 and 5), 
two (lanes 3 and 4) show low level amplification.
Lane 1-5: Random normal bone marrow Lane 6: blank. Lane 7: DNA ladder (8cm Agarose minigel, ethidium bromide 
stain, negative image).
B
PCR amplification of 219bp p globin gene DNA extracted from wax embedded tissue sections (pooled adeno carcinoma 
samples)
Amplification of 219bp product was adequate for heteroduplex analysis in four out of six samples. A background smear of 
DNA was evident in all successfully amplified samples Extraction with proteinase K only gave similar levels of amplification 
to the organic solvent extracts in lanes 4, 5 and 6. boiling without proteinase K treatment was unsuccessful with or without 
organic solvent DNA extraction
Lane 1 -  boil plus proteinase K, Lane 2 - 1 5  minute boil only, Lane 3 -  xylene dewax + Proteinase K, Lane 4, 5 and 6 as 
per lanes 1,2 and 3 but with phenol chloroform extraction. Lane 7 -  blank control. Lane 8 150bp ladder. (8cm Agarose 
minigel, ethidium bromide stain, negative image)
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Fig 3.1.4 Amplification of 219bp B-qlobin gene DNA extracted from wax 
embedded tissue sections -  titre of template DNA
1 2 3 4 5 6 7
Beta
Globin
300bp
-150bp
50bp
PCR amplification of 219bp beta globin gene DNA extracted from wax embedded tissue sections (pancreas) by boiling 
technique -  a titre of template DNA.
The gel shows the inhibitory effect of increasing quantities of DNA template in the PCR reaction. Lane 2 was the product 
amplified from the commercial control DNA used as the heteroduplex control.
Lane 1- blank; Iane2 -  control blood DNA extract; lane 3-6 2.5, 5, 7 .5 ,10ul of DNA template respectively; lane 7 -  ladder
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3.1.6 Extraction of RNA and RTPCR of PTEN in cell lines 
This reaction was designed to demonstrate RTPCR was possible using the PTEN 
cDNA primers and thus demonstrate the production of mRNA in the HL60, 
JURKAT, K562, K620, THP1 and CV605 cell lines studied. Total cellular RNA 
was extracted by an acidic phenol chloroform method then precipitated with 
alcohol. cDNA synthesis was carried out using a random hexamer primer and 
Superscript reverse transcriptase. The PCR stage used primers that generated a 
397bp product. The gel in fig 3.1.6 shows successful amplification of all cell line 
cDNA. The K562 cell sample was had been stored at -20°C  for several months 
but still showed an amplified product but with reduced band intensity compared to 
other cell lines. HL60 and CV605 show highest levels of amplification. K562,
K620 and THP1 show lower levels of product. There was faint staining in Jurkat 
PCR reaction (lane 2) despite the fact that Jurkat cells contain two mutated PTEN 
alleles in exon 7 (a 2bp deletion plus a 9 bp insertion and a 39 bp insertion) that 
introduce premature stop codons which should abolish RTPCR product 
(Georgescu etal. 1999). This could represent amplification of PTHS sequences 
or PTEN cDNA. The possibility of carry over whilst loading the gel was ruled out 
by the lack of product in the blank lane and by similar results obtained with 
subsequent reactions. Contamination with full length mRNA was the most likely 
explanation. This could have been introduced at any part of the procedure 
between cell culture and RTPCR amplification. The reproducibility of the faint 
signal in subsequent extracts suggests the initial cell culture was contaminated 
with a small population of cells expressing full-length mRNA. No distinction was 
possible here between PCR products of PTEN cDNA and PTHS genomic DNA.
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Table 3.1.6
Nucleic acid concentration of cell line total RNA extractions
Cell
line
Leukaemia Cell type Cell count 
X107 ml*1
Nucleic acid 
concentration pg ml*1
CV605 AML M2 8.1 162
K620 Plasma cell 0.5 82
THP1 Acute Monocytic 0.8 265
Jurkat Acute lymphoblastic 2.5 137
HL60 AML M2 1.2 808
K562 CML blast phase — —
Table shows high levels of nucleic acid extracted from each cell line. Quantity of nucleic acid extracted is not proportional 
to cell count with 8.1 x 107 CV605 cells yielding 162 pg whilst 1.2 x107 HL60 cells yielded 808 pg.
RNA of the K562 cells had been extracted previously by the same method
Fig 3.1.6 RTPCR amplification of PTEN mRNA in cell lines
1 2 3 5 6 7 8
Origin -
_-50Gbp
PTENcDNA- W  * .
—  300bp
Gel shows 397 bp RTPCR product PTEN gene from cultured cells. Amplification was achieved for all cell lines with very 
weak amplification in the Jurkat cells
Lanes 1-8: HL60, JURKAT, K562, K620, THP1, CV605, RTPCR Blank, 150bp Ladder respectively. (8cm Agarose 
minigel, ethidium bromide stain, negative image)
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3.2 Optimisation of PCR reactions
3.2.1Titre of magnesium concentration using primer pairs PTGS 5 and PTGS 8. 
These titres were designed to optimise reaction magnesium concentration for the 
problematic exon 5 and 8 (PTGS 5 and 8 primers) for heteroduplex analysis. 
These primers tended to give lower levels of amplification than other exon 
primers. The magnesium concentration titre was performed over the range of 0.5 
to 3.0 mM magnesium chloride in 0.5 mM increments (fig 3.2.1).
The exon 5 reaction shows increasing product levels from 1 .OmM Mg++ with a 
maximum at 2.5mM with a slight decrease in product levels at 3mM. Non-specific 
products are evident at 1.0mM but decrease with increasing Mg++concentration. 
2mM Mg++ was selected for use in subsequent reactions using the exon 5 
primers as amplification at this level provided specific amplification with 
acceptable product levels for heteroduplex analysis (Fig 3.2.1 A).
The exon 8 reaction shows increasing levels of product from 0.5mM Mg++ to a 
maximum at 2.5mM with a slight decrease in product levels at 3mM. Non-specific 
products were only evident at 0.5mM Mg++. 2mM magnesium was also chosen for 
subsequent exon 8 reactions for heteroduplex analysis. The exon 2 magnesium 
titre fails to amplify a specific product but produces two non-specific products at 
approximately 600bp and 1400bp (Fig 3.2.1B)
3.2.2 Optimisation of Magnesium concentration in RTPCR reaction 
The RTPCR reaction had shown a sudden onset of successful reaction 
magnesium concentration between 1 and 1.5 mM. A further reaction titre was 
performed to assess optimum magnesium concentration for PCR step of RTPCR  
reaction by using a finer range of magnesium concentrations over the range 0.8- 
2.0 mM magnesium chloride
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Fig 3.2.1 Titre of PCR magnesium concentration for PTEN exons
A
£ 1  '2 3 4 5 6 7 8
Qriqin-
Exon 5 f OObp OObp
1*1
Origtii-
E x r.n  ft-
A  b
r -^500bp 
— 400bp
Non specific 
Specific 
product
500bp
300bp
A
Titre of PCR magnesium concentration for PTEN exon 5 (a) and 8 (b)
Using PTGS 5 and 8 primers, optimum amplification of maximum product levels and minimum non-specific amplification 
was achieved at 2mM Mg++ for both primer sets
Lane 1-6: 0.5,1.0,1.5, 2.0, 2.5, 3.0, mM Mg++ respectively, Lane 7 blank, lane 8 :100bp ladder. (8cm Agarose minigel, 
ethidium bromide stain, negative image)
B
Titre of PCR magnesium concentration for PTEN alternative exon2 primer pair (PTGS2.1)
Gel shows PCR Mg++ titre using alternative exon 2 primers. Expected product was missing from the 400bp region. Two 
non-specific products are present at approx 600 and 1400bp
Lane 1-6: 0.5,1.0,1.5,2.0, 2.5, 3.0, mM Mg++ respectively, Lane 7 100bp ladder, lane 8 blank. (8cm agarose minigel, 
ethidium bromide stain, negative image)
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Amplification product was evident at 1.2mM magnesium chloride and band 
intensity increases with concentration to a maximum at 2mM Mg++and this 
concentration was used for subsequent reactions (Fig 3.2.2).
No distinction possible here between PCR products of PTEN cDNA and PTHS 
genomic DNA but the extraction procedure was assumed to be specific for PTEN 
total RNA. Fig 3.2.4 shows a non specific amplification product approximately 
30bp behind the specific product increases with magnesium concentration at 
same rate as specific product. The non-specific product was not evident on later 
gels (c.f. Fig 3.2.5).
3.2.3 Titre of dimethvlsulohoxide concentration in PCR reaction for PTEN exons 
1 and 3 (PTGS1 and 3)
These titres measured the effect of dimethylsulphoxide (DMSO) concentration on 
the specificity of PCR reaction for the PTEN exon 1 and 3 reactions, which 
showed non-specific amplification products in the additive free PCR . Titres were 
performed from 0-10% DMSO in 2% increments.
The exon 1 reaction shows product level increases with DMSO concentration up 
to 4% then falls to zero at 10%. Specificity increases with DMSO concentration up 
to 10%. Optimum product level and specificity was obtained at 6% and this 
concentration was used in subsequent reactions.
The exon 3 reaction shows product level decreases with increasing DMSO  
concentration until no product was visible at 10%. Specificity increases with 
DMSO concentration. Optimum product level and specificity occurs with no added
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Fig 3.2.2 Coarse tire of reaction magnesium concentration for PTEN cDNA
primers
1 2 3 4 5 6 7 8
A 4
 ^500bp
PtencDNA—  l - l t t
—  —300bp
1 2 3 4 5 6 7 8
B Origtn-
PTEN cDNA-
A
Coarse tire of reaction magnesium concentration for PTEN cDNA primers.
Amplification product was not evident until 1.5 mM Mg++ Product level above this concentration does not vary significantly 
Lane 1-7: 0.0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0 mM Mg++ respectively, lane 8: ladder. (8cm agarose minigel, ethidium bromide 
stain, negative image)
B
Fine titre of reaction magnesium concentration for PTEN cDNA primers.
Amplification was evident using 1.2 mM Mg++ and rises to maximum amplification at 2.0mM.
Lane 1-7: 0.8, 1.0, 1.2,1.4, 1.6, 1.8, 2.0 mM Mg++ respectively, lane 8: ladder. (8cm agarose minigel, ethidium bromide 
stain, negative image)
107
DMSO. Amplification was weak compared to the exon 1 reactions. Interestingly, 
the level of primer-dimer formation evident in the exon 3 reaction also falls with 
increasing DMSO concentration (Fig 3.2.3).
3.2.4 Annealing temperature gradient analysis for heteroduplex exon 2 primer 
pairs (PTEN genomic seouence (PTGS) 2 and 2.1)
Analysis of the effect of annealing temperature in the PCR reaction using the 
exon 2 primers which showed poor specificity by performing the reaction over a 
range of annealing temperatures - plus and minus 5°C  of the suggested 
annealing temperature of 55°C. The exon 2 primers showed high levels of non­
specific product and appeared to generate different length products in different 
reaction runs using identical reaction conditions. The analysis of the effect of 
annealing temperature was performed using an Eppendorf gradient thermocycler 
which generated a gradient of temperature of 10°C across the thermocycler block 
during the annealing stage of PCR.
The gel in Fig 3.2.4 shows a range of products across the temperature gradient. 
At 51 °C, large amounts of non specific product were produced along with some 
smaller bp non-specific products. As annealing temperature increases towards 
the predicted optimum temperature of 55°C, the quantity of specific product 
produced decreases and higher bp non-specific products start to appear.
At 56°C very little specific product was produced and the 1000bp non-specific 
product starts to accumulate with a maximum yield at 59°C. Alternative exon 2 
primer pairs (PTGS 2.1) showed similar low specificity with very low levels of 
specific product and high levels of higher bp non-specific products . Optimisation 
of magnesium ion concentration and use of additives DMSO and betaine in PCR 
did not increase specificity (not shown).
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Fig 3.2.3 DMSO titres for PTEN exons 1 and 3
r 1 2  3 4 5 6 7 8
Origin- ‘
PTEN exon 1-t 
Non spe
Origin-
PTEN exon 3- j
Non spec
1 2  3 4 5 6 7 8
-500 
■ 400
-500
-400
DMSO titres for PTEN exons 1 and 3.
PCR amplified DNA from pooled normal human DNA. For exon 1, maximum product specificity was obtained using 3% 
DMSO whilst exon 3 shows maximum product with no added DMSO. The non-specific product can be seen for both exons. 
Primer dimmer and non specific amplification decrease with increasing DMSO concentration with both reactions.
Lane 1-7: 0%f2%,4%I6%,8%,10%, DMSO respectively. Lane 8 100bp ladder. Exonl top row (a), exon 3 bottom row (b) 
(8cm agarose minigel, ethidium bromide stain, negative image)
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Fig 3.2.4 Annealing temperature gradient analysis of exon 2 reaction (PTGS2 
primers)
Non-specific
product
specific 
product -
,1 2 3  4 5 6  7 8 9  10
I ~900bp
~600bp
~300bp
Gel shows products produced at annealing temperatures of 51 °C, 52°C, 53°C, 54°C, 55°C, 56°C, 57°C, 58°C, 59°C and 
60°C in lanes 1-10 respectively. Very low levels of specific product are present at 51-53°C A single specific product was 
not obtained at any temperature and there was a change in product sizes obtained at 56°C annealing temperature from a 
range of products around 600 bp to a single product of around 900 bp 
(top half of 8cm agarose minigel, ethidium bromide stain, negative image)
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3.2.5 RTPCR of cell lines derived from haematoloqical malignancy and 
differentiation between PTEN cDNA and PTH2 homologous sequences.
RTPCR of leukaemia/lymphoma cell lines CV605, K260, THP1, K562, HL60 and 
Jurkat was designed to amplify PTEN cDNA and establish that amplification of 
cDNA was achieved without contamination with genomic DNA from the PTH2 
homologous sequence by using digestion with Msel restriction endonuclease 
(RE).
Fig 3.2.5 shows the 397bp sequence amplified from both sequences. The 
RTPCR product from cell lines was fully digested into fragments of 143 and 194 
bp, with only a faint trace of undigested product (337bp) in lane 2, the CV605 lane 
which could be product carry over from lane 1.
Lanes 1 and 8 show the PTH2 PCR product amplified from genomic DNA which 
was only partially digested into a 337bp sequence. Lane 9 shows undigested/full- 
length PCR product.
All cell lines show similar levels of product except Jurkat cells in (Iane7), which 
shows a very faint amplified product (as previously mentioned, Jurkat cells 
contain two mutated PTEN alleles in exon 7 - a 2bp deletion plus a 9 bp insertion 
and a 39 bp insertion - that introduce premature stop codons which should 
abolish RTPCR product (Georgescu etal. 1999)). The presence of faint but fully 
digested product in the Jurkat lane indicated the presence of RT PCR product 
not amplified PTH2 product as the product had been digested by Msel.
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Fig 3.2.5 Differentiation between PTEN cDNA and PTHS sequences by Msel 
digest
397bp- 337bp___^
194bf
143bE *■--------- i *
8 9 10
500bp
300bp
150bp
50bp
Fig 3.2.5 shows RTPCR of cell lines digested with MSE1 plus a pooled DNA extract. Lane 1&8: pooled normal DNA. Lane 
2-7: CV605, K260, THP1, K562, HL60 and Jurkat RNA. Lane 9 uncut 397bp PCR product Lane 10 PCR DNA ladder. All 
cells show amplified cDNA including weak amplification in the Jurkat cell sample, which should not show amplification due 
to a deletion of PTEN expression in both alleles. (10cm, 10% polyacrylamide gel stained with ethidium bromide. Negative 
image)
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3.3 Heteroduplex analysis.
3.3.1 Optimised heteroduplex PCR for each PTEN exon.
The gel in Fig 3.3.1 shows the optimised PCR product after magnesium 
concentration titres, DMSO titres for exons 1,2 and 3 and annealing temperature 
gradient analysis for exon 2. The reactions used normal pooled control DNA as a 
template for each PTEN exon used in the heteroduplex analysis reactions. The 
gel shows the relative quantity of product produced by each reaction. Exons 1,3,8 
and 9 amplicons show less intense staining than exons 2,4,5,6 and 7. The size 
variation between reactions was necessary to achieve efficient PCR. The exon 2 
product shows several non-specific products of increased fragment size 
compared to the specific product (approx 1000 and 600bp). Optimisation of the 
exon 2 reaction to yield only specific product proved very difficult despite the use 
of additives and optimisation of magnesium ion concentration and annealing 
temperature gradient studies. Exons 1 and 3 still have some low level non­
specific product despite addition of DMSO but the non-specific product level was 
considered acceptable for heteroduplex analysis.
3.3.2 Optimisation of Heteroduplex electrophoresis conditions
This gel was designed to show that 19:1 acrylamide/bis acrylamide was suitable 
for resolution of heteroduplex bands using a PCR-amplified section of the p globin 
gene heterozygous for the a—>t mutation coding for haemoglobin S (fig 3.3.2) 
Separation of heteroduplex and homoduplex bands was not apparent and 
resolution was very poor. Heat generated during the electrophoresis has induced 
“smiling” effect. Gel star® stain demonstrates bands faintly.
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Fig 3.3.1 Optimised PCR product for each PTEN exon
1 2  3 4 5 6 7 8 9 10 11
500bp
300bp
150bp
Fig 3.3.1 Gel shows optimised PCR product for each PTEN exon used for the heteroduplex analyses. Lane 1-11 Blank, 
Exon 1, Exon 2, Exon 3, Exon 4, Exon 5, Exon 6, Exon 7, Exon 8, Exon 9,150 bp ladder respectively. (10cm-long section 
of 15x15cm Agarose gel, ethidium bromide stain, negative image)
114
Fig 3.3.2 Heteroduplex analysis with acrylamide/bis gel
Heteroduplex 
band -
4 5 6 7 8
Fig 3.3.2 Gel shows 7cm long area of 50cm heteroduplex gel using 6% 19:1 bis acrylamide/acrylamide gel. Lane 1 and 8: 
0X174//-//nf1 digest Lanes 2-7 Pglobin PCR product heterozygous for a/t allele responsible for sickle haemoglobin 
mutation. (Gelstar® stain, negative image)
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3.3.3 Heteroduplex analysis with modified cross-linker Bis-acrvlole piperazine
In an attempt to increase band sharpness Bis-acrylamide was replaced with Bis 
acryl piperazine (BAP) in 0.5x Tris-Taurine EDTA (TTE) buffer at 19:1 ratio of 
acrylamide and bis/acrylamide using a 10% gel as specified by Ganguly etal. 
(1993) with 10% glycerol. TTE Glycerol Tolerant Buffer (20X) is a concentrated 
Tris-Taurine-EDTA buffer solution. The use of TTE buffer eliminates the band 
distortion obtained during electrophoresis of DNA samples in glycerol-containing 
gels run with borate-containing buffers (Product instruction sheet, Geneflow Ltd, 
UK).
The use of TTE buffer dramatically increased band separation but resolution of 
heteroduplex bands was still poor.
Separation of heteroduplex and homoduplex bands was not apparent but there 
was a detectable increase in resolution of heteroduplex bands compared to bis- 
acrylamide (fig 3.3.4 A).
3.3.4 Heteroduplex analysis with Bis-acrvlovl piperazine and non denaturing 
concentration of ethylene glycol and formamide.
Electrophoresis was performed with and without non denaturing concentrations of 
ethylene glycol and formamide to demonstrate the effect on resolution of 
heteroduplex bands. The gel shows improved separation and sharper resolution 
of heteroduplex bands and a clear distinction possible between homo- and 
heteroduplexes was obtained but unacceptable levels of band diffusion remained 
(Fig 3.3.4 B).
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Fig 3.3.4 Heteroduplex gels with and without formamide and ethylene glycol
Heteroduplex ’ 
band-
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Homoduplex-
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—417bp 
-413bp
427bp
417bp
413bp
A
Gel A was a 7cm long area of 50cm heteroduplex gel using 6% 19:1 acrylamide with bis acryl piperazine (BAP) modified 
cross-linker.
Heteroduplex bands are highly diffused and only partially discemable
Lanes 1 and 9: OX174/H//7f1 digest. Lanes 3-8 Pglobin PCR product carrying a/t allele responsible for sickle haemoglobin 
mutation. (Gelstar ® stain, negative image)
B
Gel shows 4cm long area of 50cm heteroduplex gel 6% 19:1 acrylamide with bis-acryloyl piperazine (BAP) with non 
denaturing concentration of formamide and ethylene glycol.
Resolution of heteroduplex bands was improved but was still insufficient for accurate delineation of bands
Lane 1- normal homoduplex, Lanes 2-5 Positive heteroduplex control pglobin PCR product carrying a/t allele. Lane 6-
0X174/Hinh ladder.
(Gelstar ® stain, negative image)
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3.3.5 Heteroduplex analysis with use of proprietary acrvlamide-based gel mix 
PaqePlus® with GelStar® or sliver staining
The PagePlus media was used in an attempt to improve heteroduplex band 
resolution and produced dramatically improved resolution of stained bands. The 
relationship between fragment size and distance migrated appeared more linear 
than standard acrylamide gels. Gel 3.3.5 shows very clear bands with low levels 
of diffusion and a clear distinction between homo-and heteroduplex bands in the 
HbS control lane.
The gel was stained with GelStar at manufacturers’ recommended concentration 
then silver stained. GelStar stained gel shows very clear distinct bands whilst the 
silver stained gel shows increased staining levels but some loss of resolution. The 
silver stained gel also shows some non-specific product in the PTEN exon 8 
reactions. Silver staining also appears more quantitative with larger differences in 
staining intensity between exons compared to GelStar.
3.3.6 Bis-acrvlole piperazine (BAP) gel with silver staining.
Difference between migration distance and fragment size obtained with BAP gel. 
The products of each exon show a greater relative difference in migration 
distance than when compared to the PagePlus gels in Fig 3.3.5 
Silver stained gel shows intense staining of PCR heteroduplex fragments and this 
represents an over-developed gel. Individual bands of hetero- and homoduplexes 
in control fragments were visible during initial development of stained gel but 
became indistinct as development of the image continued. Exon 5 reactions show 
more intense staining and overall resolution of the gel was poor due to 
overdeveloping of the silver stain. GelStar was used in subsequent runs to 
identify the position of the heteroduplex bands then photographed prior to
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Fig 3.3.5 Comparison of GelStar staining and silver staining.
A 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
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A Gel was stained with GelStar and shows excellent delineation of heteroduplex bands in the control ( lane 1) background 
staining was very low.
B Gel was silver stained. Staining was more intense showing greater sensitivity to quantity of DNA in each band. 
Delineation of the heteroduplex control was adequate but inferior to GelStar staining
7cm section of 50cm heteroduplex gel using PagePlus® medium at concentration recommended by manufacturer.
Lane 1 HbS HD control. Lanes 2-7 samples PTEN exon 5(400bp). Lanes 8-13 samples exon7 (351). Lanes 14-19 samples 
exon 8 (420bp). Lane 20 OX174/H/nfl Ladder. (Gelstar stain, negative image).
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Fig 3.3.6 Silver stained BAP gel heteroduplex reactions
1 2 3 4 5 6 7 4 $  1011 12 1314 1516 17 16 19 2D
*  *
l
*  m
Random stained bone marrow smear samples and Jurkat cells. 20x50cm, bottom 20cm of gel shown.
This gel shows the relative increased difference in distance migrated by the exon 5 7 and 8 products on the BAP gel when 
compared to the PagePlus media. Silver staining was over developed on this gel. The heteroduplex bands in the control 
have merged despite being visible in the early stages of development.
Lane 1 heteroduplex contro l. Lanes 2-6 are bone marrow smears PTEN exon 5 (400bp)..
Lanes 7-10 are bone marrow smears PTEN exon 7 (351bp). Lane 11 was Jurkat exon 7. Lanes 12-15 are bone marrow 
smears PTEN exon 8 (420bp). Lane 9 300 & 500bp marker.
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excision of the region for silver staining. Interestingly, the 438bp heteroduplex 
control migrates at approximately the same rate as the 427bp ladder fragment. 
This effect was a feature of polyacrylamide gel electrophoresis where fragment 
secondary structure affects migration rate. Jurkat cells contain two mutated PTEN 
exon 7 alleles: a 2bp deletion plus a 9 bp insertion and a 39 bp insertion (Sakai 
et al 1998)
3.3.7 Heteroduplex analysis of PTEN exons 5. 7 and 8 
All lymph node samples screened were non-Hodgkin’s lymphoma. Initial bone 
marrow smear samples for heteroduplex analysis consisted of 3 chronic 
myelogenous leukaemia, 10 chronic lymphocytic leukaemia, 12 acute 
myelogenous leukaemia, 2 hairy cell leukaemia, 10 non-Hodgkins lymphoma, 16 
myelodysplasia, 13 myeloma and 2 Waldenstrome's macroglobulinaemia 
All lymphoma samples in all exon 5, 7 and 8 PCR reactions for lymph nodes 
migrated as homoduplexes. The proportion of PCR product representing DNA 
amplified from the tumour cell clone varied between samples. Figures for the 
percentage of tumour and normal cells were unavailable for the FFPE and 
depended on the size of the tumour in relation to the individual lymph node. The 
very low positive screen rate and concerns that a sub population of mutated 
tumour cells would not produce a visible heteroduplex band led to the 
abandonment of heteroduplex screening in favour of SSCP after 18 lymph node 
and bone marrow samples
The heteroduplex gels showed a high failure rate for exon 8 PCR reactions 
characterized by faint, diffused or absent product (fig 3.3.7.1) in expected region 
of gel with only 8 of 18 lymph node FFPE samples showing product in which a 
heteroduplex band would be apparent against the diffused background signal.
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Exon 5 and 7 reactions were less variable with 3 and 1 failed reactions 
respectively. Failed reactions in the 50cm heteroduplex gel often showed some 
reaction products in the screening procedure using short runs on agarose gel. 
Loss of staining intensity was marked when comparing the same product in 8cm 
agarose and 50 cm Page Plus gels.
FFPE samples 1-6 (Fig 3.3.7.1 A) show good resolution of exon 5 and 7 products 
with no amplification products for exon 8. All visible bands have migrated as 
expected with no evidence of heteroduplex bands. The control band shows 
formation of heteroduplex.
FFPE samples 7-12 (Fig 3.3.7.1 B) show resolution of exon 5 and 7 and 8. 
Samples 9, 11 and 12 show fainter products in each exon and heteroduplex 
generation would not be apparent. All bands have migrated as expected with no 
evidence of heteroduplex bands. The control band shows formation of 
heteroduplex.
FFPE samples 13-18 (Fig 3.3.7.2 A) show good resolution of exon 5 and 7 
products with no amplification products for exon 8. All bands have migrated as 
expected with no evidence of heteroduplex bands. The control band shows 
formation of heteroduplex.
Stained bone marrow samples 1-6 (Fig 3.3.7.2 B) show resolution of exon 5 and 
7 and 8. Samples 2,4,5 and 6 show no products in exon 8. All bands have 
migrated as expected with no evidence of heteroduplex bands but sample 1 in 
lane 14 shows two bands with aberrant retarded migration patterns that were not
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Fig 3.3.7.1 Heteroduplex analysis of lymph node samples 1-12 exons 5,7 and 8
A
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Fig 3.3.7.1 A
Gel A shows heteroduplex analysis of lymph node samples 1-6.
No heteroduplex bands are evident. Exon 8 samples are highly diffused.
lane 1: heteroduplex control, in lane 2-19: lymph node samples 1-6 of exons 5, 7and 8 respectively, lane 20: 
0X174/H/nf1 Ladder (7cm section of 50cm heteroduplex PagePlus® gel, Gelstar ® stain, negative image).
Fig 3.3.7.1 B shows heteroduplex analysis of lymph node samples 7-12. lane 1: heteroduplex control, in lane 2-19: lymph 
node samples 7-12 exons 5, 7and 8 respectively. Exon 8 reactions were prone to failure at the heteroduplex 
electrophoresis stage despite adequate levels of amplification in agarose gels lane 20: OX174/H/nf1 Ladder (7cm section 
of 50cm heteroduplex PagePlus® gel, Gelstar ® stain, negative image).
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Fig 3.3.7.2 Heteroduplex analysis of lymph nodes 1 3 - 1 8  and bone marrow
samples 1-6
A
1 2 3 4 5 6 7 8 9 10 11 12 131415161718 19 20
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Fig 3.3.7.2 A Gel shows heteroduplex analysis of lymph node samples 13-18. bands have migrated as expected with no 
evidence of heteroduplex bands
lane 1: heteroduplex control, in lane 2-19: lymph node samples 13-18 exons 5, 7and 8 respectively, lane 20: 
0X174//7/'rjf1 Ladder (7cm section of 50cm heteroduplex PagePlus® gel, Gelstar ® stain, negative image).
Fig 3.3.7.2 B Gel shows heteroduplex analysis of stained bone marrow samples 1-6.
bands have migrated as expected with no evidence of heteroduplex bands lane 1: heteroduplex control, in lane 2-19: 
stained bone marrow samples 1-6 exons 5, 7and 8 respectively, lane 20: QXWAIHinft Ladder. Lane 14 shows two bands 
with aberrant retarded migration patterns that were not reproduced when the PCR was repeated. (7cm section of 50cm 
heteroduplex PagePlus® gel, Gelstar ® stain, negative image).
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reproduced when the PCR was repeated, which suggests the presence of a non­
specific amplification product in the initial reaction. Control band shows formation 
of heteroduplex.
Stained bone marrow samples 7-12 (Fig 3.3.7.3 A) show good resolution of exon 
5, 7 and 8. All bands have migrated as expected with no evidence of 
heteroduplex bands. Control band shows formation of heteroduplex.
Stained bone marrow samples 13-18 in (Fig 3.3.7.3 B) show resolution of exon 5 
and 7 and 8. Sample 16 shows a fainter products in exon 8 and heteroduplex 
generation would not be apparent. All bands have migrated as expected with no 
evidence of heteroduplex formation. Control band shows formation of 
heteroduplex.
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Fig 3.3.7.3 Heteroduplex analysis of stained bone marrow samples 7-18
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Fig 3.3.7.5 Gel shows heteroduplex analysis of stained bone marrow samples 7-12. Lane 1: heteroduplex control, n lane 2- 
19: stained bone marrow samples 7-12 exons 5, 7and 8 respectively, lane 20: <t>X174/H/n/1 Ladder (7cm section of 50cm 
heteroduplex PagePlus®gel, Gelstar® stain, negative image).
Fig 3.3.7.6 Gel shows heteroduplex analysis of stained bone marrow samples 13-18. lane 1: heteroduplex control, in lane 
2-19 stained bone marrow samples 13-18 exons 5, 7and 8 respectively, lane 20: OX174/H/nf1 Ladder (7cm section of 
50cm heteroduplex PagePlus®gel, Gelstar ® stain, negative image).
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3.4 SSCP analysis
3.4.1 PCR product specificity for SSCP analysis
Gel in Fig 3.4.1 shows all primers used in SSCP analysis which produce PCR 
products of around 300bp. Exon 1 primers showed some non-specific 
amplification products. Exon 2 primers produced a number of non-specific 
products that varied between 300 and 1000 bp. Results were highly variable for 
specificity of exon 2 PCR between batches of amplification (results not shown). 
This variability was similar to that obtained with the heteroduplex exon 2 primers 
despite a 120bp reduction in amplified fragment size. The unpredictability and 
lack of specificity in the exon 2 PCR led to its exclusion from the SSCP analysis 
as exon 2 is not identified as an area commonly subject to mutation (Bonneau 
and Longy 2000).
The PCR for SSCP analysis yielded higher levels of specific product than the 
heteroduplex reactions. The SSCP gels were also less susceptible to diffusion 
effects.
Fig 3.4.1 shows the product of each SSCP primer pair and demonstrates the 
continued lack of specificity of the exon 2 reaction.
Optimum separation of single strand amplicons was achieved at 12 W  constant 
power for 16h at a plate temperature (measured in the centre of the plate) of 
13°C, which corresponded to a coolant temperature of 10 °C.
The SSCP analysis was performed on a 30cm or 50cm-long gel but, as shown in 
Fig 3.4.2, resolution of single stranded complexes was possible using a much 
smaller and more manageable 8cm format gel with higher concentration of 
PagePlus media. Lane 3 shows clearly the aberrant migration of PTEN exon 7 
product obtained using NIH33 cells.
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Fig 3.4.1 PCR products obtained using primers for SSCP analysis
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Fig 3.4.1 Gel shows PCR products obtained using primers for SSCP analysis with random normal DNA extract from fresh 
blood. Top row, Lane 2-6: PTEN SSCP 1-5 respectively. Bottom row, lane 2-5: PTEN SSCP 6-9 respectively.. Lane 6 
100bp Ladder (8cm Agarose minigel, ethidium bromide stain, negative image)
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Fig 3.4.2 SSCP electrophoresis on 8cm and 50cm Page Plus gels
A
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A Gel shows SSCP electrophoresis on 8cm Page Plus ® gel with 2x manufacturer's recommended concentration of 
PagePlus concentrate. PTEN exon 7 PCR. Differential migration is evident on small format gel using more concentrated 
medium but result is clearer using the 30 cm format gel shown in B
Lane 1 & 2 Ladders, Lane 3 positive control NIH 33 cells Lanes 4-7 Fresh bone marrow DNA..
B shows 30 cm gel with recommended concentration of PagePlus medium PTEN exon 7 PCR 
Lanes 1-9 bone marrow samples, lane 10 (arrowed) positive control NIH 33 cells.
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3.4.2 SSCP of bone marrow samples
3.4.2.1 SSCP PTEN Exonl
SSCP analysis of PTEN exon 1 showed good PCR product levels that yielded 4 
main conformers on electrophoresis. The use of the cooling system greatly 
reduced band distortion and “smiling” in all the large format SSCP gels. Of the 
four bands, the individual band showing the strongest stain varied from sample to 
sample with no obviously dominant conformation. Some faint, background, 
slower-migrating bands were evident with silver staining, the staining intensity of 
these bands was proportional to the intensity of the four main conformers. No 
aberrant migrating bands that would suggest the presence of a mutation were 
identified in the 114 samples screened Samples 96-114 are not shown due to a 
mishap when handling the gel after silver staining.
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Fig 3.4.2.1.1 Gel shows PTEN exonl SSCP analysis of fresh bone marrow samples 1-9. Lane 1: 0X 17AIHinh Ladder, 
lane 2-10: fresh bone marrow samples 1-9 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive 
enhanced image).
Fig 3.4.2.1.2 Gel shows PTEN exonl SSCP analysis of fresh bone marrow samples 10-19. Lane 1-10: fresh bone marrow 
samples 10-19 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive enhanced image).
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Fig 3.4.2.1.3 Gel shows PTEN exonl SSCP analysis of fresh bone marrow samples 20-28. Lane 2: <t>X174/H/nf1 Ladder, 
lane 1+ 3-9: fresh bone marrow samples 20-28 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.1.4 Gel shows PTEN exonl SSCP analysis of fresh bone marrow samples 29-38. Lane 1-10: fresh bone marrow 
samples 29-38 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive enhanced image).
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Fig 3.4.2.1.5 Gel shows PTEN exonl SSCP analysis of fresh bone marrow samples 39-47. Lane 3: 0X174/H//ifl Ladder, 
lane 1-2+ 4-10: fresh bone marrow samples 39-47 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.1.6 Gel shows PTEN exonl SSCP analysis of fresh bone marrow samples 48-57. Lane 1-10: fresh bone marrow 
samples 48-57 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive enhanced image).
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Fig 3.4.2.1.7 Gel shows PTEN exonl SSCP analysis of fresh bone marrow samples 58-66. Lane 4: OX174/H//7/1 Ladder, 
lane 1-3+ 4-10: fresh bone marrow samples 58-66 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.1.8 Gel shows PTEN exonl SSCP analysis of fresh bone marrow samples 67-76. Lane 1-10: fresh bone marrow 
samples 67-76 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive enhanced image).
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Fig 3.4.2.1.9 Gel shows PTEN exonl SSCP analysis of fresh bone marrow samples 77-85. Lane 5: 0X174/W/'nf1 Ladder, 
lane 1-4 + 5-10: fresh bone marrow samples 77-85 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.1.10 Gel shows PTEN exonl SSCP analysis of fresh bone marrow samples 86-95. Lane 1-10: fresh bone 
marrow samples 86-95 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive enhanced image).
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3.4.2.2 SSCP PTEN Exon 2
Exon two was excluded from the SSCP analysis because no suitable specific 
PCR reaction could be developed. These findings mirror those of the 
heteroduplex analysis of PTEN exon 2, despite the fact that exon 2 SSCP PCR 
primers produce a fragment 150bp smaller than the PTGS exon two primers.
3.4.2.3 SSCP PTEN Exon 3
SSCP analysis of PTEN exon 3 showed good PCR product levels that yielded 4 
main conformers on electrophoresis. Of the four bands, the individual band 
showing the strongest stain, like exonl, varied from sample to sample with the 
slowest migrating conformer usually being dominant. The first or second band of 
the three fastest migrating bands was the first to show fainter staining intensity. 
No faint background bands were evident with silver staining. No aberrant 
migrating bands that would suggest the presence of a mutation were identified in 
the 114 samples screened.
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Fig 3.4.2.3.1 Gel shows PTEN exon 3 SSCP analysis of fresh bone marrow samples 1-9. Lane 1: <t>X174/H/nfl Ladder, 
lane 2-9: fresh bone marrow samples 1-9 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.3.2 Gel shows PTEN exon 3 SSCP analysis of fresh bone marrow samples 10-19. Lane 1-10: fresh bone 
marrow samples 10-19 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.3.3 Gel shows PTEN exon 3 SSCP analysis of fresh bone marrow samples 20-28. Lane 2: 0X174/H/nf1 Ladder, 
lane 1+ 3-9: fresh bone marrow samples 20-28 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.3.4 Gel shows PTEN exon 3 SSCP analysis of fresh bone marrow samples 29-38. Lane 1-10: fresh bone marrow 
samples 29-38 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
138
Fig 3.4.2.3.5 Gel shows PTEN exon 3 SSCP analysis of fresh bone marrow samples 39-47. Lane 3: OX174/H/nf1 Ladder, 
lane 1-2+ 4-10: fresh bone marrow samples 39-47 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.3.6 Gel shows PTEN exon 3 SSCP analysis of fresh bone marrow samples 48-57. Lane 1-10: fresh bone marrow 
samples 48-57 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.3.7 Gel shows PTEN exon 3 SSCP analysis of fresh bone marrow samples 58-66. Lane 4: QX174/Hinf1 Ladder, 
lane 1-3+ 5-10: fresh bone marrow samples 58-66 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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3.4.2.3.8 Gel shows PTEN exon 3 SSCP analysis of fresh bone marrow samples 67-76. Lane 1-10: fresh bone marrow 
samples 67-76 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.3.9 Gel shows PTEN exon 3 SSCP analysis of fresh bone marrow samples 77-85. Lane 5: OX174/H//7f1 Ladder, 
lane 1-4 + 6-10: fresh bone marrow samples 77-85 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.3.10 Gel shows PTEN exon 3 SSCP analysis of fresh bone marrow samples 86-95. Lane 1-10: fresh bone 
marrow samples 86-95 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.3.11 Gel shows PTEN exon 3 SSCP analysis of fresh bone marrow samples 96-104. Lane 6: d>X174/H/nf1 
Ladder, lane 1-5 + 7-10: fresh bone marrow samples 96-104 respectively. (5cm section of 50cm PagePlus®gel, Silver 
stain, positive enhanced image).
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Fig 3.4.2.3.12 Gel shows PTEN exon 3 SSCP analysis of fresh bone marrow samples 105-114. Lane 1-10: fresh bone 
marrow samples 105-114 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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3.4.2.4 SSCP PTEN Exon 4
SSCP analysis of PTEN exon 4 showed good PCR product levels which yielded 
2 or 3 main conformers on electrophoresis. The three main conformers were 
interspersed with a large number of faint bands, the staining intensity of these 
bands was proportional to the intensity of the three main conformers, the 
individual band showing the strongest stain varied from sample to sample with the 
two slowest migrating conformers usually the strongest. No aberrant migrating 
bands that would suggest the presence of a mutation were identified in the 114 
samples screened but faint aberrant conformers could be masked by the 
background signal.
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Fig 3.4.2.4.1 Gel shows PTEN exon 4 SSCP analysis of fresh bone marrow samples 1-9. Lane 1: OX174/H/nf1 Ladder, 
lane 2-9: fresh bone marrow samples 1-9 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.4.2 Gel shows PTEN exon 4 SSCP analysis of fresh bone marrow samples 10-19. Lane 1-10: fresh bone marrow 
samples 10-19 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.4.3 Gel shows PTEN exon 4 SSCP analysis of fresh bone marrow samples 20-28. Lane 2: OX174/H/Vjf1 Ladder, 
lane 1+ 3-9: fresh bone marrow samples 20-28 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.4.4 Gel shows PTEN exon 4 SSCP analysis of fresh bone marrow samples 29-38. Lane 1-10: fresh bone marrow 
samples 29-38 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive enhanced image).
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Fig 3.4.2.4.5 Gel shows PTEN exon 4 SSCP analysis of fresh bone marrow samples 39-47. Lane 3: OX174/H/nf1 Ladder, 
lane 1-2+ 4-10: fresh bone marrow samples 39-47 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.4.6 Gel shows PTEN exonl SSCP analysis of fresh bone marrow samples 48-57. Lane 1-10: fresh bone marrow 
samples 48-57 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive enhanced image).
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Fig 3.4.2.4.7 Gel shows PTEN exon 4 SSCP analysis of fresh bone marrow samples 58-66. Lane 4: OX174/H/nf1 Ladder, 
lane 1-3+ 5-10: fresh bone marrow samples 58-66 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.4.8 Gel shows PTEN exon 4 SSCP analysis of fresh bone marrow samples 67-76. Lane 1-10: fresh bone marrow 
samples 67-76 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive enhanced image).
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Fig 3.4.2.4.9 Gel shows PTEN exon4 SSCP analysis of fresh bone marrow samples 77-85. Lane 5: OX174/H/'nf1 Ladder, 
lane 1-4 + 5-10: fresh bone marrow samples 77-85 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive 
enhanced image).
Fig 3.4.2.4.10 Gel shows PTEN exon 4 SSCP analysis of fresh bone marrow samples 86-95. Lane 1-10: fresh bone 
marrow samples 86-95 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive enhanced image).
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Fig 3.4.2.4.11 Gel shows PTEN exon 4 SSCP analysis of fresh bone marrow samples 96-104. Lane 6: OX174/H/nf1 
Ladder, lane 1-5 + 6-10: fresh bone marrow samples 96-104 respectively. (5cm section of 50cm PagePlus® gel, Silver 
stain, positive enhanced image).
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Fig 3.4.2.4.12 Gel shows PTEN exon 4 SSCP analysis of fresh bone marrow samples 105-114. Lane 1-10: fresh bone 
marrow samples 105-114 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive enhanced image).
3.4.2.5 SSCP PTEN Exon5
SSCP analysis of PTEN exon 5 showed good PCR product levels which yielded 6 
conformers on electrophoresis. The conformers were composed of three clear 
bands interspersed with three fainter bands. As with previous exons, the staining 
intensity of these bands was proportional to the intensity of the three main 
conformers, the individual band showing the strongest stain was consistent from 
sample to sample with the two fastest and the slowest migrating conformers 
usually the strongest. Two aberrant migrating bands that would suggest the 
presence of a mutation were identified (Fig 3.4.2.5.13) in the 114 samples 
screened. Though six conformers were generated per sample, these were 
consistent throughout the samples and aberrant bands were easily identified. No 
faint background conformers were evident.
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Fig 3.4.2.5.1 Gel shows PTEN exon 5 SSCP analysis of fresh bone marrow samples 1-9. Lane 1: 0X 174/H/nfl Ladder, 
lane 2-9: fresh bone marrow samples 1-9 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.5.2 Gel shows PTEN exon 5 SSCP analysis of fresh bone marrow samples 10-19. Lane 1-10: fresh bone marrow 
samples 10-19 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive enhanced image).
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late 3.4.2.5.3 Gel shows PTEN exon 5 SSCP analysis of fresh bone marrow samples 20-28. Lane 2: 0X174/H/nf1 Ladder, 
lane 1+ 3-9: fresh bone marrow samples 20-28 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.5.4 Gel shows PTEN exon 5 SSCP analysis of fresh bone marrow samples 29-38. Lane 1-10: fresh bone marrow 
samples 29-38 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive enhanced image).
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Fig 3.4.2.5.5 Gel shows PTEN exon 5 SSCP analysis of fresh bone marrow samples 39-47. Lane 3: OX1741Hinft Ladder, 
lane 1-2+ 4-10: fresh bone marrow samples 39-47 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.5.6 Gel shows PTEN exon 5 SSCP analysis of fresh bone marrow samples 48-57. Lane 1-10: fresh bone marrow 
samples 48-57 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive enhanced image).
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Fig 3.4.2.5.7 Gel shows PTEN exon 5 SSCP analysis of fresh bone marrow samples 58-66. Lane 4: OX174/H/nf1 Ladder, 
lane 1-3+ 5-10: fresh bone marrow samples 58-66 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.5.8 Gel shows PTEN exon 5 SSCP analysis of fresh bone marrow samples 67-76. Lane 1-10: fresh bone marrow 
samples 67-76 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive enhanced image).
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Fig 3.4.2.5.9 Gel shows PTEN exon 5 SSCP analysis of fresh bone marrow samples 77-85. Lane 5: QX174/Hinf1 Ladder, 
lane 1-4 + 6-10: fresh bone marrow samples 77-85 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.5.10 Gel shows PTEN exon 5 SSCP analysis of fresh bone marrow samples 86-95. Lane 1-10: fresh bone 
marrow samples 86-95 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive enhanced image).
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Fig 3.4.2.5.11 Gel shows PTEN exon 5 SSCP analysis of fresh bone marrow samples 96-104. Lane 6: <t>X174/H/nf1 
Ladder, lane 1-5 + 7-10: fresh bone marrow samples 96-104 respectively. (5cm section of 50cm PagePlus® gel, Silver 
stain, positive enhanced image).
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Fig 3.4.2.5.12 Gel shows PTEN exon 5 SSCP analysis of fresh bone marrow samples 105-114. Lane 1-10: fresh bone 
marrow samples 105-114 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive enhanced image).
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Fig 3.4.2.5.13 SSCP PTEN exon 5 samples 42 & 45, in lanes 3 and 6
respectively - detail of aberrant bands (arrowed)
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3.4.2.6 SSCP PTEN Exon6
SSCP analysis of PTEN exon 6 showed good PCR product levels which yielded 2 
conformers on electrophoresis. The conformers were composed of two clear 
bands occasionally interspersed with one fainter band in stronger staining 
samples. As with previous exons, the staining intensity of these bands was 
proportional to the intensity of the main conformers, The two main conformers 
were stained with equal intensity. No aberrant migrating bands that would 
suggest the presence of a mutation were identified in the 114 samples screened. 
The two conformers present with this exon were very clear and aberrant 
conformers would have been seen easily. No faint background conformers were 
evident.
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Fig 3.4.2.6.1 Gel shows PTEN exon 6 SSCP analysis of fresh bone marrow samples 1-9. Lane 1: OX174/H/'nf1 Ladder, 
lane 2-9: fresh bone marrow samples 1-9 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.6.2 Gel shows PTEN exon 6 SSCP analysis of fresh bone marrow samples 10-19. Lane 1-10: fresh bone 
marrow samples 10-19 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive enhanced image).
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Fig 3.4.2.6.3 Gel shows PTEN exon 6 SSCP analysis of fresh bone marrow samples 20-28. Lane 2: OX174/H/nf1 Ladder, 
lane 1+ 3-9: fresh bone marrow samples 20-28 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.6.4 Gel shows PTEN exon 6 SSCP analysis of fresh bone marrow samples 29-38. Lane 1-10: fresh bone marrow 
samples 29-38 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.6.5 Gel shows PTEN exon 6 SSCP analysis of fresh bone marrow samples 39-47. Lane 3: OX174/H/nf1 Ladder, 
lane 1-2+ 4-10: fresh bone marrow samples 39-47 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.6.6 Gel shows PTEN exon 6 SSCP analysis of fresh bone marrow samples 48-57. Lane 1-10: fresh bone marrow 
samples 48-57 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.6.7 Gel shows PTEN exon 6 SSCP analysis of fresh bone marrow samples 58-66. Lane 4: <t>X174/H/nf1 Ladder, 
lane 1-3+ 5-10: fresh bone marrow samples 58-66 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.6.8 Gel shows PTEN exon 6 SSCP analysis of fresh bone marrow samples 67-76. Lane 1-10: fresh bone marrow 
samples 67-76 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.6.9 Gel shows PTEN exon 6 SSCP analysis of fresh bone marrow samples 77-85. Lane 5: 0X174//V/'nf1 Ladder, 
lane 1-4 + 6-10: fresh bone marrow samples 77-85 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.6.10 Gel shows PTEN exon 6 SSCP analysis of fresh bone marrow samples 86-95. Lane 1-10: fresh bone 
marrow samples 86-95 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
163
1 2 3 4 5  6 7 8 9  10
i L
u -
Fig 3.4.2.6.11 Gel shows PTEN exon 6 SSCP analysis of fresh bone marrow samples 96-104. Lane 6: 0X174/H/'nf1 
Ladder, lane 1-5 + 7-10: fresh bone marrow samples 96-104 respectively. (5cm section of 50cm PagePlus®gel, Silver 
stain, positive enhanced image).
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Fig 3.4.2.6.12 Gel shows PTEN exon 6 SSCP analysis of fresh bone marrow samples 105-114. Lane 1-10: fresh bone 
marrow samples 105-114 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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3.4.2.7 SSCP PTEN Exon 7
SSCP analysis of PTEN exon 7 showed good PCR product levels which yielded 4 
conformers on electrophoresis. The conformers were composed of two clear 
bands sandwiched between with one faint, faster migrating band and one faint, 
slower migrating band. As with previous exons, the staining intensity of these 
bands was proportional to the intensity of the main conformers, The two main 
conformers were stained with equal intensity. No aberrant migrating bands that 
would suggest the presence of a mutation were identified in the 114 samples 
screened. The four conformers present with this exon were very clear and 
aberrant conformers would have been seen easily as shown by the positive 
control in Fig 3.4.2.7.10. No faint background conformers were evident outside of 
the four main bands.
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Fig 3.4.2.7.1 Gel shows PTEN exon 7 SSCP analysis of fresh bone marrow samples 1-9. Lane 1: 0X 174/H/nfl Ladder, 
lane 2-9: fresh bone marrow samples 1-9 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.7.2 Gel shows PTEN exon 7 SSCP analysis of fresh bone marrow samples 10-19. Lane 1-10: fresh bone marrow 
samples 10-19 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.7.3 Gel shows PTEN exon 7 SSCP analysis of fresh bone marrow samples 20-28. Lane 2: OX174/H/nf1 Ladder, 
lane 1+ 3-9: fresh bone marrow samples 20-28 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.7.4 Gel shows PTEN exon 7 SSCP analysis of fresh bone marrow samples 29-38. Lane 1-10: fresh bone marrow 
samples 29-38 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.7.5 Gel shows PTEN exon 7 SSCP analysis of fresh bone marrow samples 39-47. Lane 3: OX174/H/nf1 Ladder, 
lane 1-2+ 4-10: fresh bone marrow samples 39-47 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.7.6 Gel shows PTEN exon 7 SSCP analysis of fresh bone marrow samples 48-57. Lane 1-10: fresh bone marrow
samples 48-57 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.7.7 Gel shows PTEN exon 7 SSCP analysis of fresh bone marrow samples 58-66. Lane 4: OX174/W/nf1 Ladder, 
lane 1-3+ 5-10: fresh bone marrow samples 58-66 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.7.8 Gel shows PTEN exon 7 SSCP analysis of fresh bone marrow samples 67-76. Lane 1-10: fresh bone marrow 
samples 67-76 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
169
1 2 3 4 5 6 7 8 9 10
/
**
Fig 3.4.2.7.9 Gel shows PTEN exon 7 SSCP analysis of fresh bone marrow samples 77-85. Lane 5: OX174/H/nf1 Ladder, 
lane 1-4 + 6-10: fresh bone marrow samples 77-85 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.7.10 Gel shows PTEN exon 7 SSCP analysis of fresh bone marrow samples 86-94. Lane 1-9: fresh bone marrow
samples 86-94 respectively. Lane 10: PTEN SSCP control (arrowed). (5cm section of 50cm PagePlus®gel, Silver stain,
positive enhanced image). Note: sample 95 excluded from exon 7 study
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Fig 3.4.2.7.11 Gel shows PTEN exon 7 SSCP analysis of fresh bone marrow samples 96-104. Lane 6: OX174/H/nf1 
Ladder, lane 1-5 + 7-10: fresh bone marrow samples 96-104 respectively. (5cm section of 50cm PagePlus®gel, Silver 
stain, positive enhanced image).
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Fig 3.4.2.7.12 Gel shows PTEN exon 7 SSCP analysis of fresh bone marrow samples 105-114. Lane 1-10: fresh bone
marrow samples 105-114 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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3.4.2.8 SSCP PTEN Exon 8
SSCP analysis of PTEN exon 8 showed good PCR product levels which yielded 2 
conformers on electrophoresis. The conformers were composed of two clear 
bands with the slowest migrating band showing stronger staining. As with 
previous exons, the staining intensity of the fainter bands was proportional to the 
intensity of the main conformer. No aberrant migrating bands that would suggest 
the presence of a mutation were identified in the 114 samples screened. The two 
conformers present with this exon were very clear and aberrant conformers would 
have been seen easily though the slowest migrating conformer showed some 
streaking in the heaviest stained samples and this could have masked weakly 
stained aberrant conformers. No faint background conformers were evident
172
Fig 3.4.2.8.1 Gel shows PTEN exon 8 SSCP analysis of fresh bone marrow samples 1-9. Lane 1: 0 X 1 7AIHinf\ Ladder,
lane 2-9: fresh bone marrow samples 1-9 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive
enhanced image).
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Fig 3.4.2.8.2 Gel shows PTEN exon 8 SSCP analysis of fresh bone marrow samples 10-19. Lane 1-10: fresh bone 
marrow samples 10-19 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.8.3 Gel shows PTEN exon 8 SSCP analysis of fresh bone marrow samples 20-28. Lane 2: <PX174/H/'nf1 Ladder, 
lane 1+ 3-9: fresh bone marrow samples 20-28 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.8.4 Gel shows PTEN exon 8 SSCP analysis of fresh bone marrow samples 29-38. Lane 1-10: fresh bone marrow 
samples 29-38 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.8.5 Gel shows PTEN exon 8 SSCP analysis of fresh bone marrow samples 39-47. Lane 3: OX174/H/nf1 Ladder,
lane 1-2+ 4-10: fresh bone marrow samples 39-47 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive
enhanced image).
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Fig 3.4.2.8.6 Gel shows PTEN exon 8 SSCP analysis of fresh bone marrow samples 48-57. Lane 1-10: fresh bone marrow 
samples 48-57 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.8.7 Gel shows PTEN exon 8 SSCP analysis of fresh bone marrow samples 58-66. Lane 4: OX174/H/nf1 Ladder, 
lane 1-3+ 5-10: fresh bone marrow samples 58-66 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.8.8 Gel shows PTEN exon 8 SSCP analysis of fresh bone marrow samples 67-76. Lane 1-10: fresh bone marrow 
samples 67-76 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.8.9 Gel shows PTEN exon 8 SSCP analysis of fresh bone marrow samples 77-85. Lane 5: 0X174/H/nf1 Ladder, 
lane 1-4 + 6-10: fresh bone marrow samples 77-85 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.8.10 Gel shows PTEN exon 8 SSCP analysis of fresh bone marrow samples 86-95. Lane 1-10: fresh bone 
marrow samples 86-95 respectively. (5cm section of 50cm PagePlus® gel, Silver stain, positive enhanced image).
177
1 2 3 4 5 6 7 8 . 9  10
Fig 3.4.2.8.11 Gel shows PTEN exon 8 SSCP analysis of fresh bone marrow samples 96-104. Lane 6 :4>X174/H/nf1 
Ladder, lane 1-5 + 7-10: fresh bone marrow samples 96-104 respectively. (5cm section of 50cm PagePlus®gel, Silver 
stain, positive enhanced image).
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Fig 3.4.2.8.12 Gel shows PTEN exon 8 SSCP analysis of fresh bone marrow samples 105-114. Lane 1-10: fresh bone 
marrow samples 105-114 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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3.4.2.9 SSCP PTEN Exon 9
SSCP analysis of PTEN exon showed good PCR product levels which yielded 2 
conformers on electrophoresis. These gels were subject to slight overdeveloping 
in the silver staining process and the main conformers are less clear in the Figs 
than when judgment was made regarding the presence of aberrant conformers. 
The conformers were composed of two clear bands with the fastest migrating 
band showing stronger staining. As with previous exons, the staining intensity of 
the fainter bands was proportional to the intensity of the main conformers. The 
heaviest stained samples show some background staining and faint aberrant 
bands that were not evident when the gel was examined initially after staining No 
aberrant migrating bands that would suggest the presence of a mutation were 
identified in the 114 samples screened. The two conformers present with this 
exon were very clear and aberrant conformers would have been seen easily.
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Fig 3.4.2.9.1 Gel shows PTEN exon 9 SSCP analysis of fresh bone marrow samples 1-9. Lane 1: 0 X 1 74/H/'nf1 Ladder,
lane 2-9: fresh bone marrow samples 1-9 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive
enhanced image).
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Fig 3.4.2.9.2 Gel shows PTEN exon 9 SSCP analysis of fresh bone marrow samples 10-19. Lane 1-10: fresh bone 
marrow samples 10-19 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.9.3 Gel shows PTEN exon 9 SSCP analysis of fresh bone marrow samples 20-28. Lane 2: <J>X174/H/nf1 Ladder, 
lane 1+ 3-9: fresh bone marrow samples 20-28 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.9.4 Gel shows PTEN exon 9 SSCP analysis of fresh bone marrow samples 29-38. Lane 1-10: fresh bone marrow 
samples 29-38 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.9.5 Gel shows PTEN exon 9 SSCP analysis of fresh bone marrow samples 39-47. Lane 3: (t>X174/H/r?f1 Ladder, 
lane 1-2+ 4-10: fresh bone marrow samples 39-47 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.9.6 Gel shows PTEN exon 9 SSCP analysis of fresh bone marrow samples 48-57. Lane 1-10: fresh bone marrow 
samples 48-57 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.9.7 Gel shows PTEN exon 9 SSCP analysis of fresh bone marrow samples 58-66. Lane 4: 0X174/H/n/1 Ladder, 
lane 1-3+ 5-10: fresh bone marrow samples 58-66 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.9.8 Gel shows PTEN exon 9 SSCP analysis of fresh bone marrow samples 67-76. Lane 1-10: fresh bone marrow 
samples 67-76 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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Fig 3.4.2.9.9 Gel shows PTEN exon 9 SSCP analysis of fresh bone marrow samples 77-85. Lane 5: OX174/H/nfl Ladder, 
lane 1-4 + 6-10: fresh bone marrow samples 77-85 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive 
enhanced image).
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Fig 3.4.2.9.10 Gel shows PTEN exon 9 SSCP analysis of fresh bone marrow samples 86-95. Lane 1-10: fresh bone 
marrow samples 86-95 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
184
1 2 3 4 5 6 7  8 9  10
Fig 3.4.2.9.11 Gel shows PTEN exon 9 SSCP analysis of fresh bone marrow samples 96-104. Lane 6: <J>X174/HinH 
Ladder, lane 1-5 + 7-10: fresh bone marrow samples 96-104 respectively. (5cm section of 50cm PagePlus®gel, Silver 
stain, positive enhanced image).
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Fig 3.4.2.9.12 Gel shows PTEN exon 9 SSCP analysis of fresh bone marrow samples 105-114. Lane 1-10: fresh bone 
marrow samples 105-114 respectively. (5cm section of 50cm PagePlus®gel, Silver stain, positive enhanced image).
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3.4.3 SSCP gels stained with GelStar
Fig 3.4.3.1 shows a composite image of all six gels in the SSCP exon 7 analysis 
stained with GelStar. This stain was used to identify the position of the 
unpredictable migration of single stranded conformers prior to excision for silver 
staining. Compared to the silver stained gels in Figs 2.5.2.7.1 -  2.4.2.7.12, 
GelStar shows less intense staining but does not resolve very faint conformers. 
Background staining was absent and aberrant migration in the SSCP control was 
apparent.
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Fig 3.4.3.1 Composite picture of 114 PCR reactions of PTEN exon 7 SSCP gels
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Fig 3.4.3.1 Composite picture of 114 PCR reactions of PTEN exon 7 SSCP gels stained with 2 x GelStar® Each excised 
strip was approx 7 cm from top to bottom. DNA ladder occupies lane one to six in successive gels as an aid to 
identification. SSCP positive control was in the last lane of the fifth gel down (negative image, fluorescence obtained at 312 
nm by transillumination
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3.4.4 SSCP analysis -  summary of results
SSCP analysis carried out on frozen bone marrow samples showed a low rate of 
reaction failure compared to fixed cells (section 3.3) . Exon 8 reactions, as with 
heteroduplex analysis, showed a higher failure rate than other exons studied. The 
only aberrant migrating band in all exons studied were found in exon five. 
Resolution of bands was much clearer using SSCP with lower levels of product 
diffusion compared to Heteroduplex analysis
Exon Number Failure Rate Aberrant migration
1 2/114 0/114
2 Not screened Not screened
3 0/114 0/114
4 0/114 0/114
5 1/114 2/114
6 0/114 0/114
7 0/113 0/113
8 8/114 0/114
9 0/114 0/114
Table 3.4.4 Table shows rate of failure of PCR reaction for each PTEN exon in the SSCP gel plus the number of lanes 
showing aberrant band migration.
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3.5 DNA sequencing of PTEN exon 5 in samples with aberrant SSCP migration.
PTEN sequences were obtained for all 9 samples studied. Base calling was most 
accurate at the beginning of the electropherogram and deteriorated as noise 
became more pronounced later in the sequence. All sequenced exons 
corresponded to published sequences.
Electropherogram of sequence sample number 4 (JW4AR) showed a possible 
mismatch at nucleotide number 116 in the reverse sequencing (relative to 
published sequence data). Forward sequencing did not show a complementary 
mismatch and corresponded to the published sequence, so the anomaly was 
ignored.
Sequence of exon 5 for bone marrow samples 42 and 45 that produced aberrant 
bands in SSCP analysis (JW 3 and 5) corresponded to the published sequence.
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Fig 3.7.2.1 Electropherogram of sequence sample number 4 (JW4AR) forward and reverse sequencing, top two rows plus 
sample number 5, bottom two rows. A possible mismatch T>G was shown in sequence 20 (JW4BR) at nucleotide number 
116 (relative to published sequence data). Forward sequencing does not show a complementary mismatch.
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1 JW1OAF.ABD 
2E JYJ10AR. ABD 3 JW10BF.ABD 
4£ JW10ER.ABD 61 JVJlAR. ABD 
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6E JW3BR.ABD 
8E JVMAR. ABD 
20E JVMBR.ABD 
2E JW5AR.ABD 
4£ JW5BR. ABD 26E JW6AR. ABD 28£ JW6BR.ABD 29 JW7AF.ABD 3 0E JV77AR. ABD 31 JW7BF.ABD 
32E JW7BR.ABD 
34E JW8AR.ABD 
36E JW8BR.ABD 37 JW9AF.ABD 3BE JW9AR.ABD 39 JW9BF.ABD 
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10 20 30 40I______ 1______ I______ IT-------- C TlATtCTGAG GTtATnTTTT tACCACAsTTTTTTTTTTTC TTATTCTGAG GTTATCTTTT TACCACAGTT----------c TKAT-CTaAG GT-ATa TTTT TACCACAGTTTTTTTTTTTC TTATTCTGAG GTTATCTTTT TACCACAGTT TTTTTTTTTC TTATTCTGAG GTTATCTTTT TACCACAGTT TTTTTTTTTC TTATTCTGAG GTTATCTTTT TACCACAGTT TTTTTTTTTC TTATTCTGAG GTTATCTTTT TACCACAGTT TTTTTTTTTC TTATTCTGAG GTTATCTTTT TACCACAGTT TTTTTTTTTC TTATC'CTGAG GTTATCTTTT TACCACAGTT TTTTTTTTTC TTATTCTGAG GTTATCTTTT TACCACAGTT TTTTTTTTTC TTATTCTGAG GTTATCTTTT TACCACAGTT TTTTTTTTTC TTATTCTGAG GTTATCTTTT TACCACAGTT TTTTTTTTTC TTATTCTGAG GTTATCTTTT TACCACAGTT TTTTTTTTTC TTATTCTGAG GTrATCTTTT TACCACAGTT TTTTTTTTTC TTATTCTGAG GTrATCTTTT TACCACAGTT TTTTTTTTTC TTATTCTGAG GTTATCTTTT TACCACAGTTTTTTTT C TTATTCTGAG GTTALATTTT TACCACAGTTTTTTTTTTTC TTATTCTGAG GTTATCTTTT TACCACAGTTT TT-C TTATrCTGAG GTLALCTTTT TACCACAGTTTrTTTTTTTC TTATTCTGAG GTTATCTTTT TACCACAGTT TLTLLTTT-C TTATTCTGAG GTTATCTTTT TACCACAGTT TTTTTTTTTC TTATTCTGAG GTTATCTTTT TACCACAGTT C TTAT-CTflAG GTTA1CTTTT TACCACAGTT TTTTTTTTTC TTATTCTGAG GTTATCTTTT TACCACAGTT C TTAT-CTGAG GGTATCTTTT TACCACAGTt TTTTTTTTTC TTATTCTGAG GTTATCTTTT TACCACAGTT TTTTTTTTTC TTATTCTGAG GTTATCTTTT TACCACAGTT     gtt
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ACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTCTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTACCCTTTTGTacccttttgtcProPheCys
140 lfcO17 0 
 1GAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA GAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCiiAT TCACTGTAAA GAAGALCTTG ACCAALGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA G^AGaTCTTG iiCCAATGGCT AAGTGALGaT GACAATCATG TTGCAGCa AT TCACTG.LAAA GAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA GAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA GAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA GAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA GAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA GAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA GAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA GAAGATCTTG ACCAALGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA GAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA GAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA GAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA GAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA GAAGALCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT 1.CACTGTAAA GAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA GAAGALCTTG aCCAALGGCT AAGTGAAGAT Gt CAALCATG TTGCAGCAAT TCt CTGTA/u  GAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA GAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA GAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA flAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTaCAcCAAT TCACTGTAAA GAAGATCTTG ACCAATGGCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTiiA GAAGATCTTG ACCAATGGCT AAGTGAAGAT GaCAALCATG TTGCAGCAAT TCACTGTAAA GAAGATCTTG ACCAATGaCT AAGTGAAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA GAAGATCTtg accaatggct aagtgaAGAT GACAATCATG TTGCAGCAAT TCACTGTAAA gaagatcttg accaatggct aagtgaagat gacaatcatg ttgcagcaat tcactgtaaa GluAspLeuA spGlnTrpLe uSerGluAsp AspAsnHisV alAlaAlall eHisCysLys
Fig 3.7.2.2 PTEN exon 5 sequencing results- nucleotides 1-160. Forward (F) and Reverse (R) sequence output after 
interpretation of electropherogram JW4BR forward sequence shows possible mismatch at nucleotide116
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171!_L 1 HO 190J. 200 210 220.1_ : !  u 240_LGCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATT TATTACATCG GGGCAAATTT TTAAAGGCAC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATT TATTACATCG GGG^AAATTT TTAAAGG^C AAGaGGCCCL GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATT TATTACATCG GGGCAAATTT TTAAAGGCAC AAGAGGCCCT GCTGGAAAGG GaCGAACrGG tUlAATG^TA TGTGCATATT TATTACATCG GGGCAAATTT TTiiAAGGCaC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCALATT TATTACATCG GGGCAAATTT TTAAAGGCAC iiAGAGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATT TATTACATCG GGGCAAATTT TTAAAGGCAC AAGcGGCCCJL GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATT TATTACATCG GGGCAAATTT TtAAAGGCAC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATT TATTACATCG GGGCAAATTT TTAAAGGCAC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATT TATTACATCG GGGCAAATTT TTAAAGgCAC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGToCATATT TATTACATCG GGGCAAATTT TTAAAGg_AC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATT TATTACATCG GGGCAAATTT TTAAAGGCAC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATT TATTACATCG GCGCAAATTT TTAAAGGCAC oAGaGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATT TATTACATCG GGGCAAATTT TTAAAGGCAC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGTjCA2_ATT TATTACATCG GGGCAAATTT TTAAAGGCAC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATT TATTACATCG GGGCAAATIT TTAAAGgCAC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATT TATTACATCG GGGCAAATTT TTAAAGGCAC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATT TATTACATCG GGGCAAATTT TTAAAGGCAC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATT TATTACATCG GGGCAAATTT TTAAAGGCAC AAGAGGCCCT GCTGGAAcGG GAcGAcCTCG TGTAATGATA TGTGCATATT TATTACATCG GGGCAAATTT TTAAAGGCAC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATT TATTACATCG GGGt AAATTT TTAAAGGtAC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATT TATTACATCG GGGCAAATTT TtAAAGGCAC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGTaCATATT TATTACATCG GGGCAAATTT TTaAAsGCAC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATT TATTACATCG GGGCAAATTT TTAAAGGCAC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TatAATGaTA TGTGCATATT TATTACATCc GGGCAAATTT TT-iAAGg-AC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TGTAATGATA TGTGCATATT TATTACATCG GGGCAAATTT TTAAAGGCAC AAGAGGCCCT GCTGGAAAGG GACGAACTGG TG2AATGATA TGTGCATATT TATTACATCG GGGCaAATTT TTiiAAgGCAC aAGAGGCCCi. GCTGGAAAGG GACGAactgg tgtaatgata tgtgcATATT TATTACATCG GGGCAAATTT TTAAAGGCAC AAGAGGCCCT gctggaaagg gacgaactgg tgtaatgata tgtgcatatt tattacatcg gggcaaattt ttaaaggcac aagaggccct AlaGlyLysG lyArgThrGl yValMotlle CysAlaTyrL euLeuHisAr gGlyLysPhe LeuLysAlaG InGluAlahe
march lla 25/11/2002 11:18
2^C 270 28C 29C1 30C1 310 320 1 11 JW10AF. ABD AGATTTCTAT GGGGaagtaa ggaccagaga caaaaaggta agttattttt tgatgttttt C
21 JVJ10AR.ABD AGATTTCtAT GGa a3 JVJ10BF.ABD AGATTTCTAT GGGGaagtaa ggaccagaga caaaaaggta agttattttt tgatgttttt cctttcctc4E JVJ10BR.ABD AGATTTCTAT CGGG6E JVJlAR. ABD AGa TTTCTAT GGGGaagtaa ggaccagaga caaaaaggta ag8E JVJ1BR. ABD AGiTTTCtAT GGGGaagtaa ggaccagaga caaaaaggta ag10E JVJ2AR.ABD AGATTTCTAT GGGGaagtaa ggaccagaga caaaaaggta a12E JW2BR.ABD AGATTTCTAT GGGGaagtaa ggaccagaga caaaaaggta agttat14[ JVJ3AR. ABD a g a t t t c a a t GGGG16E JVJ3 ER. ABD AGATTTCTAT GGGG1PE JVJ4J4R. ABD AGATTTCTAT GGGG20E JVJ4BR.ABD AGATTTCTAT GGGG
22E JW5AK.ABD AGATTTCTAT GGGG
24E JVJ5BR. ABD Aa a TTTCTa T GGGG26E JW6AR . ABD AGATTTCTAT GGGG28E JVJ6BR. ABD AGa TTTCTAT GGGG29 JVJ7AF. ABD AGATTTCTAT GGGGaagtaa ggaccagaga caaaaaggta agttattttt tgatgttttt cctt30E JVJ7AR. ABD AGa TTTCAAT GGGG31 JW7BF.ABD AGATTTCTAT GGGGaagtaa ggaccagaga caaaaaggta agttattttt tgatgttt32E JVJ7BR.ABD AGa TTTCTAT GGGG34E JVJ8AR. ABD AGATTTCTAT c GGa36£ JV.'SBR. ABD AGa TTTCTAT GGG37 JW9AF.ABD AGATTTCTAT GGGGaagtaa ggaccagaga caaaaaggta agttattttt38E JVJ9AR.ABD AGa TTTCXAT gG -rn39 JW9BF.ABD AGATTTCTAT GGGG40E JW9BR.ABD AGa TTTCTAT GGa41 cx5 all AGATTTCTAT GGGGAAGTAA GGACCAGAGA CAAAAAGGTA AGTTATTTTT TGATGTTTTT CCTTTCCTCT TCCTGGATCT42 ex5 align agatttctat ggggaagtaa ggaccagaga caaaaagg
■1843 uAspPheTyr GlyGluValA rgThrArgAs pLysLys
Fig 3.7.2.3 PTEN exon 5 sequencing results- nucleotides 170- 310. Forward (F) and Reverse (R) sequence output after 
interpretation of electropherogram
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3.6 Western blotting of PTEN protein
The heteroduplex and SSCP screening tests suggested a very low rate of point 
mutations and small deletions in the samples studied. Western blots were 
performed on frozen bone marrow samples to detect protein expression in 
leukaemia cells and thus rule out abolition of PTEN protein expression by other 
mechanisms such as large scale gene deletion. Western blots for PTEN were 
performed using a normal control, two chronic granulocytic leukaemia, one 
chronic lymphocytic leukaemia, one acute myeloid leukaemia (FAB class M1), 
one acute myeloid leukaemia (FAB class M2) and one acute myeloid leukaemia 
(FAB class M3 variant), chronic granulocytic leukaemia acute phase samples. 
All showed the expected 55kd band plus a band of unknown specificity (upper 
band) present in each lane. Lane 6 AML shows some sample degradation. Lane 
9 shows stronger signal from non-specific band compared to 55kd PTEN band 
and was probably a staining artefact as the upper band has a different shape to 
the lower specific PTEN band. All samples showed a signal corresponding to 
PTEN though at much lower levels than the p-actin control.
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Figure 3.5.1 Western blotting of PTEN primary leukaemia samples
A.
1 2 3 4 5 6 7 8 9  10
97 Kd-
66 Kd- 
45Kd- -  [3-actin 42kd
B.
1 2  3 4 5  6 7 8 9  10
97 kD -
66 kD
45 kD —55kD Pten
Fig 3.5.1 A and B. Lane 1, molecular weight marker. Lane 2 normal control, Lane 3 CGL, Lane 4 CLL, Lane 5 AML M1, 
Lane 6 AML M2, Lane 7 AML M3 variant, Lane 8 CGL acute phase. Lane 9 CGL
A. shows western blot of p-actin protein. B. shows western blot of PTEN protein. PTEN is expressed in all samples but 
staining is much reduced compared to 3-actin. PTEN blot has been exposed to photographic film for longer, so the 
difference in expression is more pronounced than apparent from the photograph. This is evident from the increased level 
of background and molecular weight marker staining on the PTEN blot
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Bradford Protein Assay BSA 
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Fig 3.5.2 Bradford assay standard curve
Figure shows absorbance at 595nm of bovine serum albumin protein solutions at 0-10 pg ml'1 Graph was used to 
interpolate the protein concentration of extracts for western blotting to achieve uniform loading quantities,
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3.7 PTEN Immunocvtochemistrv and immunofluorescence 
3.7.1 Immunofluorescence
The western blot studies showed that PTEN protein was present in the samples 
studied but the samples represented a mix of tumour and normal cells. PTEN 
expression could be absent in the tumour cell population but present in the 
residual normal cell population. Immunofluorescence was performed to establish 
that PTEN expression was present in leukaemic cells and/or normal cells. 
Immunofluorescence showed PTEN expression in all leukaemias stained 
successfully. The proportion of failed samples was 55% {11 of 20) in which PTEN 
staining was absent in all cells within the bone marrow smear, not just the tumour 
cell population. Staining in leukaemia and normal bone marrow was stronger in 
immature cells with lesser intensity in mature cells. Staining was 
compartmentalised within the cytoplasm with low levels of nuclear staining in all 
smears except the CGL, which showed a diffuse distribution throughout the 
cytoplasm, which obscured possible nuclear staining.
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Fig 3.6.1 immunofluorescence staining of PTEN protein
5 ?
N 9
B
C
Fig 3.6.1 shows immunofluorescence staining of PTEN protein (green) in Normal Marrow (A), CGL (B) and M3 AML (C). 
UV induced fluorescence with DAPI nuclear stain (blue). MagnificationlOOOx.
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3.7.2 Immunocvtochemistrv
Immunocytochemistry showed very slight staining compared to 
immunofluorescence. Staining was not obviously compartmentalised and 
showed, at best, weak signals with no apparent difference between control and 
leukaemia slides (not shown).
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Chapter 4
Discussion and Conclusion
This study involved careful optimisation of methods used to identify mutations in 
PTEN in archival bone marrow smears, formalin fixed tissue samples and frozen 
bone marrow. The findings presented here show that extraction of PCR 
amplifiable DNA was possible from formalin-fixed, paraffin-embedded lymph 
node tissue and that simple heat treatment followed by proteinase K digestion led 
to better yield of PCR products than organic solvent extraction methods. 
Amplification of 219 base pair sequences of (3-globin was successful in 50% of 
extracts but amplification of longer sequences was more refractory. Zsikla et al. 
(2004) reported that the duration of fixation is the majorfactor affecting the 
preservation of DNA in formalin fixed tissue. They proposed that unbuffered 
formalin oxidises to formic acid and the subsequent acidic environment causes 
degradation of nucleic acids since the p-glycosidic bonds in the purine 
nucleotides are hydrolysed at pH 4. This group used a real-time PCR system to 
generate a 295 bp product of the p-actin gene and claimed that up to 50 times 
more p-actin DNA molecules could be extracted from small forceps biopsy 
samples fixed in buffered formalin when compared to unbuffered formalin. All the 
FFPE samples used in the current study were fixed overnight in buffered formalin 
and thus, should not have been subject to depurination by proton donors.
Dedhia et al. (2007) report that DNA extracted from formalin fixed tissues is highly 
degraded due to cross-linking between nucleic acid strands. They extracted DNA 
from FFPE sections using heat treatment and amplified by PCR using a real-time 
system with different primer sets that gave amplimers of different sizes when 
amplifying cyclin D1 and p-globin genes. PCR product was observed with shorter 
amplimer up to 250bp in length. Longer amplimers failed to amplify with paraffin
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extracted DNA. Good results were seen with a primer concentration of 300nM 
and 5ng of template DNA. This group suggested that DNA obtained from formalin 
fixed paraffin embedded tissue is highly fragmented but can be used for 
successful amplification of shorter amplification products up to 250bp in length. 
The size of DNA amplified from FFPE in this study using a heat extraction and 
proteinase K method was similar to that reported by Rivero et al. (1997). They 
utilised a salting out method to extract DNA from FFPE tissue using 4M 
ammonium acetate followed by DNA precipitation using isopropanol. This group 
were able to amplify 167 and 268bp fragments of APC and p-globin genes 
respectively but had less success amplifying a 536bp fragment of p-globin gene. 
Coura etal. (1995) used a method based on xylene/ethanol de-waxing, followed 
by a long rehydration step prior to the DNA extraction step. In contrast to the 
findings presented in this thesis, which gave variable success rates, they reported 
100% amplification success rate for fragments of 121 bp to 227bp for FFPE 
tissue. Organic solvent extraction techniques were evaluated in this study but 
gave very poor levels of amplification compared to solvent free methods. 
Aviel-Ronen et al. (2006) used a quantitative PCR technique for whole genome 
amplification with a Bst DNA polymerase (described as Multiple-strand 
Displacement Amplification (MDA)) using proteinase K-extracted FFPE tissue. 
The amplified products obtained had amplimer sizes in excess of 23Kb. The MDA 
technique relies on the repeated random priming of large template DNA 
molecules rather than repeated cycling as in standard PCR, and generates only 
1000 fold amplification. Nevertheless, this technique demonstrates its suitability 
for replication of DNA template obtained from FFPE and again contradicts the 
findings presented here that DNA amplification of products around 200 bp only is 
possible. The failure to amplify reliably products in excess of 200bp in this study
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may be due to carry over of formalin in the DNA extraction process and 
subsequent degradation of the polymerase enzyme in the PCR mix. If formalin 
carry over was present, then it occurred despite careful washing of the nucleic 
acid sample.
Quach et al. (2004) questioned the fidelity of amplicons generated from FFPE 
extracted templates and reported that error prone trans-lesion synthesis across 
sites of damage produced in vitro artefactual mutations in their PCR products. 
Errors secondary to trans-lesion bypass were distinct from polymerase replication 
accuracy, reflecting incorporation of the wrong base opposite a damaged base 
rather than misincorporation of the wrong base opposite a normal base. 
Amplification of DNA extracted by this method varied between PTEN exons 5, 7 
and 8, with 8 being the most unreliable. Levels of amplification observed here are 
lower than those reported in other studies.
Court et al. (2001) extracted DNA from Giemsa stained smears using proteinase 
K digestion, treatment with saturated NaCI followed by DNA extracted from the 
supernatant by phenol/chloroform/isoamyl alcohol. Retrieved DNA was 
precipitated with ethanol at -20°C overnight then washed with 95% ethanol. 
Comparison of this method with a technique using frozen cells demonstrated that 
the quality of extracted DNA isolated by the two methods was comparable. The 
technique used by this group was similar to that used in this study, but used a 
final phenol chloroform extraction step prior to precipitation of DNA, Similarly, 
Boyle et al. (1998) compared proteinase K and organic solvent techniques for 
DNA extraction from Giemsa stained bone marrow smears. They reported that, 
contrary to the work reported in this thesis, prior treatment with proteinase K had 
no effect on the yield of DNA extracted from smears using a phenol/chloroform 
method and that successive failure of PCR was not related to the quantity of DNA
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isolated from the smears.
Tian et al. (2001) used BT549 cell line DNA samples with two mutations (16delAA 
and 822delG) in PTEN to assess the sensitivity of heteroduplex analysis coupled 
with capillary electrophoresis for detection of small deletion mutations. The group 
were able to identify a heterozygous mutation in PTEN in this cell line using this 
method.
Tsou et al. 1998 successfully used heteroduplex analysis to screen for novel 
germline mutations in PTEN using DNA isolated from individuals with Cowden 
syndrome. Two mutations in the PTEN gene were found: a transition (T—>C) at 
nucleotide 335 in exon 5 and a novel splice site mutation (801+2 T—>G) in intron 
7. Hansen et al. (2001) used heteroduplex analysis and SSCP to screen for 
PTEN mutations. Nine exons of the PTEN gene, including intronic flanking 
regions were analysed in 62 patients with insulin-resistant type II diabetes. No 
mutations predicted to influence the expression or biological function of the PTEN 
protein but four intronic polymorphisms were identified.
Several groups used cell line or human wild type DNA for their analysis of PTEN 
using heteroduplex analysis (Tian et al (2001), Tsou et al. (1998) and Hansen et 
al. (2001)). Their success suggests the technique is suitable for the detection of 
small deletions and point mutations. In the above studies, DNA was extracted 
from homogeneous cell types and in such cases, the heteroduplex pattern 
depends on whether the cells are heterozygous or homozygous for a specific 
allele. This contrasts with samples tested in the present study which consisted of 
a heterogeneous mix of tumour cells and normal cells. The relative percentage of 
each varied from 10% to over 90% between samples. Assuming that mutant and 
normal sequences are amplified with the same efficiency, and that hetero- and 
homoduplexes are formed with the same efficiency, the intensity of the PTEN
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homoduplex bands generated from the normal cell sequences would obscure a 
heteroduplex band generated from a small percentage of tumour cells. Even with 
the use of silver staining and its associated sensitivity, it may not be sufficient to 
demonstrate a small proportion of heteroduplex bands. The problems associated 
with heterogeneous cell types would be addressed by using a viable 
microdissection technique to select tumour cells for nucleic acid extraction that 
yielded high levels of amplified product. The loss of heteroduplex bands against a 
background of homoduplex bands would be exacerbated by the generalised loss 
of band intensity reported here. The degree of diffusion in the heteroduplex bands 
varied between exons, with exon 8 showing high levels, making resolution of 
heteroduplex bands more difficult.
The current findings of the SSCP screening presented show that SSCP using 
sequences amplified from fresh or frozen cells is preferable to archived, fixed and 
stained cells. The technique using frozen cells generated bands in all reactions, 
even when very low levels of extracted DNA were present, which appeared to 
separate well using modified cross linking agents in the commercial 
polyacrylamide-based gels. The issue of heterogeneous tumour and normal cell 
populations and the sensitivity of mutation screening methods addressed by Fan 
et al. (2001). This group compared the sensitivity of non-isotopic PCR-SSCP to 
direct sequencing of PTEN exons. The group extracted DNA from leukocytes 
derived from healthy donors as well as from the glioblastoma cell line LN319 and 
mixed these in differing proportions from 0 to 100%. (The LN319 cell line contains 
a point mutation at codon 15 exon 1 of the PTEN gene). The PCR-SSCP 
demonstrated mutations in samples containing as little as 10% tumour DNA.
Direct DNA sequencing experiments were less sensitive, requiring 30-70% of 
tumour DNA in the sample, depending on the DNA strand sequenced. They
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concluded that PCR-SSCP based detection of PTEN point mutations was more 
sensitive than automated sequencing and recommended sequencing of both 
strands, and that samples containing less than 30% tumour cells should be 
studied by PCR-SSCP in order to discriminate false negative results obtained by 
sequencing reactions. The 10% tumour cell detection limit suggested by Fan et 
al. (2001) is the same as that used as a cut-off point in this study.
Mutation screening by heteroduplex analysis and SSCP failed to demonstrate 
point mutations or small deletions in any exon of the primary leukaemia and 
lymphoma samples studied here. This was supported by the DNA sequence 
analysis results even though all positive control reactions in the screening tests 
were successful. This suggests that small deletions and mutations are rare in the 
leukaemia and lymphoma groups examined in this study. The SSCP technique 
employed here may not have been sensitive to large heterozygous or 
homozygous deletions of PTEN in the tumour cell population as the tissue 
samples contained varying levels of normal cells which would express wild type 
PTEN, which would be amplified in the PCR step.
cDNA or genomic DNA from all primary malignancies and cell lines was analysed 
successfully by Dahia et al. (1998) for the presence of mutations in the whole 
coding region of PTEN. DGGE analysis revealed no mutations in the cDNA of 43 
myeloid and 31 lymphoid primary leukaemia PTEN coding regions studied but a 
IVS4+42C—»T mutation in an intron of one transformed myelodysplastic syndrome 
(secondary acute myeloid leukaemia).
Using SSCP and DNA sequencing, Sakai et al. (1998) examined 27 
haematopoietic cell lines (representing a variety of lymphoid lineages), 65 primary 
lymphoid tumours (including 24 lymphoblastic leukaemia/lymphoma), 30 large B- 
cell lymphoma , 7 Burkitt's lymphoma, 4 anaplastic large cell lymphoma, and 25
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non-malignant lymph node controls. Six of the 27 cell lines and 3 of 65 primary 
lymphomas contained alterations of PTEN. The group reported a large 
homozygous deletion spanning exons 2 through 5 in one lymphoblastic 
leukaemia cell line, two insertions potentially resulting in premature termination in 
a second lymphoblastic leukaemia cell line. Non-conservative nucleotide 
variations were found in two other cell lines (one large B-cell lymphoma and one 
Burkitt’s lymphoma) and in one primary case of LBCL. In addition, two other cell 
lines (one BL and one myeloma) and two primary lymphomas, both LBCL, 
contained small deletions within intron 7. No point mutations were reported in the 
PTEN gene which supports the findings of this thesis
Gronbaek et al. (1998) studied 14 malignant and 4 benign lymphoid cell lines for 
deletions and mutations in all exons of the PTEN gene by combining PCR, DGGE 
and direct sequence analysis. The group reported mutations of PTEN in two of 
the malignant cell lines (a deletion of exons 2 to 5 in a T-cell ALL cell line and 
a C -> T transition at the first base of codon 17 in the myeloma cell line HS- 
Sultan) but none in the benign cell lines. Gronbaek et al. (1998) also examined all 
exons of the PTEN gene by PCR/DGGE analysis in 170 primary lymphoid 
malignancies and detected two point mutations, both in large B-cell lymphomas 
cases.
Nakahara et al. (1998) examined 29 cases of primary NHL for mutations in the 
PTEN gene. One case of diffuse large B cell lymphoma had an 11 bp deletion, but 
the remaining 28 cases showed no mutations in the gene. Butler et al. (1999) 
carried out a study of PTEN mutations in lymphoma, based on their observation 
that deletions and rearrangements of 10q22-25 have been reported in 
approximately 5%-10% of NHL, raising the possibility of PTEN involvement in 
these tumours. The group analysed cell lines and primary tumours in a panel of
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74 NHLs (which were representative of the main histological subtypes) for 
mutations and homozygous deletions of PTEN. They reported somatic 
coding/splice site variants in 20% (2 of 10) of Burkitt's lymphoma cell lines and in 
3% (2 of 64) of primary NHL cases analyzed. No homozygous deletions were 
detected. The group reported that all NHL cases with 10q22-q25 abnormalities 
displayed neither biallelic deletions nor mutations of PTEN. They also suggested 
that a tumour suppressor gene distinct from PTEN may be involved in 10q 
deletions in the subgroup of NHL cases.
Scarisbrick et al. (2000) examined 54 tumour DNA samples from patients with 
cutaneous T-cell lymphoma (CTCL) for loss of heterozygosity on 10q. Allelic loss 
was identified in 10 samples, all of which were from the 44 patients with mycosis 
fungoides (a T-cell malignancy). Samples with allelic loss on 10q were analyzed 
for abnormalities of the PTEN gene. No tumour-specific mutations in PTEN were 
detected, The group suggested that their data imply that this gene is rarely 
inactivated by small deletions or point mutations.
Aggerholm et al. (2000) screened 13 leukaemia cell lines for mutations and 
homozygous deletions in PTEN using PCR and DGGE. They identified an 
intragenic deletion including PTEN exons 2-5 in an acute myelocytic leukaemia 
cell line, HL-60 blast, and an insertion of four nucleotides in exon 5 in an acute 
monocytic leukaemia cell line, U937. The group screened 59 patients with AML, 
26 patients with MDS and 10 patients CML and only revealed a polymorphic base 
substitution in codon 44 in one AML patient. The group suggested that mutations 
in the PTEN gene are infrequent genetic aberrations in myeloid leukaemia.
Leupin et al. (2003) found 20% of B-CLL patients exhibit loss of heterozygosity 
(LOH) at 10q23.3. Microsatellite markers mapped complete LOH to 10q23.3 in 
2/41 B-CLL (5%) and allelic imbalances in 6/41 (15%). No PTEN gene mutations
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were found. PTEN protein expression was not detected in 11 B-CLL (28%), and 
was reduced in eight patients (20%). LOH or allelic imbalances at 10q23.3 were 
fairly frequent in B-CLL, but did not encompass the PTEN gene. The group 
suggested that PTEN protein may be absent in B-CLL with a normal PTEN 
genotype, suggesting a role of this phosphatase in the molecular pathology of B- 
CLL. Liu et al. (2000) screened 62 AML patients for DNA mutations in all PTEN 
exons by PCR-SSCP and direct sequencing. No mutations were observed in any 
of the coding regions and none of the AML cases had LOH.
Chang et al. (2006) analysed clonal plasma cells from patients with MM and 
plasma cell leukaemia for deletions/mutations of the PTEN gene by using 
interphase fluorescent in situ hybridisation (FISH). PTEN deletions were detected 
in 4 of 71 myeloma clones and 2 of 10 plasma cell leukaemia. DNA sequencing 
analysis did not detect PTEN mutations in 11 primary myeloma and 5 plasma cell 
leukaemia cases. The group concluded that alterations of PTEN are uncommon 
in myeloma patients, and PTEN deletions tend to occur in advanced disease 
suggesting that they are secondary rather than primary events in the 
pathogenesis of MM.
Thus, all groups referenced above have reported that point mutations and small 
deletions are rare in primary haematological malignancy and support the findings 
of this study (Sakai et al. (1998), Gronbaek et al. (1998), Nakahara et al. (1998), 
Butler et al. (1999), Scarisbrick et al. (2000), Aggerholm et al. (2000), Liu et al. 
(2000), Leupin et al. (2003), and Chang et al. (2006)). PTEN is reported to be 
mutated at a higher frequency in solid tumours than in haematological 
malignancy Bonneau and Longy (2000) reviewed somatic mutations in primary 
tumours and reported the majority of PTEN mutations in endometrial carcinomas 
and glioblastomas. 130 out of 145 cases of informative tumours had bi-allelic
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inactivation of PTEN through loss of heterozygosity by deletion of one allele and 
point mutations in the remaining allele. 23% of somatic mutation occurred in exon 
5 (encoding the phosphatase domain), particularly at arginine residues 130, 233 
and 335. A difference in location of mutations was noted between endometrial 
carcinoma (predominantly exons 7 and 8) and glioblastoma (predominantly exon 
6).
Kurose et al. (2002) demonstrate high frequencies of somatic mutations in the 
PTEN gene and p53 tumour protein in breast neoplasms using DGGE. Mutations 
in p53 and PTEN were mutually exclusive in either compartment. 15 of 50 (30%) 
breast carcinomas had somatic mutations in PTEN in either neoplastic epithelium 
or stroma. Mutations in PTEN were not accompanied by LOH. Kolasa et al.
(2006) reported PTEN mutations in 5/100 cases of primary cervical carcinoma 
and there was a reverse association of p53 and PTEN mutations.
Weng et al. (2001) examined 10 thyroid cancer cell lines and found a hemizygous 
PTEN deletion with a splice variant in the remaining allele in a single follicular 
thyroid carcinoma line. Four lines, including the FTC line, expressed PTEN 
mRNA at low levels. Transient expression of PTEN in 7 thyroid cancer cell lines 
resulted in G1 arrest in 2 well-differentiated papillary thyroid cancer lines. Cairns 
et al. (1997) screened 80 prostate tumours by microsatellite analysis and found 
chromosome 10q23 to be deleted in 23 cases; sequence analysis of cases 
showing loss of heterozygosity. 10 tumours, (43%) demonstrated a second 
mutation, thus establishing PTEN as a main inactivation target of 10q loss in 
sporadic prostate cancer. PTEN mutations occur in up to 60% of primary prostate 
cancers an LOH as a single defect is reported more frequently than LOH followed 
by mutational inactivation of the remaining allele. LOH is more common in 
metastatic prostate tumours, indicating an association of PTEN dysfunction and
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tumour progression. (Wang et al. (1998), Vlietstra et al. (1998), Pesche et al.
(1998), Feilotter et al. (1998), Dong JT et al. (1998), and Bar-Shira et al. (2006)). 
The coding region of the PTEN gene was examined in malignant melanoma from 
16 primary and 61 metastatic tumours from 67 patients. (Birck et al. 2000). 
Mutations were identified in 4 of the metastatic samples (7%) and analysis of 2 
intragenic polymorphisms showed allelic loss in 3 of 8 primary tumours (38%) and 
in 18 of 31 metastatic tumours (58%). One of the mutant cases showed allelic 
loss, suggesting that both PTEN alleles were inactivated in this tumour. The 
group proposed that mutation and deletion of PTEN may contribute to the 
development and progression of malignant melanoma. Celebi et al. (2000) 
examined 21 metastatic melanoma samples and found LOH at 10q23 in 7 of 21 
samples and identified sequence alterations in the PTEN gene in four of the 
samples.
Neither Cowden syndrome or Bannayan-Zonana syndrome predispose to cervical 
cancer, LOH of markers on chromosome 10q is however frequently observed in 
cervical cancers. To determine the potential role that PTEN mutation plays in 
cervical tumourigenesis, Kurose et al. (2000) screened 20 primary cervical 
cancers for LOH of polymorphic markers within and flanking the PTEN gene, and 
for intragenic mutations in the entire coding region and exon-intron boundaries of 
the PTEN gene. LOH was observed in 7 of 19 (36.8%) cases. Three (15%) 
intragenic mutations were found: two were somatic missense mutations in exon 5 
and the third was an occult germline intronic sequence variant in intron 7 and was 
shown to be associated with aberrant splicing. All 3 samples with the mutations 
also had LOH of the wildtype allele. In cervical cancer, unlike some other human 
primary carcinomas biallelic structural PTEN defects seem necessary for 
carcinogenesis.
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Somatic genetic inactivation of PTEN is involved in as high as 93% of sporadic 
endometrial carcinomas (EC) and can occur in the earliest precancers. Zhou et 
al. (2002) obtained 41 endometrial carcinomas and analysed PTEN expression 
and undertook mutation analysis. Mutation analysis of 20 aberrant PTEN- 
expressing tumours revealed that 17 (85%) harboured 18 somatic PTEN 
mutations. All were frameshift mutations, 10 (56%) of which involved the 6(A) 
tracts in exon 7 or 8.
Other researchers have reported primary endometrial cancers with PTEN 
mutations approaches 80% to 90% in the endometrioid class of tumour, making 
PTEN mutation the most common finding in EC mutation screening (Risinger et 
al. (1997), Tashiro et al. (1997), Lin et al. (1998), Maxwell et al. (1998), Mutter et 
al. (2000) Oda et al. (2005)).
Mutation of PTEN is seen in the earliest stages of EC including endometrial 
hyperplasia. This suggests that PTEN loss is an early event in this disease. In 
contrast to brain tumours (Wen et al. (2001)), loss of PTEN in EC is associated 
with increased survival rates Risinger etal. (1998).
The role of PTEN in head and neck squamous cell carcinomas in correlation to 
mutation and methylation of the p16 gene and to previous studies concerning loss 
of chromosomes 9 and 10 was examined by Poetsch et al. (2002). They 
screened for alterations in PTEN and p16 in 52 HNSCC of different sites and 
found mutations in 12 (23%) tumour samples; PTEN missense mutations were 
found in 7 carcinomas (13%), and a loss of chromosome 10 was detected in 5 
(71%) of these.
In their original description of PTEN, Li et al. (1997) screened genomic DNAfrom 
18 primary glioblastomas for mutations in three exons. Mutations in PTEN were 
found in three of these tumours: a 2-bp insertion at codon 15 (534 T); a point
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mutation resulting in a Gly —► Arg change at codon 129 (132T), and a 4-bp 
frameshift mutation at codon 337 (134T). The mutation at codon 129 is within the 
signature sequence for tyrosine phosphatases. All three tumours displayed LOH 
in the PTEN region. In addition, the tumour mutations were not detected in DNA 
from paired blood samples.
Wen et al. (2001) reported data indicating that PTEN regulates tumour-induced 
angiogenesis and the progression of gliomas to a malignant phenotype via the 
regulation of phosphoinositide-dependent signals. Mutation in the PTEN gene 
accompanies progression of brain tumours from benign to the most malignant 
forms. Tumour progression, particularly in aggressive and malignant tumours, is 
associated with the induction of angiogenesis, a process termed the angiogenic 
switch. Biallelic inactivation of PTEN has been reported in 30% to 40% of 
glioblastoma multiforme, in anaplastic astrocytoma, and rarely in lower-grade 
glioma and glioneuronal tumours (Liu et al. (1997); Rasheed et al. (1997); Wang 
et al (1997); Duerr et al. 1998) and Smith et al. (2001))
From the above findings, it is clear that though PTEN is not commonly subject to 
mutation in haematological malignancy, it is frequently mutated in other solid 
tumours. Sansall and Sellers (2004) commented on the discordance between the 
rate of LOH and the rate of mutation of the second PTEN allele, which has led 
some to suggest that a second tumour suppressor gene is harboured in the 
10q23 region (as suggested in haematological malignancy by Butler et al.
(1999)). However, this difference could also result from the technical inability to 
detect second mutational events in the remaining functional PTEN allele. 
Passegue et al. (2003) observed the low number of mutations necessary to 
induce leukaemia compared with solid tumours and commented on the pre­
existing immortalised character that HSCs have in common with leukaemic cells.
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It may be the case that the rapid proliferation of the stem cell compartment 
associated with turnover of HSC (1 trillion cells per day in an adult (Ogawa 
1995)), coupled with a small number of critical oncogenic mutations is enough to 
cause neoplasia, by passing PTEN and the downstream PI3/AKT pathway which 
modulates cell cycling. Kurose et al. (2002) have reported mutually exclusive 
occurrence of p53 and PTEN mutation in breast neoplasia, suggesting that the 
presence of either mutation is capable of inducing tumour formation. Also, PTEN 
is not the only phosphatase involved in modulation of the PI3/AKTpathway. The 
SH2 domain-containing inositol 5'-phosphatase (SHIP) group of proteins also 
modulate the AKT pathway but reports of its involvement in haematological 
malignancy are contradictory. Luo et al. (2003) reported that the SHIP is crucial 
in haematopoietic development. They examined primary leukaemia cells from 30 
AML patients, together with eight myeloid leukaemia cell lines. A somatic 
mutation at codon 684, replacing Val with Glu, was detected in one patient, lying 
within the signature motif 2, which is the phosphatase active site. Leukaemia cells 
with this mutation showed enhanced Akt phosphorylation following IL-3 
stimulation. K562 cells transfected with the mutated SHIP-V684E cDNA showed a 
growth advantage even at lower serum concentrations and resistance to 
apoptosis induced by serum deprivation and exposure to etoposide. The authors 
suggested that these results are evidence of possible role of the mutated SHIP 
gene in the development of acute leukaemia and chemotherapy resistance 
through the deregulation of the PI3/Akt signalling pathway.
The findings of Luo et al. (2003) contrast with an earlier study by Choi et al.
(2002) who found loss of PTEN expression in OPM2 and A47 human myeloma 
cell lines, which led to high Akt activity toward insulin-like growth factor. Down- 
regulation and over-expression of SHIP in myeloma, PCT and NIH3T3 cell lines
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did not affect Akt activity in all systems analysed (unlike PTEN), despite its ability 
to dephosphorylate a PI3K product. Expression of SHIP and SHIP2 in a PTEN- 
null myeloma line did not suppress Akt activity. Biologically, expression of only 
PTEN, but not SHIP and SHIP2, resulted in growth inhibition. Horn et al. (2004) 
analyzed the effects of SHIP on the lymphoid Jurkat cell line in which expression 
of endogenous SHIP (and PTEN) protein was not detectable. Restoration of SHIP 
expression in Jurkat cells with an inducible expression system caused a 69% 
reduction of PI3K and a 65% reduction of Akt kinase activity. This was associated 
with increased transit time through the G1 phase of the cell cycle. Restoration of 
SHIP expression did not cause a complete cell cycle arrest or apoptosis. It is 
noteworthy that Jurkat cells show abolition of PTEN and SHIP expression - both 
mechanisms that control PI3K.
If the HSC compartment is proliferating constantly to maintain homeostasis, then 
PTEN expression and an associated brake on proliferation might be reduced in 
normal haemopoetic systems. Any subsequent disruption of PTEN by mutation 
might not confer a selective growth advantage if PTEN is not an important 
regulator of proliferation in this system, particularly if the SHIP pathway is still 
intact. However, this theory is not supported by the fact that SHIP'7' mice are 
viable and are not reported to be predisposed to develop leukaemia (Luo et al. 
2003).
As reported in chapter 1 (1.7.1.3), BCR/ABL in CML cases might be able to mimic 
the physiologic IL-3 survival signal in a PI3K-dependent manner. Ship and Ship-2 
are activated in response to growth factor signals and by BCR/ABL. BCR/ABL 
interacts indirectly with the p85 regulatory subunit of PI3K via GRB-2/Gab2 and 
this appears pathologically relevant because Gab2-deficient marrow cells are 
resistant to BCR/ABL transformation (Sattler et al. 2002)
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RTPCR analysis of cell lines in this study showed amplification of full-length 
cDNA in all haemopoetic cell lines studied apart from Jurkat cells, suggesting that 
expression of full-length mRNA resulted from at least one PTEN allele. Jurkat, a 
lymphoid cell line, has expression of both PTEN alleles abolished by mutation. 
Shan et al. (2000) described the defect in expression of PTEN in Jurkat T cells as 
leading to unregulated pleckstrin homology (PH) domain interactions with the 
plasma membrane. Inhibition of phosphoinositide phosphorylation by PI3K 
inhibitors, or by expression of PTEN, blocked constitutive phosphorylation of Akt 
on Ser-473 and caused Itk (a PH domain-containing kinase) to redistribute from 
the plasma membrane to the cytosol. The PTEN-deficient cells were also hyper- 
responsive to T-cell receptor (TCR) stimulation, which suggested a negative 
regulatory role for PTEN in TCR stimulation. Cell cycle arrest and release assays 
in Jurkat cells showed that PTEN expression reduced proliferation by slowing 
progression through all phases of the cell cycle. This was associated with 
reduced levels of cyclins A, B1 and B2, cdk4, and cdc25A and increased p27KIP1 
expression. Apoptosis played no role in the antiproliferative effect of PTEN, since 
only marginal increases in the rate of apoptosis were detected upon PTEN 
expression, and inhibitors of effector caspases did not restore proliferative 
capacity. Active Akt blocked the antiproliferative effects of PTEN, indicating that 
PTEN mediates its effects through conventional PI3K-linked signalling pathways 
(Seminario et al. 2003). The results presented in this thesis are in line with the 
findings of Dahia et al. (1999) who found the level of PTEN expression varied 
widely amongst the cell lines in their study: B15, BLIN1, DHL4, DHL10, NALM6, 
HT, RS4;11 and RAJI showed high transcript levels, whereas BV173, HL60 and 
U937 had very low transcript levels and the remaining samples (207, DHL7,
DHL8 and K562) showed an intermediate level of PTEN transcription. Jurkat cells
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were not included in their study. Epigenetic silencing of PTEN by methylation was 
reported in 5% of malignant melanoma primary tumours (Zhou etal. 2000), but 
none of 58 primary gastric cancers (Sato et al. 2006).
Zysman et al. (2002) commented on the difficulty of assessing methylation status 
in PTEN due to extensive methylation of the nearby pseudogene and reported 
that PTEN promoter methylation is rare in primary malignancy.
Western blot analysis in this study showed expression of PTEN in all of the 
primary leukaemia bone marrow samples, but at low levels compared to the p- 
actin control. Protein isolated from the primary leukaemia samples will reflect both 
the leukaemic and normal cell population in the bone marrow compartment, thus 
total abolition of PTEN expression can not be ruled out. These results are in 
agreement with Min et al. (2004) who correlated Skp2 protein expression (PTEN 
regulates Skp2-mediated degradation of cell cycle inhibitor p27Kip1 ) with PTEN 
expression in 99 consecutive adults patients with de novo AML, with 4 M0; 20 
M1; 33 M2; 19 M4; 21 M5 and 2 M6 subtypes. Constitutive expression of 
phosphorylated PTEN protein was demonstrated in the majority of AML cases 
with high correlation with Skp2 expression. Zouh et al. (2003) found that 
expression of PTEN assessed by western blotting was absent in 3 of 9 ALL cell 
lines. Leupin et al. (2003) reported that PTEN protein expression was not 
detected in 11 of 41 B-CLL cases (28%), and was reduced in eight patients 
(20%).
Liu et al. (2004) found that PTEN protein was decreased in 18 of 30 (60%) JMML 
patients, and these patients had significantly lower RNA expression of PTEN than 
normal controls.
Shen et al. (2005) explored PTEN gene expression and its clinical significance in 
acute leukaemia comprising 5 leukaemia cell lines, 87 patients with acute
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leukaemias including 59 AML, 26 ALL, and 2 acute hybrid leukaemia, 21 ALL in 
complete remission (ALL-CR), 31 CML and 14 normal controls were assayed. 
The expression ratio of PTEN mRNA between CML and normal control had no 
statistical difference. The expression ratios of PTEN mRNA in ALL and ALL-CR 
were significantly lower than that in normal control ALL also has a lower 
expression ratio than that of ALL-CR (P < 0.05). The decreased level of PTEN 
mRNA had a positive correlation with poor-prognostic factors. The group 
concluded that there was a down-regulated expression of PTEN gene in ALL.
The immunofluorescence staining of PTEN in primary leukaemias in this study 
demonstrated an increased level of staining in immature cells. Two of eleven 
cases (CGL and M3 AML) show high levels of cytoplasmic expression, which 
supports the observation by Liu et al. (2005) that wild-type PTEN shows 
preferential nuclear localization in differentiated or resting cells and cytoplasmic 
localisation in immature cells. The visualisation of PTEN signal in leukaemic cells 
removes any possibility of a false positive signal generated by normal cells within 
the tumour cell sample. Cytoplasmic expression of PTEN by immunofluorescence 
staining was reported by: Furnari et al. (1997) in glioma cell lines; by Li and Sun 
(1997) in transfected HepG2 and NIH3T3 cells and by Georgescu et al. (2000) in 
transfected U87-MG cells.
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Conclusion
Deletion of PTEN causes the generation of transplantable leukaemia-initiating 
cells in a murine model and causes the depletion of normal haemopoetic stem 
cells (Yimaz et al. 2006). If these findings translate to the human system, is PTEN 
mutated in leukaemia? The findings presented here show that the PTEN gene is 
not mutated in any stages of primary haematological malignancy and the protein 
is expressed in most primary leukaemias. Epigenetic mechanisms of PTEN 
activation have not been reported. These finding assume that the mutation 
detection techniques used in this study present an accurate picture of mutation 
status. The only possible source of error is contamination of the leukaemic cell 
population with normal cells, but the high percentage of tumour cells in the 
samples analysed make this unlikely. The use of cell sorting and laser capture 
dissection techniques would remove contamination as a source of error. It is also 
possible (but improbable) that small mutations of PTEN in exon 2 are more 
common in haematological malignancy. The exon was not screened in this study 
due to technical difficulty. Bonneau and Longy (2000) catalogue 332 somatic 
PTEN mutations in primary tumours; only 18 (5%) occur in PTEN exon 2, mostly 
in EC cases - none are reported in haematological malignancy.
PTEN is essential for haemopoetic stem cell function in at least two critical areas 
associated with the malignant transformation process: control of cell cycle and 
proliferation, plus chemotaxis and localisation within the bone marrow 
compartment. PTEN therefore, would be a candidate for mutation to facilitate the 
transformation of normal cells. The PI3-kinase/Akt pathway is constitutively active 
in primary AML cells and blocking PI3-kinase has direct anti-leukaemic effects in 
AML progenitor subsets (Grandage et al. 2005). Defects in PTEN co-operate with 
complex somatic mutations in solid tumours at multiple stages (with the loss of
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other tumour suppressors and/or activation of oncogenes) to promote malignancy 
{Yamada and Araki 2002). However, the work presented in this thesis showed no 
evidence of PTEN mutation in leukaemia. Melo and Deininger (2004) 
demonstrated that p53 is genetically or functionally inactivated in a large fraction 
of CML blast crisis cases. In line with the mutually exclusive presence of p53TP 
and PTEN mutations reported in solid tumours, it may be the case that with the 
small number of oncogenic mutations required to initiate leukaemia, the function 
of PTEN, aberrant or otherwise, is not a critical factor in promoting the leukaemic 
phenotype.
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4.3 Further Work
The intrinsic involvement of PTEN with the proliferation status of haemopoetic 
stem cells demands further investigation, particularly the levels of phosphorylated 
PTEN and Akt in leukaemic and normal cells and the effect of other oncogenic 
mutations on PTEN function. Flow cytometry would be an idea means of 
correlating phenotypic markers associated with leukaemia class with levels of 
PTEN and Akt expression and phosphorylation. The tumour cells of 
haematological malignancy are particularly suitable for this method as they are 
usually discrete, single cells. The technique would be limited in the study of 
primary haematological malignancy by its requirement for very fresh cellular 
material.
The weak, poorly-characterised protein phosphatase activity of PTEN towards 
proteins such as PDGF deserves further exploration. A search for other 
substrates of PTEN may reveal an undiscovered function which may be important 
in the promotion of the leukaemic phenotype, Finally, the frequent deletion of 10q 
sequences in B-cell lymphoma that exclude the PTEN gene suggest the presence 
of a further tumour suppressor element in this region. The exon trapping 
technique used by Steck et al. (1997) in the original identification of PTEN would 
be useful if the element is a tumour suppressor gene.
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Appendix 1
World Health Organisation Classification of Haematological Malignancy (Vardiman et al. 
2002.)
W H O  c la s s ific a tio n  o f ac u te  m y e lo id  leu kem ia
Acute myeloid leukemia with recurrent genetic abnormalities 
Acute myeloid leukemia with t(8;21)(q22;q22), (AML1/ETO)
Acute myeloid leukemia with abnormal bone marrow eosinophils and inv(16)(p13q22) or 
t(16;16)(p13;q22), (CBFP/MYH11)
Acute promyelocytic leukemia with t(15;17)(q22;q12), (PML/RARa) and variants 
Acute myeloid leukemia with 11 q23 (MLL) abnormalities 
Acute myeloid leukemia with multilineage dysplasia 
Following MDS or MDS/MPD
Without antecedent MDS or MDS/MPD, but with dysplasia in at least 50% of cells in 2 or 
more myeloid lineages
Acute myeloid leukemia and myelodysplastic syndromes, therapy related 
Alkylating agent/radiation-related type
Topoisomerase II inhibitor-related type (some may be lymphoid)
Acute myeloid leukemia, not otherwise categorized Classify as:
Acute myeloid leukemia, minimally differentiated 
Acute myeloid leukemia without maturation 
Acute myeloid leukemia with maturation 
Acute myelomonocytic leukemia 
Acute monoblastic/acute monocytic leukemia
Acute erythroid leukemia (erythroid/myeloid and pure erythroleukemia)
Acute megakaryoblastic leukemia 
Acute basophilic leukemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma
W H O  c la s s ific a tio n  o f th e  m y e lo d y s p la s tic /m y e lo p ro life ra tiv e  d is e a s e s
Chronic myelomonocytic leukemia 
Atypical chronic myeloid leukemia 
Juvenile myelomonocytic leukemia 
Myelodysplastic/myeloproliferative disease, unclassifiable
I
WHO classification and criteria for the myelodysplastic syndromes
Disease Blood findings Bone marrow findings
Refractory anemia (RA) Anemia Erythroid dysplasia only
No or rare blasts < 5% blasts
< 15% ringed sideroblasts
Refractory anemia with ringed 
sideroblasts (RARS) Anemia Erythroid dysplasia only
No blasts > 15% ringed sideroblasts 
< 5% blasts
Cytopenias
Refractory cytopenia with (bicytopenia 
multilineage dysplasia (RCMD) pancytopenia)
or Dysplasia in > 10% of cells in 
2 or more myeloid cell lines
No or rare blasts < 5% blasts in marrow
No Auer rods No Auer rods
< 1 x 109/L monocytes < 15% ringed sideroblasts
Refractory cytopenia with Cytopenias 
multilineage dysplasia and (bicytopenia 
ringed pancytopenia)
or Dysplasia in > 10% of cells in 
2 or more myeloid cell lines
sideroblasts (RCMD-RS) No or rare blasts > 15% ringed sideroblasts
No Auer rods < 5% blasts
< 1 x 109/L monocytes No Auer rods
Refractory anemia with excess 
blasts-1 (RAEB-1) Cytopenias
Unilineage or multilineage 
dysplasia
< 5% blasts 5% to 9% blasts
No Auer rods No Auer rods
< 1 x 1  q9/L monocytes
Refractory anemia with excess 
blasts-2 (RAEB-2) Cytopenias
Unilineage or multilineage 
dysplasia
5% to 19% blasts 10% to 19% blasts
Auer rods ± Auer rods ±
< 1 x 1 q9/L monocytes
Myelodysplastic syndrome, 
unclassified (MDS-U) Cytopenias
Unilineage dysplasia in 
granulocytes or 
megakaryocytes
No or rare blasts < 5% blasts
No Auer rods No Auer rods
MDS associated with isolated Anemia
Norm to inc megakaryocytes 
with del(5q) hypolobated nuclei
< 5% blasts < 5% blasts
Platelets normal or
increased No Auer rods
WHO classification Diagnostic criteria for CMML
Persistent peripheral blood monocytosis greater than 1 x 109/l_
No Philadelphia chromosome or BCR/ABL fusion gene 
Fewer than 20% blasts-* in the blood or bone marrow
Dysplasia in one or more myeloid lineages. If myelodysplasia is absent or minimal, the 
diagnosis of CMML may still be made if the other requirements are present and:
an acquired, clonal cytogenetic abnormality is present in the marrow cells, or
the monocytosis has been persistent for at least 3 months and all other causes of 
monocytosis have been excluded
Diagnose CMML-1 when blasts fewer than 5% in blood and fewer than 10% in bone 
marrow
Diagnose CMML-2 when blasts are 5% to 19% in blood, or 10% to 19% in marrow, or if 
Auer rods are present and blasts are fewer than 20% in blood or marrow
Diagnose CMML-1 or CMML-2 with eosinophilia when the criteria above are present 
and when the eosinophil count in the peripheral blood is greater than 1.5 * 109/L
In this classification of CMML, blasts include myeloblasts, monoblasts, and 
promonocytes.
W H O  c la s s ific a tio n  o f c h ro n ic  m y e lo p ro life ra tiv e  d is e a s e s
Chronic myelogenous leukemia [Ph chromosome, t(9;22)(q34;q11), BCR/ABL- 
positive]
Chronic neutrophilic leukemia
Chronic eosinophilic leukemia (and the hypereosinophilic syndrome)
Polycythemia vera
Chronic idiopathic myelofibrosis (with extramedullary hematopoiesis)
Essential thrombocythemia
Chronic myeloproliferative disease, unclassifiable
WHO classification - Criteria for accelerated and blast phases of CML
CML, accelerated phase (AP)
Diagnose if one or more of the following is present:
Blasts 10% to 19% of peripheral blood white cells or bone marrow cells 
Peripheral blood basophils at least 20%
Persistent thrombocytopenia (<100><109/L) unrelated to therapy, or persistent 
thrombocytosis (> 1000 * 109/L) unresponsive to therapy
Increasing spleen size and increasing WBC count unresponsive to therapy
Cytogenetic evidence of clonal evolution (ie, the appearance of an additional genetic 
abnormality that was not present in the initial specimen at the time of diagnosis of 
chronic phase CML)
Megakaryocytic proliferation in sizable sheets and clusters, associated with marked 
reticulin or collagen fibrosis, and/or severe granulocytic dysplasia, should be considered 
as suggestive of CML-AP. These findings have not yet been analyzed in large clinical 
studies, however, so it is not clear if they are independent criteria for accelerated phase. 
They often occur simultaneously with one or more of the other features listed.
CML, blast phase (BP)
Diagnose if one or more of following is present:
Blasts 20% or more of peripheral blood white cells or bone marrow cells
Extramedullary blast proliferation
Large foci or clusters of blasts in bone marrow biopsy
IV
Appendix II
French/American/British Classification of leukaemia (Vardiman et al. 2002.)
Acute myeloid leukaemia 
MO (undifferentiated AML)
M1 (myeloblastic, without maturation)
M2 (myeloblastic, with maturation)
M3 (promyelocytic), or acute promyelocytic leukemia (APL)
M4 (myelomonocytic)
M4eo (myelomonocytic together with bone marrow eosinophilia)
M5 monoblastic leukemia (M5a) or monocytic leukemia (M5b)
M6 (erythrocytic), or erythroleukemia 
M7 (megakaryoblastic)
Acute lymphoblastic leukaemia 
ALL-L1 :small uniform cells 
ALL-L2: large varied cells
ALL-L3: large varied cells with vacuoles (bubble-like features)
Myelodysplastic syndromes
RA Refractory anemia - less than 5% primitive blood cells (myeloblasts) in the bone 
marrow and pathological abnormalities primarily seen in red cell precursors 
RARS Refractory anemia with ringed sideroblasts less than 5% myeloblasts in the 
bone marrow, 15% or greater "ringed sideroblasts";
RAEB Refractory anemia with excess blasts - 5-19% myeloblasts in the marrow; 
RAEB-T Refractory anemia with excess blasts in transformation - 20-29% 
myeloblasts in the marrow (30% blasts is defined as acute myeloid leukemia);
CMML Chronic myelomonocytic leukemia -
V
Appendix 111
Manual Staining Procedure For Blood Films
1 PRINCIPLE
The acidic groupings of the nucleic acids and proteins of the cell nuclei and 
cytoplasm determine the uptake in varying intensities of the basic dye Azure B 
whilst the presence of any basic groupings are indicated by the Eosin Y, for 
example:
■ Neutrophil granules are weakly stained by the azure complexes.
■ Eosinophilic granules containing alkaline groups stain strongly with Eosin.
■ Basophil granules stain heavily with Azure due to its heparin content.
Cells that have both groupings take up both stains in varying intensities, eg.
reticulocytes.
2 COSHH and HEALTH & SAFETY REQUIREMENTS
Blood films are still a biohazard until they are fixed.
Methanol -  toxic by ingestion and is inflammable.
May Grunwald stain -contains methanol 
Giemsa stain 
see COSHH file
3 REAGENTS 
Absolute Methanol 
Giemsa stain
May Grunwald stain 
Sorensen’s buffer concentrate 
Buffered water pH (6.8 -  7.0)
4 PREPARATION OF STAINS
BUFFER
VI
1 x 25ml bottle Sorensen’s buffer concentrate to 5 litres deionised water. Mix 
well.
MAY GRUNWALD
100ml May Grunwald stain 
200ml Buffer 
GIEMSA
20ml Giemsa stain 
280ml Buffer 
5 METHOD
METHANOL 
MAY GRUNWALD 
GIEMSA
BUFFERED WATER
5 minutes 
6minutes 
12 minutes 
2minutes
VII
Appendix IV
Immunocvtochemistry using Shandon Sequenza staining system
1. Place wax sections in a metal staining rack. Dewax sections in three 
consecutive changes of xylene - five minutes each, then take to alcohol in three 
changes of industrial ethanol five minutes each. Do not allow slides to dry at any 
time during entire staining process
2. Immerse in 0.5% hydrogen peroxide in methanol (Appendix 2) for ten minutes 
to inhibit endogenous peroxidase activity, and wash in tap water.
o3.Place slides requiring trypsinisation in distilled water for 10 mins at 37 C. Place 
slides not requiring trypsinisation in TRIS buffered saline (TBS) pH 7.6 at room 
temp.
4. Incubate trypsinisation samples in 0.1% trypsin in 0.1% calcium chloride at
opH 7.8 (Appendix 2) at 37 C for 30 mins then wash in cold water and transfer to 
TBS.
5. Place samples for microwave treatment in a polypropylene slide rack and 
immerse in 250 ml of citrate buffer (Appendix 2) in a polypropylene 1000 ml 
beaker. Place slides in a 750 Watt Toshiba microwave oven and microwave for 
twenty minutes at 80% power. Cool slowly in running tap water then placed in 
TBS.
6. Load sections onto a Shandon Sequenza staining rack and wash with TBS for 
five mins.
7. Incubate all sections with normal goat serum (1:5 with TBS) for 20 mins to 
block non specific binding of primary antibodies.
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8. Treat with relevant dilution of primary antibody for 60 mins at room temp.
9. Wash in TBS for five mins.
10. Incubated in "Biogenex" Streptavigen Multilink diluted 1:60 in TBS for 30 
mins.
11. Wash in TBS for five mins.
12. Incubate in "Biogenex" StrepABC/horse radish peroxidase label diluted 1:60 
in TBS for 30 mins
13.Wash in TBS for five mins.
14. Incubated in DAB solution (Appendix 2) for 5 mins.
15 Wash in tap water 5mins.
16. Counterstain with Harris's Haematoxylin for 10 seconds and blue in tap water.
17 Dehydrate through consecutive changes of ethanol, clear in xylene and mount 
in non aqueous mounting media.
(Internal Standard Operating Procedure, Dept of Histopathology, Arrowe Park 
Hospital.2003)
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